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ABSTRACT
 Localized delivery is vital for the successful development of novel and effective 
therapeutics for the treatment of cancer, as discussed in Chapter 1. Currently, most 
targeting methods are based on cancer markers, such as cell surface receptors. However, 
this approach suffers from two major drawbacks: biomarkers are not specific to cancer 
cells, which can result in off-target toxicity, and cancer cells have a tendency  to evolve 
quickly, which can lead to a loss of biomarkers, thus therapy resistance. However, nearly 
all solid tumors have a low extracellular pH, regardless of their tissue or cellular origin. 
Moreover, tumors' aggressiveness and metastatic potential are fostered at low 
extracellular pH. For these reasons, acidosis is a hallmark of tumor progression and may 
provide an opportunity for tumor-targeted therapy.
 The targeting and delivery described in Chapter 2 is based on the pH(Low) 
Insertion Peptide (pHLIP), a unique delivery peptide that can selectively target tumors in 
mice based solely on their acidity rather than a specific marker. pHLIP is a soluble 
peptide in aqueous solutions at normal pH, but inserts unidirectionally  (C-terminus 
across) into cell membrane as a transmembrane helix under acidic conditions. This 
research focuses on developing new strategies to inhibit cancer cell growth by delivering 
therapeutics to cells using pHLIP. We hypothesize that the localized targeting achievable 
with pHLIP when combined with potent therapeutics will synergize to create an 
advantageous treatment for cancer. 
 This dissertation focuses on developing new strategies to inhibit cancer cell and 
tumor growth by  delivering therapeutics to cells using pHLIP. We investigated several 
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different therapeutics with varying mechanisms conjugated to pHLIP to test the efficacy 
in cultured cells. The works of Chapter 3, include the delivery  of clinically relevant 
cytotoxins, derivatives of the auristatin family. Our initial approach was to test the 
efficacy of the cell permeable monomethyl auristatin E (MMAE) with two pHLIP 
variants. We show that pHLIP−MMAE conjugates induce a potent cytotoxic effect 
(>90% inhibition of cell growth) in a concentration- and pH-dependent manner after only 
2 h incubation without any apparent disruption of the plasma membrane. Furthermore, 
we demonstrate that a pHLIP−MMAE drug conjugate effectively targets triple-negative 
breast tumor xenografts in mice. With the hopes of finding the most efficacious pHLIP-
auristatin therapeutic, our efforts turned to the cell impermeable monomethyl auristatin F 
(MMAF) conjugated to several variants of pHLIP with varying pH50 of insertions. We 
investigated, six pHLIP variants conjugated to MMAF to compare their efficacy  in vitro 
against cultured cancer cells. While all pHLIP-MMAF conjugates exhibit potent pH- and 
concentration-dependent killing, their cytotoxicity profiles are remarkably different. We 
also show that the lead conjugate exhibits significant  therapeutic efficacy in mouse 
models without overt toxicities. These studies confirm that pHLIP−monomethyl 
auristatin conjugates are possibly new therapeutic options for cancer treatment and 
supports their further development. This work is described in an article published in 
Molecular Pharmaceutics, and in one that has been recently submitted.
 The strategy described in Chapter 4, is a novel way to selectively target and 
modulate the activity of a transmembrane receptor, specifically a G-Protein Coupled 
Receptor (GPCR). We find that when conjugated to pHLIP a peptide mimic of the third 
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intracellular loop (i3) of the protease-activated receptor 1 (PAR1), targeted to the 
cytosolic region of the receptor is successful at the down-regulation of PAR1 activity. 
Moreover, we observe a potent cytotoxic effect in a pH- and concentration-dependent 
manner across a panel of cancer cells that is proportional to the level of receptor 
expression. This strategy  allows for more selective targeting and offers new possibilities 
for developing novel anti-cancer drugs targeting GPCRs. This work was published in 
Biochemical Journal.
 Another therapeutic peptide-based project deals with the intracellular delivery of 
antimicrobial peptides (AMPs) for mitochondrial membrane disruption and ultimately 
cell death. As described in Chapter 5, the focus of this project is with the AMP 
(KLAKLAK)2, and identifying a lead conjugate with optimized selective cytotoxicity 
towards cancer cells. We analyzed a family  of analogs with varying size, polarity and 
charge and each was shown to inhibit cancer cell growth in a concentration- and pH-
dependent manner upon pHLIP-mediated translocation. Furthermore, we identified 
pHLIP-KLAKLAK as a lead conjugate because of its low cytotoxicity at physiological 
pH, chemical stability, high anti-proliferation potency and specific induction of 
mitochondrial membrane disruption at lower pH. This work is described in an article 
recently accepted for publication in Scientific Reports.
 With the work in this thesis, we believe that we have contributed greatly to the 
advancement and development of pHLIP as a viable drug delivery  system. While more 
work needs to be developed in animal studies, we believe these studies support the 
further development of pHLIP-drug conjugates as a viable treatment of cancer.
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Chapter 1:
Cancer Therapeutics
1.1 Background and Introduction
 Cancer is a group of diseases characterized by the uncontrolled growth and 
spread of abnormal cells, ultimately leading to malignant tumors.1 Tumor cell invasion of 
surrounding tissue and distant organs is the primary cause of morbidity and mortality  for 
most cancer patients.2 Mutations occur during the swift  replication and division patterns 
of cancerous cells, resulting in diverse mutations within the same group of cells. This 
leads to heterogeneity of cells within a tumor, making treatment much more challenging.  
 Understanding how healthy  cells transform to abnormal cancerous cells has 
become a large area of research endeavors. It  was first suggested that the hallmarks of 
the transformation of cells is a manifestation of six essential alterations in cell 
physiology that collectively dictates malignancy: (1) self-sufficiency in growth signals, 
(2) insensitivity  to growth-inhibitory  signals, (3) evasion of programmed cell death 
(apoptosis), (4) limitless replicative potential, (5) sustained angiogenesis (formation of 
new blood vessels), and (6) tissue invasion and metastasis.3  After a decade of cancer 
research, two additional core hallmarks of malignancy  were added: (7) deregulating 
cellular energetics and (8) the ability  to avoid immune destruction.3  It is understood that 
the enabling characteristics for manifestation of these hallmarks are due to genome 
instability leading to increased mutability, including chromosomal rearrangement and the 
inflammatory state of cells which are driven by the immune system.3,4
4
 Despite these research efforts, cures or long-term management strategies for 
metastatic cancer are as challenging today as they were 45 years ago, when President 
Richard Nixon declared a war on cancer (National Cancer Act of 1971).2,5,6 According to 
the American Cancer Society, about  1.6 million patients are expected to be diagnosed 
with cancer in 2016, and approximately 595,690 American cancer patients are expected 
to die this year, amounting to 1,700 patients per day.7 Furthermore, by  2020 the Centers 
for Disease Control and Prevention (CDC) projects new cancer cases to rise to 1.9 
million per year and expects 630,000 deaths due to cancer.8 Even though there has been a 
steady  increase in survival rates (~23% since 1991) owing to the progression of 
prevention, treatments and diagnostics, alternative approaches to treatment are obviously 
necessary.9
1.2 Traditional Chemotherapeutics
 Initial efforts to develop cancer therapeutics were based on the nitrogen mustard 
agents similar to mustard gas, a poison gas that caused terrible blisters upon contact first 
used by Germany in July 1917.10 Although, gases were not used on the battlefield during 
World War II nations stockpiled it, which led to an accidental spill from a bombed ship in 
Bari Harbor, Italy in 1943 affecting many  soldiers, who were all found to have depleted 
levels of bone marrow and lymph nodes.11,12 Scientists at Yale University began 
researching the mustard compounds and found that they could be used as therapeutics, as 
they  observed tumor regression when treating mice with lymphoid tumors.11 It was later 
found out the mechanism of these compounds are to crosslink DNA. Alkylating agents 
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are classically  potent particularly to fast  dividing cells, such as cancerous ones, as they 
are very sensitive to DNA damage. Indeed, these agents impair DNA replication and 
repair by covalently binding base pairs in a sequence with an alkyl group causing a 
cross-linkage of the DNA strands, either within a single strand or bridging two strands 
together. The site of cross-link and the number of cross-links formed are drug specific.13 
When the cell tries to replicate the DNA or repair the cross-link, in any  phase of the cell 
cycle, it  causes the DNA strand to break and consequently cell death. In addition to the 
nitrogen mustard derivatives, there are families of Nitrosoureas and Alkyl Sulfonates 
alkylating agents.  
 Coincidently, another class of drugs was being developed, which are 
antimetabolites that either interferes with the synthesis of DNA or mimic DNA 
precursors that halts replication or causes mistakes in DNA replication, subsequently 
leading to cell death and decreased tumor growth.14 Antimetabolites bear structural 
similarities to substances such as vitamins, nucleosides or amino acids and compete for 
the active site on an essential enzyme or receptor.13 The most common classes are folic 
acid antagonists, pyrimidine and purine analogues, which all interfere with the 
biosynthesis of nucleic acids in one way or another.13 The discovery of these early 
classes of chemotherapeutics led to the development of several drug families aimed at 
inhibiting enzymes responsible for DNA replication and therapeutics that interrupt cell 
division.  
 Another large class of chemotherapeutics are the topoisomerase inhibitors, which 
are the enzymes responsible for the coiling and uncoiling of DNA by snipping the DNA, 
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which aids in replication, chromatid segregation and transcription.13 Topoisomerase I 
works by  cutting a single strand of the DNA double helix, while topoisomerase II cuts 
both strands, allowing the coil to relax and replication to take place.  Once replication or 
repair is complete, the enzymes aid in reforming the strands and coil.  Inhibitors of each 
enzyme act very  similarly  by binding the enzyme-DNA complex, halting its activity.13 
Camptothecin acts on topoisomerase I and its successful efficacy  led to the discovery of 
two more topoisomerase I inhibitors, Irinotecan and Topetecan. An example of a well 
known and clinically used topoisomerase II inhibitor is Doxorubicin.  
 An additional class of chemotherapeutics are anti-mitotics derived from natural 
sources that inhibit mitosis (i.e., cell division) by interfering with microtubules, which 
are long polymers consisting of tubulin monomers and which provide mechanical 
support to the cell and allow for cell division and movement. This class of anti-mitotic 
agents  disrupt or stabilize the polymerization of tubulin by binding to it. For example, 
Paclitaxel promotes and stabilizes microtubule polymerization preventing its 
disassembly  and the formation of mitotic spindles.15 Contrastingly, the vinca alkaloids 
Vincristine and Vinblastine act by inhibiting further tubulin assembly and thus mitosis.13  
 Many of the newer classes of chemotherapeutics were designed to destroy cancer 
cells by targeting the activity of one of the hallmarks of malignancy. Anti-angiogenesis 
drugs inhibit the formation of blood vessels by blocking the signaling processes that 
initiate the growth of new vessels. For example, the FDA approved inhibitor Avastin®, a 
monoclonal antibody that recognizes and binds to the vascular endothelial growth factor 
(VEGF) making it unable to activate its cognitive receptor VEGF.16  Another newer class 
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of drugs induces apoptosis in cancer cells by interfering with proteins along the apoptotic 
signaling cascade. Malignant cells have acquired evasion of apoptosis through several 
mechanisms including a misbalance in pro-apoptotic and anti-apoptotic proteins, reduced 
caspase function and impaired death receptor signaling.17 Therefore, the potential to 
induce apoptosis through any  of these mechanisms are vast. Some efforts include the 
inhibition of the anti-apoptotic Bcl-2 family proteins by  either inhibiting their activity or 
silencing the genes that encode them, silencing the genes that encode for inhibitor of 
apoptosis proteins (IAPs), restoration of the tumor suppressor protein 53 (p53), and 
activation of caspase signaling pathways.17
 While cancer cells may initially  be susceptible to a therapeutic, over time they 
can evolve to gain resistance, through a myriad of defenses including drug inactivation, 
drug target alteration, drug efflux and DNA damage repair.18 Some chemotherapeutics 
require metabolic activation through interactions with proteins although, cells can 
modify  proteins involved rendering the drug inactive. Similarly, cells can evade drug 
activity by mutating or modifying directly the drug’s target or by altering its signaling 
mechanisms. There is a family of transmembrane proteins, ATP-binding cassette (ABC) 
transporters that are responsible for transporting substances across plasma membranes 
and when over-expressed can contribute to acquiring drug resistance by increasing the 
amount of drugs getting shuttled out of the cell.18,19 Cells can also combat drug activity 
by simply  repairing the effects of their activity. For example, resistance to drugs that 
induce DNA damage such as Cisplatin, that  causes crosslinks in DNA arise due to 
nucleotide excision repair and homologous recombination.18,20,21 For these reasons, anti-
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tumor efficacies of a single drug are limited due to tumor heterogeneity and will likely 
lead to acquired resistance.
 Combination therapy arrived in the 1960s, resulting in major improvements in 
patient outcomes.14 The motivation is to combine drugs with differing activity 
mechanisms in order to decrease the chances of the cancer cells building up  resistance. 
Resistance to a single therapeutic can be acquired through only a few mutations, while 
becoming resistant to multiple therapeutics with different targets requires multiple 
mutations.14 As some drugs exert  their activity at a specific phase of the cell cycle while 
others are not phase specific, it is reasonable to attack cells at  multiple phases of growth 
to prevent mutations and resistance.  Additionally, the drug “cocktail” is strategically 
chosen to include drugs with different targets, mechanism of actions and toxicity 
profiles.  
  Concerningly, the majority of therapeutics found for biological targets located 
inside a cell are molecules that cannot cross the membrane.22-25 The cellular membrane is 
selectively permeable as it moves ions, nutrients and waste across but is also a 
determining factor in drug efficacy.  Some drugs that are small and hydrophobic are able 
to passively diffuse across the membrane, while some exploit membrane protein-
mediated transport.  In 1997, Christopher Lipinski developed the rule of five, which 
determines the drugs likelihood of being orally active. Some of these rules have been 
extended to the drugs’ potential of crossing the membrane, including the octanol-water 
partition coeffecient (logP) between -0.5 to 5.0 and a molecular weight under 500 
daltons.26
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1.3 Delivery Methods
 In an effort to overcome the barriers of crossing the cellular plasma membrane 
nano-sized carrier agents have been developed to encapsulate therapeutics that are not 
able to penetrate the membrane for delivery. Importantly, these carriers have additional 
numerous advantages, including large loading capacity and protecting the drug against 
degradation.27  Nano-sized drug carrier systems with long circulating time can provide 
stability  to the therapeutic, improved pharmacokinetics and some “passive” targeting to 
tumor sites by relying on the enhanced permeability  and retention (EPR) effects for 
preferential extravasation from tumor vessels, a schematic representation of the leaky 
vasculature is shown in Figure 1.1.28,29
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Figure 1.1 The Enhanced Permeability and Retention Effect. 
Defects in blood vessels at tumor sites allow nano-sized carriers 
to accumulate in tumor tissue.29
International Journal of Nanomedicine 2012:7 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1045
Cancer and nanomedicine drug-delivery systems
on their application. In this review we shall discuss different 
kinds of nanomaterial-based drug-delivery systems, with a 
focus on their components, applications, advantages, and 
limitations of the preparations.
Liposomes
Liposomes are self-assembled phospholipid membranes 
with an inner core where drugs can be entrapped. Liposomes 
are relatively stable, biodegradable, and do not elicit any 
immune response. They are efficient vehicles for targeted 
delivery of hydrophobic drugs. Liposomes are vesicular 
formulations of lipid bilayers prepared synthetically. 
The water-soluble drugs are present in aqueous compart-
ments while lipid-soluble drugs and amphiphilic drugs 
insert themselves in the phospholipid bilayer. Liposomes 
have been in vogue for varied applications such as DNA 
delivery in gene therapy and genetic engineering, drug 
delivery in nutrition and dietary supplements, or  cosmetics. 
 Liposomes may be synthesized in various sizes and shapes, 
however, nanoscale liposomes called nanosomes are of 
specific interest in targeting cancer. Such nanosomes are 
several nanometers in size and most commonly contain 
 anticancer drug(s).5,6 Since nanosomes are soluble in 
 aqueous solvents (like blood), they can carry hydrophilic as 
well as hydrophobic molecules, thus allowing administra-
tion of anticancer drugs that showed poor efficacy due to 
their limited solubility. A nanosome is essentially a vesicular 
lipid bilayer with the polar heads facing the solvent and 
the tail regions facing each other. The anticancer drug, if 
hydrophobic, can thus be contained in the tail region, and 
if hydrophilic, solubilized in the liposomal core. Surface 
modification of liposomes using polyethylene glycol (PEG), 
confers the liposomes stealth property, from being destroyed 
by the reticuloendothelial system. PEGylated (STEALTH) 
liposomal doxorubicin (Doxil®, Caelyx; Schering-Plough 
Pharmaceuticals, Kenilworth, NJ) was the first liposomal 
anticancer drug for the treatment of ovarian cancers to be 
approved by the US Food and Drug Administration. Several 
lipid-based formulations like liposomes have been synthe-
sized and characterized. We will review significant types 
for their novelty in composition, synthesis, size, shape, and 
applications. Newer generations of liposomes containing 
two anticancer agents within a single liposome are under 
development.
KEY
Targeted
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Figure 1 The enhanced permeability and retention effect operating in tumor milieu permitting accumulation of nanometer-sized particles in cancer cells. Blood vessels in 
tumor tissue have defective architecture with gaps as large as 200–1000 nm allowing nanoparticles to extravasate and accumulate inside the tumor tissue. The retention 
time of drugs packed in nanoparticles is ten times higher than that of unpacked drugs, which eventually return to the vascular system. This phenomenon of permeability of 
molecules due to their size is a boon to cancer therapy and is known as the enhanced permeability and retention effect.
 EPR was first  described by Maeda in the 1980s when it was found that large 
macromolecules, such as polymers and proteins (> 4-40 kDa) accumulated in tumor 
tissues and were retained for long periods of time (> 24 hours).30 As described 
previously, one of the hallmarks of malignancy  is sustained angiogenesis, although due 
to the aggressive growth of cell populations disorganized blood vessel networks are 
developed and compromised blood flow is commonly observed.31,32 Most blood vessels 
within the tumor are defective in that they have perforations between the endothelial 
cells and lack smooth muscle layers. These perforations are just large enough for the 
macromolecules to leak out into the tumor.  Furthermore, the lymphatic vessels are also 
defective and are inefficient at clearing the macromolecules. Many drug delivery  systems 
have been developed around these EPR effects for passive targeting and delivery of 
therapeutics to tumor sites.30,33-39 
 Nanoparticles containing encapsulated, dispersed, adsorbed or conjugated drugs 
have unique characteristics that lead to enhanced performance in a variety of dosage 
forms including improved therapeutic index, bioavailability, and pharmacokinetics. 
Nanoparticles range in size from 3-200 nm and can be made from a variety  of materials 
including polymers (polymeric nanoparticles, micelles, or dendrimers), lipids 
(liposomes), viruses (viral nanoparticles), and even organometallic compounds. 40  Viral 
nanoparticles are capsids or envelopes of cored out viruses from plants, insects and 
animals that carry drugs, although their associated toxicity is still being researched. 
 Liposomes were described as a drug delivery system capable of entrapping drugs 
as early  as 1971.41-45  They are composed of a lipid bilayer with an aqueous core, in 
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which hydrophilic drugs are encapsulated, allowing for their release in the cytoplasm 
upon liposome fusion with the plasma membrane (Figure 1.2). For example, the first 
FDA approved (1995) liposomal drug system Doxil consists of the chemotherapeutic 
Doxorubicin encapsulated in 80-90 nm sized unilamellar liposome coated with PEG 
groups anchored to the bilayer surface to enhance circulation time.  It has been estimated 
that 10-15 thousand drug molecules can be contained within each liposome.46 Myocet, 
the non-pegylated formulation has been approved for use in Europe and Canada as a first 
line of defense against metastatic breast cancer in combination with the alkylating agent 
cyclophosphamide and is also being tested for use in combination therapy with other 
compounds.46 Currently, there are a variety  of liposomal drug systems in clinical trials 
for the treatment of various types of cancer.   For example, CPX-351 which encapsulates 
a combination of cytarabine and daunorubicin is in phase III trials for the treatment of 
leukemia. Another product in that is in phase II clinical trials is CPX-1 which 
encapsulates the combination of irinotecan HCl and floxuridine.47 
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Figure 1.2 Schematic representation of lipid fusion. Liposomes 
deliver payload by fusing with the lipids of the cellular membrane 
Liposome
Drug
Similarly  micelles are capable of encapsulating drugs for delivery. In this case, however, 
hydrophobic and poorly water soluble therapeutics can be delivered. Micelles are 
colloidal particles ranging in size from 5-100 nm and consist of two distinct regions, 
mostly  hydrophilic head-group and a hydrophobic tail. To date, there are several 
polymeric micelle drug systems in phase II and III clinical trials including the drugs 
Doxorubicin and Cisplatin, respectively  and a FDA approved polymeric micelle 
containing Paclitaxel. 48-55 
 Another drug delivery  system that relies on EPR effects are polymer-drug 
conjugates (PDCs) in which a chemotherapeutic is covalently  linked to a water-soluble 
polymer. 56,57  Polymers used for drug delivery  can come in a variety of architectures, 
some examples include linear polymers, dendrimers, and the aforementioned polymeric 
micelles. Linear polymers are the simplest homopolymers that  form random coiled 
structures and maintain ease at introducing functional groups for a variety  of drug 
linkage strategies. Many linear polymers utilize polysaccharides, peptides, and/or poly 
(ethylene glycols) (PEGs). Dendrimers are branched polymers that form symmetrical 
star-like structures.  These branches allow for many  more drugs to be loaded per 
structure, although there have been some concerns over their biocompatibility and 
toxicity.58 Almost all of the nano-sized carrier systems utilize endocytosis for cellular 
delivery (Figure 1.3), although the linking strategy may vary and include, disulfide, 
esters, and protease recognizable sequences.  
 While these carriers rely on passive tumor targeting, they still lack the ability  to 
discriminate between healthy and cancer cells, which can lead to unacceptable toxicity 
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profiles similar to that of the free drug. Common side effects may include pain, fatigue, 
nausea, vomiting, diarrhea, constipation, blood disorders, changes in mental capacity, 
sexual and reproductive issues, appetite loss, and hair loss. These side effects will 
invariably  diminish with improved targeting of chemotherapeutics to tumor tissue. 
Therefore, research focused on developing therapeutics that specifically  target and 
deliver chemotherapeutics directly to cancer cells is vital to continue the trend of 
increased survival in cancer patients.  
1.4 Targeting Methods
 The previously described carrier systems all rely  on the passive targeting of nano-
sized drug carriers by taking advantage of the tumor microenvironment characteristic 
feature of EPR effects. Contrastingly, active targeting relies on a specific affinity 
between drug and its carrier to the target cells, such as ligand or antibody receptor 
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Figure 1.3 Schematic Representation of Endocytosis. Drug 
entrapped nano-sized carriers are delivered most frequently through 
endocytosis, undergo a physical change in the lysosome and release 
the payload into the cytosol. Release occurs in the lysosome due the 
presence of digestive enzymes and environmental changes, such as 
decreased pH, which does not occur in the endosome.
interactions. Any  of the aforementioned passive targeting carrier systems can be 
modified with ligands and/or antibodies to gain active targeting. The use of monoclonal 
antibodies (mAb) in chemotherapy has become one of the most successful therapeutic 
strategies in the last 20 years.59 These mAb can be used to trigger the immune system to 
recognize and attack cancer cells and also used for the specific delivery of cytotoxic 
agents to tumor cells commonly using antibodies against over-expressed receptors in 
certain cancer cell lines.  
 The function of the immune system is to protect the body from disease, pathogens 
and foreign bodies. However, due to similarities to healthy  cells it is unable to 
distinguish cancer cells as diseased. A mAb can be used to bind to an over-expressed 
transmembrane receptor known to be associated with malignancy  and thus marking the 
cell for the immune system to recognize and attack. Rituximab is ne of the first FDA 
approved mAb and is used as an immunotherapeutic, as a treatment for non-Hodgkin’s 
lymphoma and lymphocytic leukemia.   
 Antibody Drug Conjugates (ADCs) combine the unique targeting abilities of 
mAb with the cytotoxic effects of therapeutic drugs and allow for sensitive 
discrimination between cancer and healthy  cells. Upon antigen binding a signaling 
cascade is initiated and the complex is internalized through endocytosis. At some point 
within the endosome or lysosome, the drug is released from the antibody through 
cleavable linkers including disulfides, hydrazones or cleavable peptide sequences, as 
shown in Figure 1.4.
15
 To date, only two ADCs have gained FDA approval, Adcertis® (brentuximab 
vedotin) in 2011 and Kadcyla® (ado-trastuzumab emtansine) in 2013.   Adcertis® is 
composed of the monoclonal antibody brentuximab, which is against the CD30 
membrane receptor and the anti-mitotic drug monomethyl auristatin E (MMAE). 
Brentuximab is ineffective alone and MMAE is far too potent to be administered without 
the use of a targeting agent. The linker employed in this ADC is a cathepsin recognizable 
sequence which is cleaved in the late lysosome. Adcertis® is used for the treatment of 
Hodgkin lymphoma and in the phase II clinical trial, 34% percent of the patients 
achieved complete remission for a median duration of 20.5 months and an additional 
40% had a decrease in tumor size by more than half for 3.5 months on average. 60
 Kadcyla® is comprised of the monoclonal antibody  trastuzumab (Herceptin) 
which is against the human epidermal growth factor receptor 2 (HER2) and a tubulin 
inhibitor mertansine. HER2 is over-expressed in approximately 20% of breast cancer and 
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Figure 1.4 Schematic Representation of Receptor-Mediated 
Endocytosis. Upon binding of an ADC to its antigen cause 
endocytosis and linker degradation to release the payload to the 
cytosol.
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Drug
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is associated with shortened survival.61-64 When trastuzumab alone is treated to HER2 
positive cells, it  prevents dimerization of HER2 and thus shuts down HER2 signaling 
pathway, and when combined with first-line chemotherapeutics, increases the time to 
progression and overall survival. 61,65,66 Kadcyla® was specifically approved for 
treatment in patients that have previously been treated with the combination of 
trastuzumab and either Paclitaxel or Docetaxel and developed tumor recurrence within 
six months.61
1.5 General Cancer Biomarkers
 As previously described, active targeting strategies like ADCs are based on the 
targeting of specific biomarkers, such as membrane receptors. However, most cancer 
biomarkers that are over-expressed in certain cancer cells are also expressed in healthy 
cells, leading to off targeting delivery. Different cancer cell lines also have different 
biomarkers and identifying a specific biomarker for each has become a laborious 
process.  Moreover, this approach is also hampered by tumor heterogeneity, which can 
promote tumor evolution and lead to the loss of cell surface proteins, and eventually  to 
therapy resistance and disease progression. Thus, relying on a general feature of tumors 
as the basis for developing a targeted therapy may be more beneficial than relying on a 
single cancer biomarker. 
 In addition to the recognized hallmarks of cancer, aerobic glycolysis or the 
Warburg effect is also a robust metabolic hallmark of most tumors.2,67-73 While no 
specific gene mutation or chromosomal abnormality is common to all cancers, nearly all 
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solid tumors have a low extracellular pH, regardless of their tissue or cellular origin. This 
phenomenon is due to the abnormal nutritional requirements and metabolic traits of the 
rapidly  expanding cancer cells, which create a unique microenvironment that 
distinguishes malignant solid tumors from surrounding normal tissues. Many cancer cells 
consume glucose avidly  in the presence of oxygen to produce ATP (Warburg effect), 
leading to the accumulation of lactic acid in the cytoplasm and subsequent excretion of 
protons out of the cell72,73 Other factors, such as the release of carbon dioxide from 
cancer cells, contribute to tumor extracellular acidity.  
 In 2009 another hypothesis was proposed for the observed acidic tumor 
microenvironment. It postulates that aerobic glycolysis takes place in tumor associated 
fibroblasts not in cancer cells, and the hypothesis was termed “The Reverse Warburg 
Effect”.74   In this model, it is the fibroblasts that are associated with tumors that undergo 
aerobic glycolysis and transfer lactic acid to the cancer cells. Furthermore, the increased 
ATP production in cancer cells from the oxidative mitochondrial metabolism promotes 
tumor growth. 74   
 Nevertheless, the extracellular environment of tumors exhibit a low pH (6.0-6.9) 
as compared to normal tissues (7.4), which is likely  to be lowest at the cellular surface 
and increase with distance from cellular membrane.75-80 Importantly, tumors' 
aggressiveness and metastatic potential are promoted at low extracellular pH; thus, 
targeting tumor acidity  is hypothesized to be less prone to the development of acquired 
resistance than targeting a single protein antigen.81-83 For these reasons, acidosis is a 
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hallmark of tumor progression from early to advanced stages and may provide an 
opportunity for tumor-targeted therapy.4
 
 Toward this end, many pH sensitive nano-systems have been developed to target 
therapeutics to tumors while sparring healthy  tissue. The fine tuning of a pH responsive 
carrier has proven to be a challenge, because the tumor pH is different enough from 
healthy tissue to change the function of cells, but  similar enough that  precise tuning of 
chemical properties are required for a carrier to be successful.80 One approach is to use 
acid-labile chemical bonds to attach therapeutics to a nanocarrier. These bonds are 
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Table 1.1: pH Responsive Linkers and Their Degradation Products84
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constructed so that they  are stable at neutral pH but degrade or hydrolyze in an acidic 
environment, the most common acid-labile linkers employed and their degradation 
products are shown in Table 1.1.84
 Another approach is to incorporate ionizable chemical groups, including amines, 
phosphoric acids, and carboxylic acids. These groups are capable of accepting and 
donating protons based on the environmental pH and can induce physical and chemical 
changes such as swelling, solubility or partition into or across the membrane resulting in 
cargo release.84 Many passive targeting drug delivery systems have been modified with 
various pH-sensitive polymers to add a more specific targeting moiety including 
micelles, nanoparticles, liposomes, hydrogels and dendrimers.84  Many of the micelles, 
liposomes and dendrimers that are modified with pH responsive behavior are crosslinked 
with acid labile linkers so that in the tumor microenvironment, the bonds are degraded 
and the drug is released.85 Both pH responsive nanoparticles and hydrogels are 
developed so that at low pH, they  undergo physical changes that  cause swelling and 
release of drug. Peptides that are fine-tuned to preferentially bind to lipid bilayers at low 
pH have been of great interest. A great deal of interest and research has gone into the 
modification and development of cell penetrating peptides to gain targeting effects. The 
synthetic GALA peptide is such a peptide that was designed to undergo a conformational 
change and partition the membrane for cargo delivery at low pH.86 GALA has also been 
shown to be effective when conjugated to delivery  systems such as, dendrimers and 
liposomes. GALA has been shown to aggregate and arrange as transmembrane helices to 
form aqueous pores in lipid membranes.86 While GALA might not be the ideal peptide 
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for tumor targeting and drug delivery, the pH(Low) Insertion Peptide (pHLIP), 
developed in the Engelman laboratory, has been demonstrated to target tumors in vivo 
and translocate cargo across the plasma membrane in a pH-dependent manner. 
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Chapter 2:
pH(Low) Insertion Peptide (pHLIP)
2.1 Background and Introduction
 The delivery approach herein is based on a unique 36 amino acid peptide derived 
from bacteriorhodopsin (BR), a light driven integral membrane protein that moves 
protons across the membrane and out of the cell in Archea.87 The native tertiary  structure 
of BR is comprised of 7 membrane spanning α-helices, and the aspartic acid residues in 
helix C (residues 72-107) have been shown to play a crucial role in native BR as Asp 85 
acts as a proton acceptor while Asp 96 acts as a proton donor while moving protons 
across the membrane, sequence shown in Figure 2.1 Asp  residues shown in blue.87 When 
the peptides corresponding to each of the helices were studied individually to see 
whether they  could spontaneously reassemble into a functional protein in the presence of 
lipids, it was found that six of the 7 helices are strongly and irreversibly associated to 
membrane vesicle. Helix C, however, was found to be only  weakly associated with 
vesicles at  neutral pH but inserted perpendicularly  into the membrane at lower pH.87,88 
The Asp acid residues allow for this pH based environmental modulation of the peptide 
hydrophobicity.
 Helix C, now referred to as pH(Low) Insertion Peptide (pHLIP), can exist in 
three states (Figure 2.1): At pH above 7, pHLIP is soluble in aqueous environments 
(State I) and it associates with the surface of lipid bilayers as an unstructured peptide 
(State II).  In an acidic environment pHLIP inserts across the lipid bilayer, forming a 
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transmembrane alpha-helix (State III).89,90 This process is thought to be driven by the 
protonation at low pH of the carboxyl groups of one or both of the aspartic acid residues 
present in the transmembrane region (Figure 2.1).  This protonation increases the 
hydrophobicity of the peptide resulting in a higher affinity  for the membrane.87,91 The 
pH-mediated transition can be followed by biophysical methods such as circular 
dichroism and tryptophan fluorescence, occurring with an insertion pH50 (the pH at 
which 50% of peptide is inserted into the membrane) of ~ 6.0 (Figure 2.2).87,92,93 
Furthermore, the insertion has been shown to exhibit unidirectionality  (C-terminus across 
the membrane) and causes minimal membrane disturbance89,91,94. 
2.2 Biophysical Studies
 As is the case with many membrane peptides, pHLIP has the tendency to 
aggregate, especially at higher concentrations and/or lower pHs. The oligomeric state of 
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Figure 2.1 Schematic Representation of pHLIP. Sequence of pHLIP, the hypothesized 
TM region shown in bold and the Asp acid residues important to native BR function and 
that become protonated for insertion shown in blue. At state I pHLIP is soluble and 
unstructured. State II pHLIP associates with the membrane.  State III pHLIP inserts into 
the membrane with an alpha-helical structure. ΔG determined by ITC.90  
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coefficient of 2.44! 0.10 (similar to WT), with pH-dependent
helix formation characteristic of a pHLIP (as confirmed by
CD; Supporting Information, Figure S2). However, the
D25C-3C variant lost the coil-to-helix transition: its CD
signal is already weakly helical at pH 8 and there is no
increase in helicity at pH 4 (Supporting Information, Fig-
ure S2). Compared to State I, its “State II” Trp fluorescence
shows significant increase in intensity and emission lmax blue-
shift (Supporting Information, Figure S2). Further lmax blue-
shift from “State II” to “III” is unusually narrow (5.5 nm for
D25C-3C vs. 8–12 nm for all other variants), and the pH vs.
lmax transition is poorly defined (n= 0.9). Such data indicate
that D25C-3C is not a typical pHLIP, possibly because the
additional methylene group increases the tendency of aggre-
gation. In D25C-2C, the electron withdrawing ability of the
sulfur atom increases side-chain acidity, shifting the pH50
unfavorably down. However, D25C-2C gave hope that its
carbon isostere Asp25Aad would still behave as a pHLIP.
Indeed, Asp25Aad pHLIP has clear coil-to-helix transi-
tion from State II to III (Supporting Information, Figure S1).
More importantly, Asp25Aad has a pH50 of 6.74! 0.14
(Figure 3), closely matching average tumor pHe in vivo.
Asp25Aad is also consistent with the trend observed from
WT to D25E: as the number of methylene groups in the side-
chain increased, the pH50 rose (WT 6.16 to D25E 6.27 to
Asp25Aad 6.74). Since the peptide backbone is electron-
withdrawing, as it became more distant, the innate acidity of
the side-chain carboxylic acid decreased, shifting pH50 up.
When D14 instead of D25 is replaced with Aad, the resulting
Asp14Aad variant has proper pH-dependent insertion (Sup-
porting Information, Figure S3), yet the pH50 is only 6.37!
0.03. Therefore, factors other than the inherent side-chain
pKa, such as the precise location and the polarity of the
protonation environment in State II, also influence the pH50.
The side-chain at position 25 seems to dominate the setting of
pH50.
However, the Hill coefficient of Asp25Aad insertion into
POPC membrane is 1.73! 0.17, lower than that of WT (2.48).
Insertion at neutral pH may hamper the selectivity of pHLIP-
mediated drug delivery. Thus, a sharp pH-response, that is,
insertion over a narrow pH range, is desirable. Engelman and
co-workers postulated that more carboxylic acid residues in
the TM region may increase the insertion cooperativity.[19]
Although their attempts at introducing additional carboxyl
group were not successful, we thought to revisit this hypoth-
esis. First, the Asp14 or Asp25 residue was replaced with
a pair of Glu residues, giving the variants D14EE or D25EE.
CD confirmed that D14EE and D25EE have pH-dependent
coil-to-helix transition characteristic of a pHLIP (Supporting
Information, Figure S3). But to our disappointment, D14EE
has a pH50 of 6.19! 0.04 with a Hill coefficient of 1.41! 0.02
while D25EE has a pH50 of 6.60! 0.14 with a Hill coefficient
of 1.34! 0.26. Both of these variants insert over a wider range
than WT pHLIP (Supporting Information, Figure S3).
Next, the D14 or D25 residue was substituted with the
noncanonical amino acid Gla, which has two carboxyl groups
appended to the g-carbon of the side-chain (Figure 2),
resulting in the variants Asp14Gla or Asp25Gla. Compared
with D14EE and D25EE variants, this modification allows for
more precise introduction of the additional carboxyl group at
locations critical for pHLIP insertion. CD showed that
Asp14Gla and Asp25Gla both have clearly defined pH-
dependent coil-to-helix transition (Supporting Information,
Figures S1 and S3). Asp25Gla turned out to be unremarkable,
with pH50 of 6.20! 0.02 and a Hill coefficient of 1.90! 0.19
(Supporting Information, Figure S3). On the other hand,
Asp14Gla has a pH50 of 6.24! 0.05 but with a transition Hill
coefficient of 3.98! 0.40 (Figure 3). Thus, the Asp14Gla
variant has the sharpest pH response recorded to date for
Figure 3. Trp fluorescence of Asp25Aad, Asp14Gla, and Asp14Gla/
Asp25Aad pHLIP variants, which show improved pH response at the
tumor pHe range of 6.5–7.0. Left column (top to bottom): insertion is
monitored through Trp fluorescence lmax blue-shift (different colors
denote experimental repeats); compared to the WT, the Asp25Aad
insertion shifted to a higher pH range closely matching tumor acidity
but suffers from poor cooperativity; the Asp14Gla variant has strikingly
sharp pH response; the Asp14Gla/Asp25Aad double variant maintains
a high pH50 of 6.8 with cooprativity restored to WT level. Right
column: For the pHLIP variants studied, Trp fluorescence spectra of
State I (black), II (blue), and III (red) show an increase in fluorescence
intensity and lmax blue-shift from State II to State III (that is, pHLIP
insertion into POPC liposome membrane).
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pHLIP has been studied using a variety of techniques including fluorescence, CD 
spectroscopy, size exclusion chromatography, and analytical ultracentrifugation (AUC).89 
 Experiments using size-exclusion chromatography coupled with on-line laser 
light scattering, ultraviolet and refractive index detection (SEC-LS/UV/RI) were done in 
order to determine the mass of pHLIP in solution over a wide range of concentrations.  It 
was shown that over a wide range of concentrations (36-170 µg/mL) pHLIP eluted at a 
mass corresponding to the peptide in the tetrameric state, although since the peptide was 
not completely eluted, the presence of pHLIP monomer could not be ruled out. 
Spectroscopic efforts were utilized with CD, with an observed exciton at a minima of 
232 nm, indicative of aromatic amino acids stacking from peptide aggregation. 
Furthermore, a maxima at 341 nm from tryptophan (trp) fluorescence was reported, 
consistent with tryptophan residues partially buried in the protein interior.89,95 Upon 
dilution,  the CD and trp fluorescence indicated thatpHLIP exhibited a random coil 
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Figure 2.2 pHLIP(WT) Biophysical Assays. (A) Circular dichroism (B) Tryptophan 
fluorescence of the three states of pHLIP.89 (C) Tryptophan fluorescence extrapolated to 
identify pH50 insertion.107
structure fully  exposed to a polar environment.  Ultimately, AUC showed the presence of 
pHLIP monomer in solution at pH 8.0 and concentrations < 30 µg/ mL (~7 µM).89 
 Numerous biophysical assays have been utilized to better understand the 
characteristic behavior of pHLIP. The directionality of insertion was investigated by 
using fluorescence quenching assays of a 4-chloro-7-nitrobenz-2-oxa-1,3 diazole (NBD) 
conjugated to either termini of pHLIP.  Using liposomes with the membrane 
impermeable dithionite ion (S2O4-2) quencher encapsulated within it was found that 
insertion always moves the C-termini across the membrane showing quenching of NBD 
fluorescence when conjugated to the C-terminus. In support  of this observation, when 
NBD is conjugated to the N-terminus, quenching is only observed with the addition of 
dithionite.  These findings are indicative of the inserted pHLIP adopting the native helix 
C topology.91 It  has also been demonstrated that the insertion process is fully  reversible 
as evidenced by  the reproducibility  of titration experiments up and down in pH in both 
lipid vesicles and cells.87,89,91,96
 The inserting C-terminus of pHLIP contains several charged acidic residues 
which could challenge the insertion process if each remains charged, and facilitate the 
process if protonated. It  has been hypothesized that  after insertion these residues 
deprotonate in the cytosolic region and act as a charged anchor to resist insertion 
reversal.97 Truncated variations to the C-terminus have been studied and they exhibit 
much faster clearance in vivo, possibly  due to the loss of retention in an acidic 
environment when the charged intracellular anchor is removed, supporting the 
hypothesis.97,98
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 Importantly, it has been demonstrated that pHLIP does not disrupt the integrity  of 
membrane vesicles, as observed using calcein release and Förster Resonance Energy 
Transfer (FRET) assays, or plasma membranes in cancer cells, as observed using the cell 
impermeable dye SYTOX-orange.89,91,94 In order to monitor whether pHLIP induces lipid 
membrane fusion, two populations of vesicles made of lipids labeled with either NBD or 
Rhodamine and were monitored for mixing usingFörster resonance energy  transfer 
(FRET) experiments upon treatment with pHLIP. No energy transfer was observed 
indicating that pHLIP does not induce liposomal fusion.89 Significantly, lytic response 
against red blood cells (RBCs) was monitored by the release of hemoglobin and no lysis 
was observed up to 10 µM pHLIP treatments either.99 It was noted that pHLIP causes, at 
neutral pH, distortion of the biconcave discoid RBC morphology observed by  the 
formation of spicules. These spicules are likely  due to the area occupied by  pHLIP on the 
outer leaflet, and significantly  decreased upon transition to state III.99 According to a 
membrane insertion scale, which takes together the hydrophobicity and the associated 
ΔG to predict the likeliness of membrane insertion is to occur, it has been shown that a 
protonated form of Asp more readily inserts into a lipid bialyer than the charged state to 
insert into a lipid bilayer.91,100 The partition between states is associated with a release of 
energy and experiments including fluorescence spectroscopy, isothermal titration 
calorimetry (ITC), and acid titration calorimetry were preformed to calculate the 
transition energies.90,96  Parameters such as adsorption constants (K) and Gibbs free 
energies (ΔG) from the transitions between states were determined from Scatchard plots 
obtained from tryptophan fluorescence and ITC experiments.
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90 It  was found that the ΔG associated with the transition from state I to state II is about 
-7.2 kcal/mol and ΔG  of l -1.8 kcal/mol is associated with transition from state II to state 
III upon a drop in pH.90 
 Recently, there has been some controversy over the effect of negatively charged 
lipid head groups on the association with and insertion into the vesicle bilayer. While one 
study reported the absence of state II in the presence of negatively charged lipids (POPG 
and POPE) due to electrostatics, another showed that  the presence of POPS had no effect 
on the initial binding of pHLIP.101,102 Both studies agree on pHLIP insertion upon 
acidification, but they noted differences in the effect on pH50.  One study noted an 
increase in pH50 with the presence of negatively  charged lipids due to the higher 
concentration of protons electrostatically  attracted to the membrane interface which 
mediates the transition of pHLIP from solution to inserted into the bilayer.101 The other 
study described a decrease in pH50 with the presence of POPS due to the change in 
membrane depth of aspartate residues on pHLIP at state II to a shallower position with 
greater hydration.102 The interaction of pHLIP with vesicles containing negatively 
charged lipid head groups is currently being investigated.
2.3 pHLIP Variants
 pHLIP variants have been shown to cover a wide range of properties with the 
objective to tune/improve selectivity and translocation in cultured cells, and tumor 
localization in vivo. Indeed, it is hypothesized that an increased pH50 might be beneficial 
to pHLIP-based drug delivery, as it may match better the tumor microenvironment as 
most solid tumors exhibit an average extracellular pH of about 6.8. However, a lower 
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pH50 may provide better selectivity  in vivo by increasing pHLIP’s sensitivity  to acidic 
environments, thereby  decreasing off-targeted delivery. Several variants of pHLIP (Table 
2.1) have been investigated with the goal to finely tune the behavior, including the pH50 
of insertion, enhancement of the cooperativity  (steepness of pH response, i.e. the pH 
range where the insertion takes place), and improvement of peptide solubility. 
*N/D: Not Determined due to solubility issues 
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Table 2.1 of the Sequences of pHLIP Variants Discussed
Variant Sequence pH50 of Insertion 
WT AAEQNPIYWARYADWLFTTPLLLLDLALLVDADEGTCG 6.1
P20G AAEQNPIYWARYADWLFTTGLLLLDLALLVDADEGTCG 6.8
D14E AAEQNPIYWARYAEWLFTTPLLLLDLALLVDADEGTCG 6.4
D25E AAEQNPIYWARYADWLFTTPLLLLELALLVDADEGTCG 6.5
R11Q GGEQNPIYWAQYADWLFTTPLLLLDLALLVDADEGTCG 5.8
D14Up GGEQNPIYWARYDAWLFTTPLLLLDLALLVDADEGTCG 5.7
D14Down GGEQNPIYWARYAWDLFTTPLLLLDLALLVDADEGTCG 6.2
D25Up GGEQNPIYWARYADWLFTTPLLLDLLALLVDADEGTCG N/D*
D25Down GGEQNPIYWARYADWLFTTPLLLLLDALLVDADEGTCG N/D*
R11Q; D14Up GGEQNPIYWAQYDAWLFTTPLLLLDLALLVDADEGTCG 5.6
R11Q; D14UpUp GGEQNPIYWAQDYAWLFTTPLLLLDLALLVDADEGTCG 5.7
D14Aad GGEQNPIYWARYAAadWLFTTPLLLLDLALLVDADEGTCG 6.4
D25Aad GGEQNPIYWARYADWLFTTPLLLLAadLALLVDADEGTCG 6.7
D14Gla GGEQNPIYWARYAGlaWLFTTPLLLLDLALLVDADEGTCG 6.2
D25Gla GGEQNPIYWARYADWLFTTPLLLLGlaLALLVDADEGTCG 6.2
D14Gla; D25Aad GGEQNPIYWARYAGlaWLFTTPLLLLAadLALLVDADEGTCG 6.8
These properties, when fine tuned should provide a targeting peptide that is capable of 
providing better selectivity thus reducing off target effects, get optimal pHLIP insertion 
in an acidic environment (i.e. increase the effective concentration of therapeutic 
delivered intracellularly), and produce a higher concentration of pHLIP-conjugate to 
reach the tumor in the highly ionic environment in vivo.
 It has been shown that the P20G variant exhibits an increased pH50 due to Gly 
having a higher alpha helical propensity than Pro in a hydrophobic environment.93 The 
P20G variant remains soluble in solution and alpha-helicity  is observed in the presence 
of lipids at neutral pH and intensified when pH is lowered.93 An earlier study looked at 
sequence variations to better understand the behavior of pHLIP, specifically if the 
number of Asp residues have an effect, by either substitution (with Ala or Glu) or the 
addition of an Asp residue. The Ala variants exhibited some secondary structure at 
neutral pH in the presence of lipids and possible aggregation in solution, indicating the 
importance of the Asp to maintain solubility.103 The addition of an Asp (replacement of a 
Thr with Leu and an addition of Leu to make up for hydrophilicity of the added Asp) also 
showed aggregation tendencies at concentrations as low as 3 µM. From this study  two 
variants, D14E and D25E, exhibited no aggregation while maintaining pH dependent 
insertion into liposomes with a greater than WT pH50 (~6.5 vs ~6.0) due to the greater 
hydrophobicity of Glu.103   
 While the previous study investigated the effects of the number of Asp residues in 
the pHLIP sequence, another study looked at whether the position of the Asp have an 
effect on the pH50 by moving each one separately  either up or down one position. 
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Evidence was provided that D14Down, D25Up and D25Down variants all exhibited 
some sort of aggregated state as observed on the CD and Trp fluorescence spectra, 
conversely the D14Up variant maintained similar behavior to WT.104  Another position of 
interest is Arg 11, as it has been reported that arginine has the ability  to raise TM  peptide 
regions towards the polar head group interface (“snorkeling” effects).104-106 To study 
these effects, Arg is substituted with Gln to not perturb the peptide’s overall 
hydrophobicity while maintaining the characteristic insertion behavior. As both the R11Q 
and D14Up variants showed similar properties to WT, variants incorporating both were 
studied, R11Q;D14Up and R11Q;D14UpUp (moved the Asp up two positions). These 
four variants all showed pH50  lower than WT and superior aggregation resistance, 
confirming the idea that the position or depth of Asp in the membrane play a role in 
pH50. This observation is reasonable as Asp’s proton affinity varies based on its position 
in the bilayer where the water profile is uneven.104  
 Further investigation into the 
effects of increasing hydrophobicity 
and charge at the D14 and D25 
positions as conducted using the 
noncanonical amino acids, Ɣ-
carboxyglutamic acid  (Gla) and α-
aminoadipic acid (Aad) (Figure 2.3). The D25Aad variant exhibited state II-III transition 
with a greater pH50 than both WT and D25E (6.74 vs. 6.16 and 6.27, respectively) 
confirming the hypothesis that increased hydrophobicity results in an increased pH50 
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Figure 2.3 Nonconical Amino Acid Structures. 
Structures of (A) Ɣ-carboxyglutamic acid and (B) 
α-aminoadipic acid 
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although a less cooperativity is observed. The D14Aad variant exhibited a pH50 of 6.37 
confirming the dependence of positioning and depth in the bilayer on insertion 
properties.107 The substitution at  either position with Gla maintained insertion behavior, 
but remarkably the the D14Gla variant had the sharpest pH response of any  pHLIP 
variant studied to date, as insertion occurs over a half pH unit as opposed to one pH unit 
for WT.107 The double variant D14Gla; D25Aad was then investigated to see if the 
effects were additive and the pH50 remained high at 6.79 with cooperativity similar to 
WT.107
 Despite their hypothesized benefits, it is difficult  to predict which variant(s) 
would be more efficacious at targeting and delivering cargo molecules to tumor in animal 
settings. It is thus essential to compare these variants head-to-head in multiplexing 
experiments. With this approach, two pHLIP variants (labeled with two different probes) 
can be injected simultaneously, allowing for the imaging of tumor uptake, retention, 
systemic and tumor clearance, and biodistribution of both probes simultaneously in a 
single mouse. These experiments are currently underway. 
  
2.4 Applications and Uses
 Importantly, it has been demonstrated that fluorescently labeled pHLIP is able to 
target tumors and discriminate between cancer and normal tissues in vivo with tumors of 
different origins, varying sizes and at differing stages of growth.99,108-110  The accuracy of 
the targeting ability  of labeled pHLIP was shown using whole-body  near-infrared 
fluorescent images of mice bearing GFP expressing tumors (Figure 2.4). Tumor targeting 
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was observed only 4 hours after injection of an Alexa750-pHLIP construct and persisted 
within the tumor over several days.108 
 Importantly, pHLIP has been shown to target murine small 4T1 mammary 
xenograft tumor, which closely mimic stage IV of human breast  cancer and generates a 
significant level of lactate making it a good model for aggressive tumor.111-115 As shown 
in Figure 2.5, tumor localization of fluorescently  labeled pHLIP occurs within the first 2 
hours, maximizes at 4 hours post injection and persist  through 48 hours with some 
decline in signal with minimal accumulation in the liver, kidney, and muscle.116 When 
small tumors were compared for homogenous distribution to that of larger tumors, the 
smaller tumors exhibit maximal accumulation at the core while minimal signal was 
observed at the necrotic core of the larger tumors.116 In support of many previous 
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Figure 2.4 Whole-Body NIR (Alexa750-pHLIP) and GFP Fluorescence. Fluorescently 
labelled pHLIP was given as a single iv injection (0.8 mg/kg). Tumor indicated by 
arrows. Tumor targeting was observed already after 4 hours after injection of fluorescent 
pHLIP, and peptide stays in tumor during several days. 
imaging studies that have shown that pHLIP 
uniformly labels the entirety of the tumors with no 
adjacent tissue labeling, investigation with transgenic 
mice proved that pHLIPdiscriminates between 
regions of tumor cells and nonmalignant stromal 
tissues.88,109,110,116 Interestingly, the colocalization of 
pHLIP with 2-deoxyglucose, a hypoxia marker 
Pimonidazole and lactate dehydrogenase A (LDHA) 
was studied and, while pHLIP accumulation 
overlaped with each marker, the highest degree 
occurred with LDHA, suggesting pHLIP targeting is 
related to the production of acidic glucose 
metabolites.116
 It has also been shown that pHLIP has 
potential to target 1.5-1.6 times better more 
aggressive tumors than non-aggressive tumors, which 
may be correlated to the differences in pH, ~6.9 vs 
~7.1 respectively.110 As L-amino acid peptides may 
be more susceptible to proteolytic degradation, a 
pHLIP composed of all D-amino acids was 
investigated in vivo and showed similar targeting results, but more accumulation in the 
tumors and/or less in the kidneys which may be attributed to its better stability.99 The 
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Figure 2.5 Distribution of 
pHLIP in small 4T1 mammary 
tumors, muscle kidney  and 
liver.  Fluorescent images 
obtained at 2, 4, 24 and 48 
h o u r s a f t e r i n t r a v e n o u s 
administration of Alexa 546 
conjugated to pHLIP.111
studies that investigated the tumor targeting potential of pHLIP are summarized in Table 
2.2.
Year Modality Model Reference
2007 Fluorescence JC mouse mammary adenocarcinoma in C3D2F1 
mouse and rheumatoid arthritis in rat knee
Andreev et al. 99
2009 Fluorescence GFP-expressing M4A4 human melanoma in 
athymic mouse
Andreev et al. 108
2009 Fluorescence GFP-expressing HeLa tumor in athymic mouse Segala et al. 109
2009 PET PC-3 and LNCaP human prostate carcinoma in 
athymic mouse
Vavere et al. 123
2011 Fluorescence GFP-expressing HeLa tumors, M4A4 and NM2C5 
human melanomas in athymic mouse.  TRAMP 
mouse prostate tumor
Reshetnyak et al. 110
2012 PET PC-3 and LNCaP human prostate carcinoma in 
athymic mouse
Daumer et al. 124
2012 SPECT Lewis lung carcinoma in C57B1/6 mouse Macholl et al. 125
2013 PET SKOV3 human ovarian adenocarcinoma in 
athymic mouse
Emmetiere et al. 126
2013 Fluorescence Influenza virus infected mouse lung Li et al. 127
2013 Fluorescence Human tumor biopsies Loja et al. 128
2013 Fluorescence In situ infarct and ex vivo gloabal low-flow 
myocardial ischemia in mouse
Sosunov et al. 121
2013 Fluorescence GFP-expressing HeLa tumor in athymic mouse Weerakkody et al. 98
2013 Optical GFP-expressing HeLa tumor in athymic mouse Yao et al. 129
2014 Fluorescence 4T1 mouse mammary tumors in BALB/c mouse 
and transgenic mouse mammary tumors
Adochite et al. 111
2014 Fluorescence Luciferase-labeled Capan-2 human pancreatic 
ductal adenocarcinoma in mouse
Cruz-Monserratte et al. 
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Table 2.2 Published reports of imaging agents delivered by pHLIPs to acidic disease 
sites in vivo or ex vivo97
2014 PET PC-3 and LNCaP human prostate carcinoma in 
athymic mouse
Viola-Villegas et al. 131
2014 Fluorescence Human tumor biopsies Luo et al. 132
2014 Fluorescence 4T1 mouse mammary tumors in BALB/c mouse Karabadzhak et al. 133
2015 Fluorescence miR-155 dependent mouse model of lymphoma Cheng et al. 134
2015 Fluorescence MDA-MB-231 human breast cancer in NCr nu/nu 
mouse
Burns et al. 177 & Chapter 
3
2015 Fluorescence S2VP10 and S2013 human pancreatic cell line in 
mouse
Kimbrough et al. 135
 Besides the tumor microenvironment, many other pathological states, such as 
inflammation, ischemia, stroke, arthritis and others are characterized by acidity in the 
extracellular space, which may broaden the potential applications of pHLIP.117-120 
pHLIP has been shown to target areas of inflammatory  arthritis, as demonstrated in a rat 
inflammatory arthritis model, where inflammatory activity was induced in the knee joint. 
It was shown that the fluorescence signal of the arthritic knee joint was 4-5 times greater 
than the control knee.99 In a subsequent study, pHLIP was shown to target  ischemic 
myocardium tissue and not influence its mechanical or electrical activity.121  pHLIP has 
also been shown to discriminate between normal healthy lung tissue to target inflamed 
regions of the lung due to infection of influenza.122
 It has been demonstrated that pHLIP can improve the delivery of nanoparticles 
and liposomes to the tumor microenvironment.121,129,136-139 Importantly, targeting gold 
nanoparticles to cancerous tissue are of particular interest  as they enhance the effects of 
radiation, laser and radiofrequency thermotherapeutics which allows for a higher dose of 
radiotherapy  to be concentrated at  the tumor site.139-142 Toward this end, Davies et al. 
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first established pHLIPs’ ability  to translocate complex luminescent europium coated 
gold nanoparticles up  to 13 nm in size in vitro using optical and electron microscopy 
techniques.137 It has also been demonstrated that pHLIP can improve the delivery of gold 
nanoparticles to tumor sites and extend the retention over several days.139,143-146
 While the majority of reported studies employs pHLIP for imaging purposes, 
only few studies have investigated the efficacy of pHLIP in translocating and releasing 
cargo molecules into the cytoplasm of cancer cells in a pH-dependent manner. For 
example, pHLIP was shown to deliver and release (via the reduction of a linking 
disulfide bond) cell-permeable molecules such as a dansyl dye, a fluorescently labeled 
peptide nucleic acid and the fluorescently labeled cyclic peptide phalloidin.91
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Figure 2.6 Investigation of Cargo Peptides for pHLIP Translocation (A) Structures of 
the cargo peptides (NC)X with the variable positions and fluorescent NBD highlighted. 
(B) Monitoring pHLIP-mediated translocation of NC(Asp)4 and NC(Ser)4 cargo peptides 
(5 µM) into HeLa cells at pH 7.4 (top panels) and pH 6.2 (bottom panels) by  confocal 
microscopy. (C) Table of pHLIP-mediated cargo translocation into liposomes at pH 
4.0147
pHLIP: A Targeting and Delivery Agent
fluorescent 
probe
variable  
positions
Thévenin et al. Chem. Biol. (2009)
cyclic peptide NC(Ser)4 (0.585 mg, 0.79 mmol, 1 eq.) in 340 ml of A, followed
by a solution of pHLIP-Cys (3.6 mg, 0.85 mmol, 1.08 eq.) in 340 ml of A. This
mixture was stirred at room temperature and in the dark for 20 min. To this
reduced mixture, an oxidizing solution of K3Fe(III)CN6 (6 mg, 18.2 mmol,
23.1 eq.) in 60 ml of aqueous NH4HCO3 buffer (200 mM; pH 8) was added.
This reaction mixture was stirred at room temperature for 5 hr, and then
allowed to sit at 0!C for 16 hr. The desired product was isolated via
reverse-phase HPLC (Hewlett Packard Zorbax semi-prep 9.4 3 250 mm
SB-C18 column; flow rate: 2 ml/min; phase A: water + 0.01% TFA; phase
B: acetonitrile + 0.01% TFA; gradient: 70 min from 99:1 A/B to 1:99 A/B).
Lyophilization provided the desired pHLIP-S-S-NC(Ser)4 adduct (0.4 mmol)
in "50% yield. The product was quantified using UV-vis absorbance of the
NBD group (3 280 nm "2,080 M#1cm#1, 3 348 nm "9,800 M#1cm#1, 3 480
nm "26,000 M#1cm#1) and pHLIP peptide (3 280 nm "13,940 M#1cm#1).
MS (MALDI-TOF MS+): molecular weight calculated for pHLIP-S-S-NC(Ser)4
(C223H329N55O71S2): 4980.5. Found (MH
+): 4980.6.
Syntheses of pHLIP-S-S-NC(X)4 Where X = Asp, Asn, or Arg
Other pHLIP-S-S-NC(X)4 conjugates were prepared in similar fashions but
often using a simplified, milder procedure in which the TCEP reduction
step is omitted, thus allowing the use of less oxidizing reagent (K3Fe(III)CN6;
1–1.5 eq.). The desired adducts pHLIP-S-S-NC(X)4 were isolated in 30%–
40% yields. In the case of NC(Arg)4, the reaction proceeded as a heteroge-
neous mixture (perhaps due to aggregation between the multiple positive
charges on NC(Arg)4 and the multiple negative charges on pHLIP). MS
(MALDI-TOF MS+): molecular weight calculated for pHLIP-S-S-NC(Asp)4
(C227H329N55O75S2): 5092.5. Found (MH
+): 5100.6. Molecular weight calcu-
lated for pHLIP-S-S-NC(Asn)4 (C227H333N59O71S2): 5088.6. Found (MH
+):
5084.5.
Syntheses of C-Terminal pHLIP-NBD and N-Terminal
NBD-pHLIP Adducts
To a solution of pHLIP-Cys (3 mg, 0.7 mmol, 1 eq.) or Cys-pHLIP in 900 ml of
argon-saturated aqueous potassium phosphate buffer (100 mM; pH 7.25)
Figure 3. pHLIP Can Translocate Polar Molecules across Lipid Membrane
(A and B) Monitoring dithionite quenching of NBD fluorescence of pHLIP-NC(X)4 constructs (2 mM) in the presence of liposomes at pH 8.0 (A) and pH 4.0 (B). The
arrows indicate the time of addition of the quencher sodium dithionite. The circles indicate the first data point collected after the addition of dithionite.
(C) Monitoring pHLIP-mediated translocation of NC(X)4 cargo peptides (5 mM) into HeLa cells at pH 7.4 (top panels) and pH 6.2 (bottom panels) by confocal
microscopy.
Table 2. Percentage of Protection from Dithionite Quenching of
NBD Fluorescence via pHLIP Insertion-Mediated Cargo
Translocation into Liposomes at pH 4.0
C-Terminal
Cargo
Percentage of
Protectiona
Log Po/w
(pH 4.0)b MW Translocation
NBD 91 ± 9% #0.83 293.3 U
NC(Ser)4 76 ± 8% #2.68 742.7 U
NC(Asp)4 85 ± 7% #2.87 854.8 U
NC(Asn)4 0.4 ± 1.8% #8.52 850.8 X
NC(Arg)4 3 ± 5% #4.34 1025.2 X
a Percentage of Protection is given as mean ± SEM.
b Log Po/w at pH 4.0 is calculated from the fully protonated cyclic peptide
structures.
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Translocation
into ells
cyclic peptide NC(Ser)4 (0.585 mg, 0.79 mm l, 1 eq.) in 340 ml of A, follow d
by a solution of pHLIP-Cys (3.6 mg, 0.85 mmol, 1.08 eq.) in 340 ml of A. This
mixture was stir ed at room temperature and in the dark for 20 min. To this
reduced mixture, a xidizing solution of K3Fe(III)CN6 (6 mg, 18.2 mmol,
23.1 eq.) in 60 ml of aq eous NH4HCO3 buffer (200 mM; pH 8) was adde .
This reaction mixture was stirred at r om temperature for 5 hr, and then
allowed to sit at 0!C fo 16 hr. The desired product was isolated via
reverse-phase HPLC (Hewlett Packard Zorbax semi-prep 9.4 3 250 mm
SB-C18 column; flow rate: 2 ml/min; phase A: water + 0.01% TFA; phase
B: acetonitrile + 0.01% TFA; gradient: 70 min from 99:1 A/B to 1:99 A/B).
Lyophilization provided the desired pHLIP-S-S-NC(Ser)4 adduct (0.4 mmol)
in "50% yield. The pro ct was quantified usi g UV-vis absorbance of the
NBD group (3 280 nm "2,080 M#1cm#1, 3 348 nm "9,800 M#1cm#1, 3 480
nm "26,000 M#1cm#1) and pHLIP peptide (3 280 nm "13,940 M#1cm#1).
MS (MALDI-TOF MS+): molecular weight calculated for pHLIP-S-S-NC(Ser)4
(C223H329N55O71S2): 4980.5. Found (MH
+): 4980.6.
Syntheses of pHLIP-S-S-NC(X)4 Where X = Asp, Asn, or Arg
Other pHLIP-S-S-NC(X)4 conjugates were prepared in similar fashions but
often using a simplified, milder proc dure in which the TCEP reduction
step is omi ted, thus allowing the us of less oxidizing reagent (K3Fe(III)CN6;
1–1.5 eq.). The desired adducts pHLIP-S-S-NC(X)4 were isolated in 30%–
40% yields. In the cas of NC(A g)4, th reaction proceeded as a heteroge-
neous mixture (perhaps due to aggregation b tween the multiple positive
charges on NC(Arg)4 and th multiple negative charges on pHLIP). MS
(MALDI-TOF MS+): molecular weight calculated for pHLIP-S-S-NC(Asp)4
(C227H329N55O75S2): 5092.5. Found (MH
+): 5100.6. Molecular weight calcu-
lated for pHLIP-S-S-NC(Asn)4 (C227H333N59O71S2): 5088.6. Found (MH
+):
5084.5.
Syntheses of C-Terminal pHLIP-NBD and N-Terminal
NBD-pHLIP Adducts
To a solution of pHLIP-Cys (3 mg, 0.7 mmol, 1 eq.) or Cys-pHLIP in 900 ml of
arg n-saturated aque us potassium phosphate buffer (100 mM; pH 7.25)
Figure 3. pHLIP Can Translocate Polar Molecules ac oss Lipid Membrane
(A and B) Monitoring dithionite quenching of NBD fluorescence of pHLIP-NC(X)4 constructs (2 mM) in the presence of liposomes at pH 8.0 (A) and pH 4.0 (B). The
arrows in icate the time of addition of the quencher sodium dithionite. T circles indicate the first d ta point collected after the addition of dithionite.
(C) Monitoring pHLIP-mediated translocation of NC(X)4 cargo peptides (5 mM) into HeLa cells at pH 7.4 (top panels) and pH 6.2 (b tt m panels) by confocal
microscopy.
T ble 2. Percentage of Protect on from Dithionite Quenching of
NBD Fluorescence via pHLIP Insertion-Mediated Cargo
Translocation into Liposomes at pH 4.0
C-Terminal
Carg
Percentage of
rotectiona
Log Po/w
(pH 4.0)b MW Translocation
NBD 91 ± 9% #0.83 293.3 U
NC(Ser)4 76 ± 8% #2.68 742.7 U
NC(Asp)4 85 ± 7% #2.87 854.8 U
NC(Asn)4 0.4 ± 1.8% #8.52 850.8 X
NC(Arg)4 3 ± 5% #4.34 1025.2 X
a Perce tage of Protection is given as mean ± SEM.
b Log Po/w t pH 4.0 is calculated from the fu ly rotonated cyclic peptide
structures.
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y lic eptide NC(Ser)4 (0. 85 mg, 0.79 mmol, 1 eq.) in 340 ml of A, f llowed
by a solution of pHLIP-Cys (3.6 mg, 0.85 mmol, 1.08 eq.) in 340 ml of A. This
mixture was stirred at room temperature and in th dark for 20 min. To this
reduced mixture, an oxidiz ng solution of K3Fe(III)CN6 (6 mg, 18.2 mmol,
23.1 eq.) in 60 ml of aqueous N 4HCO3 buffer (200 mM; pH 8) was ad ed.
This reaction mixture wa stirred at room temper tu e for 5 hr, and then
allowed to sit at 0!C for 16 hr. The desired product was isolated via
r verse-phase HPLC (Hewlett Packard Zorbax semi-prep 9.4 3 250 m
SB-C18 column; flow rate: 2 ml/min; phase A: water + 0.01% TFA; phase
B: acet nitrile + 0.01% TFA; gradient: 70 min from 99:1 A/B to 1:99 A/B).
Lyophilization provi ed the desi ed pHLIP S-NC(Ser)4 adduct (0.4 mmol)
in "50% yield. The product was quantified using UV-vis absorbance of the
NBD group (3 280 nm "2, 80 M#1c #1, 3 348 nm "9,800 M#1c #1, 3 480
nm "26, 00 M#1cm#1) and pHLIP eptide (3 280 nm "13,940 M#1cm#1).
MS (MALDI-TOF MS+): molecular weight calculated for pHLIP S-NC(Ser)4
(C22 H329N55O71S2): 4980.5. Found (MH
+): 4980.6.
Synth es of pHLIP S-NC(X)4 Wh re X = Asp, Asn, or Arg
Other pHLIP S-NC(X)4 conjugates were prepared in s milar f shions but
often using a simplified, milder proc ure in which the TCEP reduction
step is omitted, thus allowing the use of less oxidizing reagent (K3Fe(III)CN6;
–1.5 eq.). The desired adducts pHLIP S-NC(X)4 were isolated in 30%–
40% yields. In the case of NC(Arg)4, th reaction proce d as a heteroge-
neous mixture (p rhaps due to aggregation between the multiple positive
charges on NC(Arg)4 and the multiple negative charges on pHLIP). MS
(MALDI-TOF MS+): molecular weight cal l ted for pHLIP S-NC(Asp)4
(C227H329N55O75S2): 5092.5. Found (MH
+): 5100.6. Molecular weight cal -
lated for pHLIP S-NC(Asn)4 (C227H333N59O71S2): 5088.6. Found (MH
+):
5084.5.
Synth es of C-Terminal pHLIP-NBD and N-Terminal
NBD-pHLIP Adducts
To a solution of pHLIP-Cys (3 mg, 0.7 mmol, 1 eq.) or Cys-pHLIP in 900 ml of
argon-saturated aqueous po assium phos hate buffer (100 mM; pH 7.25)
Figure 3. pHLIP Can Translocate Polar Molecules ac oss Lipid Membrane
(A and B) Monitoring d thionite que ching f NBD fluorescence of pHLIP-NC(X)4 constructs (2 mM) in the pr sence of lip somes at pH 8.0 (A) and pH 4.0 (B). The
arrows indica e the time of addition of the quencher sodium d thionite. The ircles i dica e the first data point collected after the addition of d ionite.
(C) Monitoring pHLIP-mediated translocation of NC(X)4 rgo eptides (5 mM) into HeLa cells at pH 7.4 (to panels) and pH 6.2 (b ttom panels) by confoc l
microscopy.
Table 2. Percentage of Prot ction from Dithionite Quenc ng of
NBD Fluorescence via pHLIP Insertion-Mediat d Cargo
Translocatio into Lip somes at pH 4.0
C-Terminal
Cargo
Perc ntage of
Protectiona
Log Po/w
(pH 4.0)b MW Translo ation
NBD 91 ± 9% #0.83 293.3 U
NC(Ser)4 76 ± 8% #2.68 742.7 U
NC(Asp)4 85 ± 7% #2.87 854.8 U
NC(Asn)4 0.4 ± 1.8% #8.52 850.8 X
NC(Arg)4 3 ± 5% #4.34 1025.2 X
a Percentage of Protection is given as mean ± SEM.
b Log Po/w at pH 4.0 is calculated from the fully pr t nated y lic eptid
structures.
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pHLIP-mediated Translocation of Membrane-impermeable Molecules into Cells
Damien Thévenin, Ming An and Donald M. Engelman
Department of Molecular Biophysics and Biochemistry, Yale University (New Haven, CT 06520) 
Introduction
• One characteristic that distinguish almost all malignant solid tumors from surrounding normal tissues is the lower 
extracellular pH of tumors when compared with healthy tissues (pH 6.5-7.0 vs. pH 7.2-7.4). 
• Our method is based on pHLIP (pH Low Insertion 
Peptide) - a peptide that inserts into lipid bilayers at 
acidic pH. pHLIP can simultaneously target tumors, 
carry the cargo and translocate the payload across the 
plasma membrane at low pH.
• pHLIP is a 36 amino acid peptide derived from the C-
helix of bacteriorhodopsin [1]. At pH above 7, pHLIP is 
soluble as a monomer in aqueous buffers and associate 
with lipid bilayer surfaces. Under acidic conditions, 
pHLIP inserts across a lipid bilayer with an apparent pK 
of 6 in vitro, forming a transmembrane helix (Fig. 1) [1].
• pHLIP insertion seems to be reversible and unidirectional, with its C-terminus translocated across the membrane 
[2,3]. Once inserted, pHLIP helices cause minimal disturbance to phospholipid bilayers: they do not form pores or 
induce membrane permeabilization [2, 4].
• pHLIP can accumulate and persist in vivo in tissues with mildly acidic environments (pH 6.5-7.0), including solid 
tumors in mice and inflammatory foci in rats [5].
• The insertion of pHLIP into lipid bilayers is associated with an energy release. We have established that this energy 
can be used to move cargo molecules across a membrane, raising the possibility of targeted drug delivery [2].
• The goal of the present study is to define the useful range of chemical properties for 
cargo molecules deliverable by pHLIP-mediated translocation.
Figure 1. The three major states of pHLIP. pHLIP’s sequence: 
AAEQNPIYWARYADWLFTTPLLLLLALLVDADEGT. The transmembrane domain is in bold.
• Taken together, notwithstanding the NC(Arg)4 exception, CD 
and fluorescence results indicate that conjugating a NC(X)4 
cargo peptide to pHLIP does not disturb its characteristic 
shape-shifting behavior.
[1] Hunt J et al., Biochemistry 1997, 36 (49), 15177-92. [2] Reshetnyak Y et al., PNAS 2006, Apr 25; 103(17): 6460-5. [3] Reshetnyak YK et al. Biophysical Journal 
2007 (93). [4] Zoonens M et al,. Biophysical Journal 2008, 95, 225-235.[5] Andreev OA et al., PNAS 2007, May 8; 104(19): 7893-8. , 2363-72. [6] Duffy EM and 
Jorgensen WL, J. Am. Chem. Soc. 2000, 122, 2878-2888. [7] Wimley WC and White SH, Biochemistry 1996, Apr 23; 35(16): 5109-24.
Figure 6. pHLIP can translocate polar 
molecules across l ip id membrane. 
Monitoring dithionite quenching of NBD 
fluorescence of pHLIP-NC(X)4 constructs (2 
!M) in the presence of liposomes at pH 8.0 (A) 
and pH 4.0 (B). The arrows indicate the time of 
addition of the quencher sodium dithionite.
• Figure 3A: addition of dithionite leads to rapid, complete quenching of NBD fluorescence of all four NC(X)4 peptides, 
indicating that the C-terminus of pHLIP is located inside the vesicles at pH 4, thus protecting NBD from dithionite 
quenching, while the NC(X) cargos stay outside.
• Figure 3B: Indeed, with the exception of a few dead cells, no fluorescence is observed in the cytoplasm of the cells. 
These cargo peptides do not cross the membrane of HeLa cells when incubated at pH 6.2.
Figure 3. Cargo peptides do not cross lipid membrane on their own. (A) Dithionite quenching of NBD fluorescence signals of the NC(X)4 cargo peptides (2 !M) not attached to pHLIP and of both N-term 
NBD-pHLIP and C-term pHLIP-NBD constructs (2 !M) in the presence of liposomes (peptide:lipid = 1:400) at pH 4.0. The arrows indicate the time of addition of dithionite. (B) Upper panels: NBD fluorescence 
images (excitation at 488 nm) of NC(X)4 cargo peptides in DMSO (5 !M) incubated with HeLa cells at pH 6.2. Lower panels: corresponding phase contrast images. 
(A)
+ dithionite
(B)
pH 6.2 pH 6.2 pH 6.2 pH 6.2
pH 6.2 pH 6.2 pH 6.2 pH 6.2
Methodology
• We chose cyclic hexa-peptides (NBD-Cyclic-(X)4) as model cargo molecules (Fig. 2) in this study, to avoid 
ambiguities that might arise from alternative conformations that linear peptides might adopt.
• The NC(X)4 peptides contain four X positions allowing adjustments of cargo polarity, as shown by their octanol/water 
partition coefficients (Log Po/w) (Fig. 2). These cargo molecules were designed to be quite hydrophilic (Log Po/w < 
-2.5)
• To follow the cargo and test for topology, we included a Lys residue carrying the NBD (7-Nitrobenz-2-Oxa-1,3-
Diazole) fluorescence probe, and to serve as the point of attachment to the carrier pHLIP peptide via a S-S disulfide 
bond we have a SH group.
C-term Cargo
Log Po/w  
(deprotonated)
Log Po/w 
(protonated)
MW
NC(Ser)4 -2.686 -2.686 742.7
NC(Asp)4 -11.92 -2.871* 854.8
NC(Asn)4 -8.525 -8.525 850.8
NC(Arg)4 -4.345 -4.345 1025.2
NBD -0.835 -0.835 293.3
A. Design of cargo molecules
Figure 2: The pHLIP+NC(X)4 construct (2 !M) in 100 mM NaH2PO4, pH 8.0 is incubated at room temperature over-night. POPC vesicles (1:400 peptide/lipid ratio) are added the next day and the mixture is 
incubated at room temperature and in the dark for 3h. pH is then lowered to 4.0. After 30 min equilibration, the fluorescence signal of NBD is monitored at 530 nm when excited at 480 nm. Sodium dithionite 
(S2O42-) is then added to the mix and the fluorescence signal is followed again.
B. Monitoring translocation in presence of lipid vesicles
ABSTRACT (poster # 1351; program # 796.7)
Our goal is to define the properties of cell-impermeable cargo molecules that can be delivered into cells by pHLIP (pH 
(Low) Insertion Peptide), which can selectively target tumors in vivo based on their acidity. Using biophysical methods 
and fluorescence microscopy, we show that pHLIP can successfully deliver polar and membrane-impermeable cyclic 
peptides linked to its C-terminus through the membranes of lipid vesicles and cancer cells. Our results also indicate that 
the translocation of these cargo molecules is pH-dependent and mediated by transmembrane helix formation. Since a 
broad range of cell-impermeable molecules is excluded from discovery efforts because they cannot traverse membranes 
on their own, we believe that pHLIP has the potential to expand therapeutic options for acidic tissues such as tumors and 
sites of inflammation.
Results
A. Cargos are membrane-impermeable
Figure 5. Interactions of pHLIP-cargo constructs with lipid bilayers. Circular dichroism spectra of pHLIP-
cargo variants (7 !M) in the presence of POPC vesicles at pH 8.0 (A) and pH 4.0 (B). (C) Tryptophan 
fluorescence spectra of pHLIP-cargo variants (2 !M) mixed in the presence of POPC vesicles at pH 8.0 (red 
spectra) and at pH 4.0 (blue spectra). The corresponding maxima of fluorescence emission are indicated by 
dotted lines. 
(C)
• Figure 7: NC(Asp)4 and NC(Ser)4 cargos are translocated and released into cell ytoplasms (since the S-S bond that 
conjugates the cargo to pHLIP is cleaved in cells) only when the cells are incubated at pH 6.2. On the other hand, 
pHLIP-NC(Asn)4 and pHLIP-NC(Arg)4 do not deliv r t eir cargos into cell cytoplasms, regardless of the pH.
B. Interaction of pHLIP-cargos with lipid bilayers
C. pHLIP-mediated translocation into liposomes
(B)
(pH 4.0)
(A)
(pH 8.0)
C-term cargo Log P @ pH4 MW
% Protection 
(liposomes)
Translocation 
into cells
NBD -0.84 293.3 91 ± 8.9 % !
NC(Ser)4 -2.69 742.7 75.9 ± 8.1 % !
NC(Asp)4 -2.87 854.8 85.2 ± 6.8 % !
NC(Asn)4 -8.53 850.8 0.4 ± 1.8 % "
NC(Arg)4 -4.35 1025.2 3.0 ± 4.9 % "
Tabl  2. Percentage of protection from dithionite quenching of NBD fluorescence via 
pHLIP insertion mediated cargo translocation into liposomes at pH 4.0.
• Figure 6A: addition of dithionite quenches NBD fluorescence in a rapid and complete fashion for all four pHLIP-NC(X)4 
conjugates, i.e. cargo molecules stay outside of the liposomes and are not translocated across lipid bilayers at neutral 
pH. 
• Figure 6B: near complete protection from dithionite quenching is observed for pHLIP-NBD, pHLIP-NC(Asp)4 and 
pHLIP-NC(Ser)4 conjugates, showing that these three C-terminal cargos, are successfully translocated into or across 
lipid bilayers by pHLIP. On the other hand, for pHLIP-NC(Asn)4 and pHLIP-NC(Arg)4 conjugates, NBD fluorescence are 
completely quenched by dithionite, suggesting that these two conjugates leave their cargos outside of the liposomes 
under acidic conditions.  
Figure 7. pHLIP can translocate polar molecules into the cytoplasm of cancer cells. (A) Monitoring pHLIP-mediated translocation of NC(X)4 cargo peptides (5 !M) into HeLa cells at pH 7.4 
(upper panels) and pH 6.2 (lower panels) by confocal microscopy. (B) Repres ntative ex mple of pHLIP-assisted translocation nd release of cargo molecules into the cytoplasm of HeLa cells. 
Confocal fluorescence microscopy images of pHLIP-NC(Asp)4 (5 !M) incubated in the pr sence of HeLa c lls at pH 6.2. (1) ingl  pr j ction of a z-stack of 15 confocal sections, (2) yz cross 
section (red axis) and (3) xz cross section (blue axis).
(A) (B)
Significance
In conventional drug design aimed at intracellular targets, a constraint has been to create molecules that are sufficiently 
hydrophobic and small to traverse membranes on their own (Log Po/w from -0.4 to +5.6 and MW of 160 to 480 g.mol-1). 
As a result, cell-impermeable molecules are usually excluded. Furthermore, many cancer drugs have off-target side 
effects that severely limit the efficacy of chemotherapy. In this work, we have explored the properties of pHLIP as a 
targeting and delivery system by defining some of the properties of molecules that can be translocated into cells, thus 
establishing boundary conditions for a new arena of drug design using this approach. Our method is based on pHLIP, a 
36 amino-acid peptide that is soluble at physiological pH, and binds to membrane lipid bilayer surfaces if they are 
present. Unlike other strategies, it can simultaneously target tumors, carry the cargo, insert as a transmembrane helix 
and translocate the payload across the plasma membrane at low pH. We find that cargo molecules with Log Po/w of ~ -3 
and molecular weights of ~ 800 are efficiently delivered into cancer cells. Thus, pHLIP may help to expand the chemical 
space for anti-cancer (and anti-inflammatory) drugs to include polar, cell-mpermeable molecules aimed at cytoplasmic 
targets. Because such drug molecules will not easily cross cell membranes in normal tissues, certain of the side effects 
associated with conventional chemotherapy may also be mitigated. 
This work is supported by the National Health Institute grants GM073857 and CA133890, and by an Anna Fuller Fellowship to MA.
• When compared to pHLIP alone, the cyclic peptides NC(Ser)4 and NC(Asp)4 influence greatly the pK of insertion of 
pHLIP from ~6 to ~ 7. This may be due to interaction between the cargos and the Asp residues at the C-term of 
pHLIP, which protonation is believed to be coupled to the insertion process. However, more studies are needed to be 
understand in more details this mechanism.
• We are also investigating the influence of the cargos on the kinetic of insertion by stop-flow fluorescence.
Figure 8. Determining the pK of insertion of pHLIP-NC(Ser)4 and pHLIP-NC(Asp)4 into the membrane of lipid vesicles. Samples (3 !M) are prepared in the presence of liposomes as explained 
above, and "max of Trp emission is monitored (exc. at 295 nm) after lowering the pH with HCl. Average of 2, error bars represent range. Graph for pHLIP is adapted from [1].
D. Influence of cargo on insertion in the membrane of liposomes
pKapp = 6.0 pKapp = 7.15 ± 0.252 pKapp = 6.87 ± 0.233
pHLIP
(A) (B)
(pH 8.0)
(pH 4.0)
• In the ca e of pHLIP-NC(Arg)4, the conjugate seems to 
stick to cell plasma membranes and aggregate on the 
glass window at both pHs, further confirming what we 
observed by CD and Trp fluorescence.
• In the case of pHLIP-NC(Asn)4, we suggest that it is the 
polarity of the cargo (Log Po/w ~ -8.5) that prevents 
pHLIP constructs from inserting across lipid bilayers, 
since its CD and Trp fluorescence data are consistent 
with the notion that this pHLIP conjugate undergoes a 
clear transition from random coil to helix when pH is 
decreased from 8 to 4. 
D. pHLIP-mediated translocation into cancer cells
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( 2 42-) is then added to the ix and the fluorescence signal is follo ed again.
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r  r  f ll-i r l  l l  i  l  fr  i r  ff rt   t  t tr r  r  
 t ir ,  li  t t I   t  t ti l t   t r ti  ti  f r i i  ti    t r   
it  f i fl ti .
i re 5. I teracti s f I -car  c str cts it  li i  ilayers. ircular dichrois  spectra of p LI -
cargo variants (7 ! ) in the presence of  vesicles at p  8.0 ( ) and p  4.0 ( ). ( ) ryptophan 
fluorescence spectra of p LI -cargo variants (2 ! ) ixed in the presence of  vesicles at p  8.0 (red 
spectra) and at p  4.0 (blue spectra). he corresponding axi a of fluorescence e ission are indicated by 
dotted lines. 
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a l  2. ercentage of protection fro  dithionite quenching of  fluorescence via 
p LI  insertion ediated cargo translocation into liposo es at p  4.0.
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l t l    it i it , ti  t t t  t  j t  l  t ir r  t i  f t  li  
r i i  iti .  
i re 7. I  ca  tra sl cate lar lec les i t  t e cyt las  f ca cer cells. ( ) onitoring p LI - ediated translocation of ( )4 cargo peptides (5 ! ) into eLa cells at p  7.4 
(upper panels) and p  6.2 (lo er panels) by confocal icroscopy. ( ) epresentative exa ple of p LI -assisted translocation and release of cargo olecules into the cytoplas  of eLa cells. 
onfocal fluorescence icroscopy i ages of p LI - ( sp)4 (5 ! ) incubated in the pr sence of eLa c lls at p  6.2. (1) ingl  p j ction of a z-s ack of 15 confocal sections, (2) yz cross 
section (red axis) and (3) xz c oss sec ion (blue axis).
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i re 8. eter i i  t e  f i serti  f I - ( er)4 a  I - ( s )4 i t  t e e ra e f li i  vesicles. a ples (3 ! ) are prepared in the presence of liposo es as explained 
above, and "max of rp e ission is onitored (exc. at 295 n ) after lo ering the p  ith l. verage of 2, error bars represent range. raph for p LI  is adapted fro  [1].
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cyclic peptide NC(Ser)4 (0.585 mg, 0.79 mmol, 1 eq.) in 340 ml of A, followed
by a solution of pHLIP-Cys (3.6 mg, 0.85 mmol, 1.08 eq.) in 340 ml of A. This
mixture was stirred at room temperature and in the dark for 20 min. To this
reduced mixture, an oxidizing solution of K3Fe(III)CN6 (6 mg, 18.2 mmol,
23.1 eq.) in 60 ml of aqueous NH4HCO3 buffer (200 mM; pH 8) was added.
This reaction mixture was stirred at room temperature for 5 hr, and then
allowed to sit at 0!C for 16 hr. The desired product was isolate via
reverse-phase HPLC (Hewlett Packard Zorbax semi-prep 9.4 3 250 mm
SB-C18 column; flow rate: 2 l/min; phase A: water + 0.01% TFA; phase
B: acetonitrile + 0.01% TFA; gradient: 70 min from 99:1 A/B to 1:99 A/B).
Lyophilization provided the desired pHLIP-S-S-NC(Ser)4 adduct (0.4 mmol)
in "50% yield. The product was quantified using UV-vis absorbance of the
NBD group (3 280 nm "2,080 M#1cm#1, 3 348 nm "9,800 M#1cm#1, 3 480
nm "26,0 0 M#1c #1) and pHLIP peptide (3 280 nm "13,940 M#1cm#1).
MS (MALDI-TOF MS+): molecular weight calculated for pHLIP-S-S-NC(Ser)4
(C223H329N55O71S2): 4980.5. Found (MH
+): 4980.6.
Syntheses of pHLIP-S-S-NC(X)4 Where X = Asp, Asn, or Arg
Other pHLIP-S-S-NC(X)4 conjugates were prepared in similar fashions but
often using a simplified, milder procedure in which the TCEP reduction
step is omitted, thus allowing the use of less oxidizing reagent (K3Fe(III)CN6;
1–1.5 eq.). The desired adducts pHLIP-S-S-NC(X)4 were isolated in 30%–
40% yields. In the case of NC(Arg)4, the reaction proceeded as a heteroge-
neous mixture (perhaps due to aggregation between the multiple positive
charges on NC(Arg)4 and the multiple negative charges on pHLIP). MS
(MALDI-TOF MS+): molecular weight calculated for pHLIP-S-S-NC(Asp)4
(C227H329N55O75S2): 5092.5. Found (MH
+): 5100.6. Molecular weight calcu-
lated for pHLIP-S-S-NC(Asn)4 (C227H333N59O71S2): 5088.6. Found (MH
+):
5084.5.
Syntheses f C-Termi al pHLIP-NBD an N-Terminal
NBD-pHLIP Adducts
To a solution of pHLIP-Cys (3 mg, 0.7 mmol, 1 eq.) or Cys-pHLIP in 900 ml of
argon-saturated aqueous pota sium phosphate buffer (100 mM; pH 7.25)
Figure 3. pHLIP Can Translocate Polar Molecules across Lipid Membrane
(A and B) Monitoring dithionite quenching of NBD fluorescence of pHLIP-NC(X)4 constructs (2 mM) in the presence of liposomes at pH 8.0 (A) and pH 4.0 (B). The
arrows indicate the time of addition of the quencher sodium dithionite. The circles indicate the first data point collected after the addition of dithionite.
(C) Monitoring pHLIP-mediated translocation of NC(X)4 cargo peptides (5 mM) into HeLa cells at pH 7.4 (top panels) and pH 6.2 (bottom panels) by confocal
microscopy.
Table 2. Percentage of Protection from Dithionite Quenching of
NBD Fluorescence via pHLIP Insertion-Mediated Cargo
Translocation into Liposomes at pH 4.0
C-Terminal
Cargo
Percentage of
Protectiona
Log Po/w
(pH 4.0)b MW Translocation
NBD 91 ± 9% #0.83 293.3 U
NC(Ser)4 76 ± 8% #2.68 742.7 U
NC(Asp)4 85 ± 7% #2.87 854.8 U
NC(Asn)4 0.4 ± 1.8% #8.52 850.8 X
NC(Arg)4 3 ± 5% #4.34 1025.2 X
a Percentage of Protection is given as mean ± SEM.
b Log Po/w at pH 4.0 is calculated from the fully protonated cyclic peptide
structures.
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cyclic peptide NC(Ser)4 (0.585 mg, 0.79 mmol, 1 eq.) in 340 ml of A, followed
by a solution of pHLIP-Cys (3.6 mg, 0.85 mmol, 1.08 eq.) in 340 ml of A. This
mixture was stirred at room temperature and in th dark for 20 min. To this
reduced mixture, an oxidiz ng solution of K3Fe(III)CN6 (6 mg, 18.2 mmol,
23.1 eq.) in 60 ml of aqueous NH4HCO3 buffer (200 mM; pH 8) was added.
This reaction mixture was stirred at room temper tu e for 5 hr, and then
allowed to sit at 0!C for 16 hr. The desired product was isolated via
reverse-phase HPLC (Hewlett Packard Zorbax semi-prep 9.4 3 250 mm
SB-C18 column; flow rate: 2 ml/min; phase A: water + 0.01% TFA; phase
B: acet nitrile + 0.01% TFA; gradient: 70 min from 99:1 A/B to 1:99 A/B).
Lyophilization provided the desi ed pHLIP-S-S-NC(Ser)4 adduct (0.4 mmol)
in "50% yield. The product was quantified using UV-vis absorbance of the
NBD group (3 280 nm "2,080 M#1c #1, 3 348 nm "9,800 M#1c #1, 3 480
nm "26,000 M#1cm#1) and pHLIP peptide (3 280 nm "13,940 M#1cm#1).
MS (MALDI-TOF MS+): molecular weight calculated for pHLIP-S-S-NC(Ser)4
(C223H329N55O71S2): 4980.5. Found (MH
+): 4980.6.
Syntheses of pHLIP-S-S-NC(X)4 Where X = Asp, Asn, or Arg
Other pHLIP-S-S-NC(X)4 conjugates were prepared in similar f shions but
often using a simplified, milder proc ure in which the TCEP reduction
step is omitted, thus allowing the use of less oxidizing reagent (K3Fe(III)CN6;
1–1.5 eq.). The desired adducts pHLIP-S-S-NC(X)4 were isolated in 30%–
40% yields. In the case of NC(Arg)4, th reaction proce d d as a heteroge-
neous mixture (p rhaps due to aggregation between the multiple positive
charges on NC(Arg)4 and the multiple negative charges on pHLIP). MS
(MALDI-TOF MS+): molecular weight cal l ted for pHLIP-S-S-NC(Asp)4
(C227H329N55O75S2): 5092.5. Found (MH
+): 5100.6. Molecular weight cal -
lated for pHLIP-S-S-NC(Asn)4 (C227H333N59O71S2): 5088.6. Found (MH
+):
5084.5.
Synthese of C-Terminal pH IP-NBD a d N-Termi al
NBD-pHLIP Adducts
To a solution of pHLIP-Cys (3 mg, 0.7 mmol, 1 eq.) or Cys-pHLIP in 900 ml of
argon-saturated aqueous po assium phos hate buffer (100 mM; pH 7.25)
Figure 3. pHLIP Can Translocate Polar Molecules ac oss Lipid Membrane
(A and B) Monitoring dithionite que ching f NBD fluorescence of pHLIP-NC(X)4 constructs (2 mM) in the presence of liposomes at pH 8.0 (A) and pH 4.0 (B). The
arrows indicate the time of addition of the quencher sodium dithionite. The circles i dicate the first data point collected after the addition of di ionite.
(C) Monitoring pHLIP-mediated translocation of NC(X)4 rgo peptides (5 mM) into HeLa cells at pH 7.4 (top panels) and pH 6.2 (bottom panels) by confoc l
microscopy.
Table 2. Percentage of Prot ction from Dithionite Quenc ng of
NBD Fluorescence via pHLIP Insertion-Mediat d Cargo
Translocation into Liposomes at pH 4.0
C-Terminal
Cargo
Perc ntage of
Protectiona
Log Po/w
(pH 4.0)b MW Translocation
NBD 91 ± 9% #0.83 293.3 U
NC(Ser)4 76 ± 8% #2.68 742.7 U
NC(Asp)4 85 ± 7% #2.87 854.8 U
NC(Asn)4 0.4 ± 1.8% #8.52 850.8 X
NC(Arg)4 3 ± 5% #4.34 1025.2 X
a Percentage of Protection is given as mean ± SEM.
b Log Po/w at pH 4.0 is calculated from the fully prot nated cyclic peptid
structures.
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cyclic peptide NC(Ser)4 (0.585 mg, 0.79 m l, 1 eq.) in 340 ml of A, followed
by a solution of pHLIP-Cys (3.6 mg, 0.85 mmol, 1.08 eq.) in 340 ml of A. This
mixture was stirred at room temperature and in the dark for 20 min. To this
reduced mixture, an oxidizing solution of K3Fe(III)CN6 (6 mg, 18.2 mmol,
23.1 eq.) in 60 ml of aqueous NH4HCO3 buffer (20 mM; pH 8) was added.
This reaction mixture was stirred at room temperatur for 5 hr, and then
allowed to sit at 0!C for 16 hr. The desired product was isolated via
r v rse-phas HPLC (Hewlett Packar Z rbax semi-prep 9.4 3 250 mm
SB-C18 column; flow rate: 2 ml/min; phase A: water + 0.01% TFA; phase
B: acetonitrile + 0.01% TFA; gradient: 70 min from 99:1 A/B to 1:99 A/B).
Lyophilization provided the desired pHLIP-S-S-NC(Ser)4 adduct (0.4 mmol)
in "50% yield. The product was quantified u ing UV-vis absorbance of the
NBD group (3 280 nm "2,080 M#1cm#1, 3 348 nm "9,800 M#1cm#1, 3 480
nm "26,000 M#1cm#1) and pHLIP peptide (3 280 nm "13,940 M#1cm#1).
MS (MALDI-TOF S+): molecular weight calculated for pHLIP-S-S-NC(Ser)4
(C223H329N55O71S2): 4980.5. Found (MH
+): 4980.6.
Syntheses f pHLIP-S-S-NC(X)4 Where X = Asp, Asn, or Arg
Other pHLIP-S-S-NC(X)4 conjugates were prepared in similar fashions but
often using a simplified, milder proc dure in which the TCEP reduction
step is omitted, thus allowing the use of less oxidizing reagent (K3Fe(III)CN6;
1–1.5 eq.). The desired adducts pHLIP-S-S-NC(X)4 were isolated in 30%–
40% yields. In the case of (Arg)4, the reaction proceeded as a heteroge-
neous mixture (perhaps d to aggr gation betw en th multiple positive
charges on NC(Arg)4 and the multiple negative charges on pHLIP). MS
(MALDI-TOF MS+): molecular weight calculated for pHLIP-S-S-NC(Asp)4
(C227H329N55O75S2): 5092.5. Found (MH
+): 5100.6. Molecular weight calcu-
lated for pHLIP-S-S-NC(Asn)4 (C227H333N59O71S2): 5088.6. Found (MH
+):
5084.5.
Sy these of C-Terminal pHLIP-NBD and N-Terminal
NBD-pHLIP Adducts
To a solutio of pHLIP-Cys (3 mg, 0.7 mmol, 1 eq.) or Cys-pHLIP in 900 ml of
argon-saturated aqueous potassium phosphate buffer (100 mM; pH 7.25)
Figure 3. pHLIP Can Translocate Polar Molecules across Lipid Membrane
(A and B) Monitoring dithionite quenching of NBD fluorescence of pHLIP-NC(X)4 constructs (2 mM) in the presence of liposomes at pH 8.0 (A) and pH 4.0 (B). The
arrows indicate the time of addition of the quencher sodium dithionite. The circles indicate the first data point collected after the addition of dithionite.
(C) Monitoring pHLIP-mediated translocation of NC(X)4 cargo peptides (5 mM) into HeLa cells at pH 7.4 (top panels) and pH 6.2 (bottom panels) by confocal
microscopy.
Table 2. Percentage of Protection from Dithionite Quenching of
NBD Fluorescence via pH IP Insertion Mediated Cargo
Translocation into Liposomes at pH 4.0
C-Terminal
Cargo
Percentage of
Protectiona
Log Po/w
(pH 4.0)b MW Translocation
NBD 91 ± 9% #0.83 29 . U
NC(Ser)4 76 ± 8% #2.68 742.7 U
NC(Asp)4 85 ± 7% #2.87 854.8 U
NC(Asn)4 0.4 ± 1.8% #8.52 850 8 X
NC(Arg)4 3 ± 5% #4.34 1025.2 X
a Percentage of Protection is given as mean ± SEM.
b Log Po/w at pH 4.0 is calculated from the fully protonated cyclic peptide
structures.
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Translocation
into ell
cyclic peptide NC(Ser)4 (0.585 mg, 0.79 mm l, 1 eq.) in 340 ml of A, follow d
by a solution of pHLIP-Cys (3.6 mg, 0.85 mmol, 1.08 eq.) in 340 ml of A. This
mixture was stir ed at room temperature and in the dark for 20 min. To this
reduced mixture, a xidizing solution of K3Fe(III)CN6 (6 mg, 18.2 mmol,
23.1 eq.) in 60 ml of aq eous NH4HCO buffer (200 mM; pH 8) was adde .
Thi r acti n mixture was stirr d at r om t mperature for 5 hr, and then
allowed to sit at 0!C fo 16 hr. The desired product was isolated via
revers -phase HPLC (Hewlett Packard Zorbax semi-prep 9.4 3 250 mm
SB-C18 column; flow rate: 2 ml/min; phase A: water + 0.01% TFA; phase
B: acetonitrile + 0.01% TFA; gradient: 70 min from 99:1 A/B to 1:99 A/B).
Lyophilization provided the desired pHLIP-S-S-NC(Ser)4 a duct (0.4 mmol)
in "50% yield. Th pro ct w s quantified usi g UV-vis absorbance of the
NBD group (3 280 n "2,080 M#1cm#1, 3 348 nm "9,800 M#1cm#1, 3 480
nm "26,000 M#1cm#1) and pHLIP peptide (3 280 nm "13,940 M#1cm#1).
MS (MALDI-TOF MS+): molecular weight calculated for pHLIP-S-S-NC(Ser)4
(C223H329N55O71S2): 4 80.5. Found (MH
+): 4980.6.
Syntheses of pHLIP-S-S-NC(X) Where X = Asp, Asn, or Arg
Other pHLIP-S-S-NC(X)4 conjugates were prepared in similar fashions but
often usi g a simplifi d, milder p oc dure in which the TCEP reduction
step is omi ted, thus allo ing the us of less oxidizing reagent (K3Fe(III)CN6;
1–1.5 eq.). The desired adducts pHLIP-S-S-NC(X)4 were isolated in 30%–
40% yields. In the cas of NC(A g)4, th reaction proceeded as a heteroge-
neou mixture (perhaps du to aggregation b tween the multiple positive
charges on NC(Arg)4 and th multiple negative charges on pHLIP). MS
(MALDI-TOF MS+): molecular weight calculated for pHLIP-S-S-NC(Asp)4
(C 27H32 N55O75S2): 092.5. Found (MH
+): 5100.6. Molecular weight calcu-
lated for pHLIP-S-S-NC(Asn)4 (C227H333N59O71S2): 5088.6. Found (MH
+):
5084.5.
Synthe es of C-Terminal pHLIP-NBD and N-Terminal
NBD-pHLIP Adducts
To a solution of pHLIP-Cys (3 mg, 0.7 mmol, 1 eq.) or Cys-pHLIP in 900 ml of
arg n-saturated aque us potassium phosphate buffer (100 mM; pH 7.25)
Figure 3. pHLIP Can Translocate Polar Molecules ac oss Lipid Membrane
(A and B) Monitoring dithionite quenching of NBD fluorescence of pHLIP-NC(X)4 constructs (2 mM) in the presence of liposomes at pH 8.0 (A) and pH 4.0 (B). The
arrows in icate the time of addition of the quencher sodium dithionite. T circles indicate the first d ta point collected after the addition of dithionite.
(C) Monitoring pHLIP-mediated translocation of NC(X)4 cargo peptides (5 mM) into HeLa cells at pH 7.4 (top panels) and pH 6.2 (b tt m panels) by confocal
microscopy.
T ble 2. Percentage of Protect on from Dithionite Quenching of
NBD Fluorescence via pHLIP Insertion-Mediat d Carg
T anslocati n into Lip some a pH 4.0
C-Terminal
Carg
Percentage of
Protectiona
Log Po/w
(pH 4.0)b MW Translocation
NBD 91 ± 9 #0.83 293.3 U
NC(Ser)4 76 ± 8% #2.68 742.7 U
NC(Asp)4 85 ± 7% #2.87 854.8 U
NC(Asn)4 0.4 ± 1.8% #8.52 850.8 X
NC(Arg)4 3 ± 5% #4.34 1025.2 X
a Perce tag of Protection is given as mean ± SEM.
b Log Po/w t pH 4.0 is calculated from the fu ly rotonated cyclic peptide
structures.
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y lic eptide NC(Ser)4 (0. 85 mg, 0.79 mmol, 1 eq.) in 340 ml of A, f llowed
by a solution of pHLIP-Cys (3.6 mg, 0.85 mmol, 1.08 eq.) in 340 ml of A. This
mixture was stirred at room temperature and in th dark for 20 min. To this
reduced mixture, an oxidiz ng solution of K3Fe(III)CN6 (6 mg, 18.2 mmol,
23.1 eq.) in 60 ml of aqueous N 4HCO3 buffer (20 mM; pH ) was ad ed.
This reaction mixture wa stirred at ro m t per tu e for 5 hr, and then
allowed to sit at 0!C for 16 hr. The desired product was isolated via
r v rse-phas HPLC (Hewlett Packard Zorbax semi-prep 9.4 3 250 m
SB-C18 column; flow rate: 2 ml/min; phase A: water + 0.01% TFA; phase
B: acet nitrile + 0.01% TFA; gradient: 70 min from 99:1 A/B to 1:99 A/B).
Lyophilization provi ed the desi ed pHLIP S-NC(Ser)4 adduct (0.4 mmol)
in "50% y eld. The produc as quan ified using UV-vis absorbance f the
NBD gr up (3 28 m "2, 80 M#1cm#1, 3 348 nm "9,800 M#1c #1, 3 480
nm "26, 00 M#1cm#1) and pHLIP eptide (3 280 nm "13,940 M#1cm#1).
MS (MALDI-TOF MS+): molecular weight calculated for pHLIP S-NC(Ser)4
(C22 H329N55O71S2): 498 .5. Found (MH
+): 498 .6
Synth e of pHLIP S-N (X)4 Wh r X = Asp, Asn, or Arg
Other pHLIP S-NC(X)4 conjugates were prepared in s milar f shions but
often using a simplified, milder p oce ure i which the TCEP reduction
step is omitted, thus allowing the use of less oxidizing reagent (K3Fe(III)CN6;
–1.5 eq.). The desired adducts pHLIP S-NC(X)4 were isolated in 30%–
40% yields. In the case of NC(Arg)4, th reaction proce d as a heteroge-
n ous mixt re ( rhaps du to aggregation between the multiple positive
charges on NC(Arg)4 and the multiple negative charges on pHLIP). MS
(MALDI-TOF MS+): molecular weight cal l ted for pHLIP S-NC(Asp)4
(C227H329N55O75S ): 5092.5. Found (MH
+): 51 0. Molecular weight cal -
lated for pHLIP S-NC(Asn)4 (C227H333N59O71S2): 5088.6. Found (MH
+):
5084.5.
Synth es f C-Ter inal pHLIP-NBD and N-Termi al
NBD-pHLIP Add cts
To a solution of pHLIP-Cys (3 mg, 0.7 mmol, 1 eq.) r Cys-pHLIP in 900 ml of
argon-saturated aqueous po assium phos hate buffer (100 mM; pH 7.25)
Figure 3. pHLIP Can Translocate Polar Molecules ac oss Lipid Membrane
(A and B) Monitoring d thionite que ching f NBD fluorescence of pHLIP-NC(X)4 constructs (2 mM) in the pr sence of lip somes at pH 8.0 (A) and pH 4.0 (B). The
arrows indica e the time of addition of the quencher sodium d thionite. The ircles i dica e the first data point collected after the addition of d ionite.
(C) Monitoring pHLIP-mediated translocation of NC(X)4 rgo eptides (5 mM) into HeLa cells at pH 7.4 (to panels) and pH 6.2 (b ttom panels) by confoc l
microscopy.
Table 2. Percentage of Prot ction from Dithionite Quenc ng of
NBD Fluorescence via pH IP Insertion-Mediat d Cargo
Translocatio into Lip somes at pH 4.0
C-Terminal
Cargo
Perc ntage of
Protectiona
Log Po/w
(pH 4.0)b MW Translocation
NBD 91 ± 9% #0.83 293.3 U
NC(Ser)4 76 ± 8% #2.68 742.7 U
NC(Asp)4 85 ± 7% #2.87 854.8 U
NC(Asn)4 0.4 ± 1.8% #8.52 850.8 X
NC(Arg)4 3 ± 5% #4.34 1025.2 X
a Percentage of Protection is given as mean ± SEM.
b Log Po/w at pH 4.0 is calculated from the fully pr t nated y lic eptid
structures.
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Damien Thévenin, Ming An and Donald M. Engelman
Department of Molecular Biophysics and Biochemistry, Yale University (New Haven, CT 06520) 
Introduction
• One characteristic that distinguish almost all malignant solid tumors from surrounding normal tissues is the lower 
extracellular pH of tumors when compared with healthy tissues (pH 6.5-7.0 vs. pH 7.2-7.4). 
• Our method is based on pHLIP (pH Low Insertion 
Peptide) - a peptide that inserts into lipid bilayers at 
acidic pH. pHLIP can simultaneously target tumors, 
carry the cargo and translocate the payload across the 
plasma membrane at low pH.
• pHLIP is a 36 amino acid peptide derived from the C-
helix of bac eriorhodopsin [1]. At pH above 7, pH IP is 
soluble as a monomer in aqueous buffers and associate 
with lipid bilayer surfaces. Under acidic conditions, 
pHLIP inserts across a lipid bilayer with an apparent pK 
of 6 in vitro, forming a transmembrane helix (Fig. 1) [1].
• pHLIP insertion seems to be reversible and unidirectional, with its C-terminus translocated across the membrane 
[2,3]. Once inserted, pHLIP helices cause minimal disturbance to phospholipid bilayers: they do not form pores or 
induce membran  permeabilization [2, 4].
• pHLIP can accumulate and persist in vivo in tissues with mildly acidic environments (pH 6.5-7.0), including solid 
tumors in mice and inflammatory foci in rats [5].
• The insertion of pHLIP into lipid bilayers is associated with an energy release. We have established that this energy 
can be used to move cargo molecules across a membrane, raising the possibility of targeted drug delivery [2].
• The goal of the present study is to define the useful range of chemical properties for 
cargo molecules deliverable by pHLIP-mediated translocation.
Figure 1. The three major states of pHLIP. pHLIP’s sequence: 
AAEQNPIYWARYADWLFTTPLLLLLALLVDADEGT. The transmembrane domain is in bold.
• Taken together, notwithstanding the NC(Arg)4 exception, CD 
and fluorescence results indicate that conjugating a NC(X)4 
cargo peptide to pHLIP does not disturb its characteristic 
shape-shifting behavior.
[1] Hunt J et al., Biochemistry 1997, 36 (49), 15177-92. [2] Reshetnyak Y et al., PNAS 2006, Apr 25; 103(17): 6460-5. [3] Reshetnyak YK et al. Biophysical Journal 
2007 (93). [4] Zoonens M et al,. Biophysical Journal 2008, 95, 225-235.[5] Andreev OA et al., PNAS 2007, May 8; 104(19): 7893-8. , 2363-72. [6] Duffy EM and 
Jorgensen WL, J. Am. Chem. Soc. 2000, 122, 2878-2888. [7] Wimley WC and White SH, Biochemistry 1996, Apr 23; 35(16): 5109-24.
Figure 6. pHLIP can translocate polar 
molecules across l ip id membrane. 
Monitoring dithionite quenching of NBD 
fluorescence of pHLIP-NC(X)4 constructs (2 
!M) in the presence of liposomes at pH 8.0 (A) 
and pH 4.0 (B). The arrows indicate the time of 
addition of the quencher sodium dithionite.
• Figure 3A: addition of dithionite leads to rapid, complete quenching of NBD fluorescence of all four NC(X)4 peptides, 
indicating that the C-terminus of pHLIP is located inside the vesicles at p  4, thus protecting NBD from dithionite 
quenching, while the NC(X) cargos stay outside.
• Figure 3B: Indeed, with the exception of a few dead cells, no fluore c nc  s observed in the cytoplasm of the cells. 
These cargo peptides do not cross the membrane of HeLa cells when incubated at pH 6.2.
Figure 3. Cargo peptides do not cross lipid membrane on their own. (A) Dithionite quenching of NBD fluorescence signals of the NC(X)4 cargo peptides (2 !M) not attached to pHLIP and of both N-term 
NBD-pHLIP and C-term pHLIP-NBD constructs (2 !M) in the presence of liposomes (peptide:lipid = 1:400) at pH 4.0. The arrows indicate the time of addition of dithionite. (B) Upper panels: NBD fluorescence 
images (excitation at 488 nm) of NC(X)4 cargo peptides in DMSO (5 !M) incubated with HeLa cells at pH 6.2. Lower panels: corresponding phase contrast images. 
(A)
+ dithionite
(B)
pH 6.2 pH 6.2 pH 6.2 pH 6.2
pH 6.2 pH 6.2 pH 6.2 pH 6.2
Methodology
• We chose cyclic hexa-peptides (NBD-Cyclic-(X)4) as model cargo molecules (Fig. 2) in this study, to avoid 
ambiguities that might arise from alternative conformations that linear peptides might adopt.
• The NC(X)4 peptides contain four X positions allowing adjustments of cargo polarity, as shown by their octanol/water 
partition coefficients (Log Po/w) (Fig. 2). These cargo molecules were designed to be quite hydrophilic (Log Po/w < 
-2.5)
• To follow the cargo and test for topology, we included a Lys residue carrying the NBD (7-Nitrobenz-2-Oxa-1,3-
Diazole) fluorescence probe, and to serve as the point of attachment to the carrier pHLIP peptide via a S-S disulfide 
bond we have a SH group.
C-term Cargo
Log Po/w  
(deprotonated)
Log Po/w 
(protonated)
MW
NC(Ser)4 -2.686 -2.686 742.7
NC(Asp)4 -11.92 -2.871* 854.8
NC(Asn)4 -8.525 -8.525 850.8
NC(Arg)4 -4.345 -4.345 1025.2
NBD -0.835 -0.835 293.3
A. Design f argo molecules
Figure 2: The pHLIP+NC(X)4 construct (2 !M) in 100 mM NaH2PO4, pH 8.0 is incubated at room temperature over-night. POPC vesicles (1:400 peptide/lipid ratio) are added the next day and the mixture is 
incubated at room temperature and in the dark for 3h. pH is then lowered to 4.0. After 30 min equilibration, the fluorescence signal of NBD is monitored at 530 nm when excited at 480 nm. Sodium dithionite 
(S2O42-) is then added to the mix and the fluorescence signal is followed again.
B. Monitoring translocation in presence of lipid vesicles
ABSTRACT (poster # 1351; program # 796.7)
Our goal is to define the properties of cell-impermeable cargo molecules that can be delivered into cells by pHLIP (pH 
(Low) Insertion Peptide), which can selectively target tumors in vivo based on their acidity. Using biophysical methods 
and fluorescence microscopy, we show that pHLIP can successfully deliver polar and membrane-impermeable cyclic 
peptides linked to its C-terminus through the membranes of lipid vesicles and cancer cells. Our results also indicate that 
the translocation of these cargo molecules is pH-dependent and mediated by transmembrane helix formation. Since a 
broad range of cell-impermeable molecules is excluded from discovery efforts because they cannot traverse membranes 
on their own, we beli ve that pHLIP has the potenti l to expand therapeutic options for acidic tissues such as tumors and 
sites of inflammation.
Results
A. Cargos are membrane-impermeable
Figure 5. Interactions of pHLIP-cargo constructs with lipid bilayers. Circular dichroism spectra of pHLIP-
cargo variants (7 !M) in the presence of POPC vesicles at pH 8.0 (A) and pH 4.0 (B). (C) Tryptophan 
fluorescence spectra of pHLIP-cargo variants (2 !M) mixed in the presence of POPC vesicles at pH 8.0 (red 
spectra) and at pH 4.0 (blue spectra). The corresponding maxima of fluorescence emission are indicated by 
dotted lines. 
(C)
• Figure 7: NC(Asp)4 and NC(Ser)4 c rgos ar  translocated and released into cell ytoplasms (since the S-S bond that 
conjugates the cargo to pHLIP is cleav d i  c lls) only when th  cells are incubat d at pH 6.2. O  th  oth r h nd, 
pHLIP-NC(Asn)4 and HLIP-NC(Arg)4 d  t deliv r t eir cargos into cell cyt plasms, regardless of the pH.
B. Interaction of pHLIP-cargos with lipid bilayers
C. pHLIP-mediated translocation into liposomes
(B)
(pH 4.0)
(A)
(pH 8.0)
C-term cargo Log P @ pH4 MW
% Protection 
(liposomes)
Translocation 
into cells
NBD -0.84 293.3 91 ± 8.9 % !
NC(Ser)4 -2.69 742.7 75.9 ± 8.1 % !
NC(Asp)4 -2.87 854.8 85.2 ± 6.8 % !
NC(Asn)4 -8.53 850.8 0.4 ± 1.8 % "
NC(Arg)4 -4.35 1025.2 3.0 ± 4.9 % "
Tabl  2. Percentage of protection from dithionite quenching of NBD fluorescence via 
pHLIP insert on mediated cargo translocation into lip somes at pH 4.0.
• Figure 6A: addition of dithionite quenches NBD fluorescence in a rapid and complete fashion for all four pHLIP-NC(X)4 
conjugates, i.e. cargo molecules stay outside of the liposomes and are not translocated across lipid bilayers at neutral 
pH. 
• Figure 6B: near complete protection from dithionite quenching is observed for pHLIP-NBD, pHLIP-NC(Asp)4 and 
pHLIP-NC(Ser)4 conjugates, showing that these three C-terminal cargos, are successfully translocated into or across 
lipid bilayers by pHLIP. On the other hand, for pHLIP-NC(Asn)4 and pHLIP-NC(Arg)4 conjugates, NBD fluorescence are 
completely quenched by dithionite, suggesting that these two conjugates leave their cargos outside of the liposomes 
under acidic conditions.  
Figure 7. pHLIP can translocate polar molecules into the cytoplasm of cancer cells. (A) Monitoring pHLIP-mediated translocation of NC(X)4 cargo peptides (5 !M) into HeLa cells at pH 7.4 
(upper panels) nd pH 6.2 (lower panels) by confocal microscopy. (B) Repres ntative ex mple of pHLIP-assisted translocation nd release of cargo molecules into the cytoplasm of HeLa cells. 
Confocal fluorescence mi r scopy images of pHLIP-NC(Asp)4 (5 !M) incubated in the pr sence of HeLa c lls at pH 6.2. (1) ingl  pr j ction of a z-stack of 15 confocal sections, (2) yz cross 
section (red axis) and (3) xz cross section (blue xis).
(A) (B)
Significance
In conventional drug design aimed at intracellular targets, a constraint has been to create molecules that are sufficiently 
hydrophobic and small to traverse membranes on their own (Log Po/w fro  -0.4 to +5.6 and MW of 160 to 480 g.mol-1). 
As a result, cell-impermeable molecules are usually excluded. Furthermore, many cancer drugs have off-target side 
effects that severely limit the efficacy of ch motherapy. In this work, we have explored the properties of pHLIP as a 
targeting and delivery system by defining some of the properties of molecules that can be translocated into cells, thus 
establishing boundary conditions for a new arena of drug design using this approach. Our method is based on pHLIP, a 
36 amino-acid peptide that is soluble at physiological pH, and binds to membrane lipid bilayer surfaces if they are 
present. Unlike other strategies, it can simultaneously target tumors, carry the cargo, insert as a transmembrane helix 
and translocate the payload across the plasma membrane at low pH. We find that cargo molecules with Log Po/w of ~ -3 
and molecular weights of ~ 800 are efficiently delivered into cancer cells. Thus, pHLIP may help to expand the chemical 
space for anti-cancer (and anti-inflammatory) drugs to include polar, cell-mpermeable molecules aimed at cytoplasmic 
targets. Because such drug molecules will not easily cross cell membranes in normal tissues, certain of the side effects 
associated with conventional chemotherapy may also be mitigated. 
This work is supported by the National Health Institute grants GM073857 and CA133890, and by an Anna Fuller Fellowship to MA.
• When compared to pHLIP alone, the cyclic peptides NC(Ser)4 and NC(Asp)4 influence greatly the pK of insertion of 
pHLIP from ~6 to ~ 7. This may be due to interaction between the cargos and the Asp residues at the C-term of 
pHLIP, which protonation is believed to be coupled to the insertion process. However, more studies are needed to be 
understand in more details this mechanism.
• We are also investigating the influence of the cargos on the kinetic of insertion by stop-flow fluorescence.
Figure 8. Determining the pK of insertion of pHLIP-NC(Ser)4 and pHLIP-NC(Asp)4 into the membrane of lipid vesicles. Samples (3 !M) are prepared in the presence of liposomes as explained 
above, and "max of Trp emission is monitored (exc. at 295 nm) after lowering the pH with HCl. Average of 2, error bars represent range. Graph for pHLIP is adapted from [1].
D. Influence of cargo on insertion in the membrane of liposomes
pKapp = 6.0 pKapp = 7.15 ± 0.252 pKapp = 6.87 ± 0.233
pHLIP
(A) (B)
(pH 8.0)
(pH 4.0)
• In the ca e of pHLIP-NC(Arg)4, the c nj gate s ems to 
stick to cell plasma membranes and aggregate on the 
glass window at both pHs, further confirming what we 
observed by CD and Trp fluorescence.
• In the case of pHLIP-NC(Asn)4, we suggest that it is the 
polarity of the cargo (Log Po/w ~ -8.5) that prevents 
pHLIP constructs from insertin  across lipid bilayers, 
since its CD and Trp fluorescen  data are consistent 
with the notion that this pHLIP conjugate undergoes a 
clear transition from random coil to helix when pH is 
decreased from 8 to 4. 
D. pHLIP-mediated translocation into cancer cells
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 In another study, it  was shown that pHLIP can translocate and release cell-
impermeable model cyclic peptides with varying polarities (Figure 2.6) into cancer cells.
147 This study was the first to investigate systematically the polarity, charge and size of 
cargo that pHLIP may be able to translocate.  Thus, pHLIP may help to expand the 
chemical space for anti-cancer drugs to include polar, cell-impermeable molecules aimed 
at cytoplasmic targets, which are usually excluded from discovery efforts because they 
cannot traverse membranes on their own. Because such drug molecules will not easily 
cross cell membranes in normal tissues, certain side effects associated with conventional 
chemo-therapy may also be mitigated. 
 Prior to the efforts in this thesis, pHLIP had been tested as a drug delivery 
vehicle: Several studies showed that pHLIP facilitates the translocation of phalloidin, a 
cell-impermeable polar toxin, which leads to the inhibition of the proliferation of 
cultured cancer cells in a pH-dependent fashion.91,138,148 However, the anti-proliferative 
effect was observed only when a hydrophobic facilitator (rhodamine) was attached to the 
peptide inserting end91 or when the hydrophobicity of phalloidin was tuned by  adding 
hydrocarbon chains of different length to facilitate translocation.22 A summary  of 
therapeutic cargo that pHLIP has been found to translocate is shown in Table 2.2.
Year Agent Model Reference
2006 Phalloidin-TRITC In vitro cultures of HeLa, TRAMP mouse prostate 
adenocarcinoma and JC mouse mammary 
adenocarcinoma
Reshetnyak et al.91
2010 Aminophalloidin In vitro cultures of HeLa, JC mouse mammary 
adenocarcinoma and M4A4 human melanoma 
cells
An et al.148
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Table 2.3 Intracellular delivery of therapeutic cargos by pHLIP97
2011 Phallacidin In vitro cultures of HeLa cells Wijesinghe et al.22
2013 α-Amanitin In vitro cultures of HeLa, M4A4 human 
melanoma, U2OS human osteosarcoma and 
MDA-MB-231 human breast carcinoma cells
Moshnikova et al.151
2013 Liposomal 
ceramide
In vitro cultures of HeLa and A549 human lung 
carcinoma cells
Yao et al.139
2013 Liposomal 
Gramicidin A
In vitro cultures of HeLa, M4A4 human 
melanoma and A549 human lung carcinoma cells
Wijesinghe et al.138
2015 Anti-miR-155 PNA Mouse model of miR-155 addicted large B-cell 
lymphoma
Cheng et al.134
2015 Paclitaxel In vitro cultures of A549 human lung carcinoma 
cells
Onyango et al.107
2015 Auristatin: MMAE In vitro cultures of HeLa and MDA-MB-231 
breast carcinoma cells
Burns et al.177 & 
Chapter 3
2015 Doxorubicin In vitro cultures of MCF7 breast carcinoma cells Song et al.152
2015 truncated tissue 
factor (tTF)
MDA-MB-231 human breast cancer-bearing nude 
mice
Li et al.153
2015 Antagonist PAR1 
peptide mimic
In vitro cultures of HeLa, MCF7, PAR1 
transfected MCF7 and MDA-MB-231 breast 
carcinoma cells
Burns et al.181 & 
Chapter 4
2016 Antimicrobial 
Peptides
In vitro cultures of MDA-MB-231 breast 
carcinoma cells
Unpublished data 
Chapter 5
2016 Auristatin: MMAF In vitro cultures of HeLa cells Unpublished data 
Chapter 3
 Coinciding with the works described herein, several other studies were done 
employing pHLIP for the delivery of relevant therapeutics, including Paclitaxel and 
Doxorubicin.  An investigation of particular interest showed success with the delivery of 
peptide nucleic acids (PNAs) anti-microRNA to depress gene expression.  The target in 
this study was miR-155 as its over-expression occurs in many cancers and is able to 
induce the development of lymphomas.134,149,150  Treatment of pHLIP-anti-miR-155 in 
mice resulted in a significant decrease in subcutaneous lymphoma, survival advantage 
was demonstrated and metastatic spread to other organs was inhibited.134
 Importantly, these studies show that the entry of pHLIP into the membrane and 
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the translocation of molecules is not mediated by endocytosis, cell receptor interactions, 
or by the formation of pores within the membrane. Rather, it is the energy release 
associated with the transmembrane helix formation (~2 kcal/mole) that can be used to 
translocated cargo molecules across the lipid bilayer. Thus, pHLIP offers a completely 
novel method of homing anti-cancer agents specifically to tumor sites by simultaneously 
targeting tumors, carrying the cargo, and translocating the payload across the cell 
membrane at low pH.  
 Since peptide synthesis is central to all projects described herein, it was 
advantageous for our lab to develop  an expertise in peptide chemistry. It now gives us 
great independence and flexibility  (at lower costs) in the synthesis and purification of all 
the peptide variants needed for our studies. Automated peptide synthesizers tend not 
afford high yields and many  truncations are observed making the purification much more 
challenging. Remarkably, to the best of our knowledge, our group is the first and only lab 
to have optimized the synthesis and purification of pHLIP rather than purchasing it form 
commercial sources that use automated methods.  
 
2.5 Synthesis of pHLIP
 pHLIP is prepared by  standard Fluorenylmethyloxycarbonyl (Fmoc) Solid Phase 
Peptide Synthesis (SPPS). After the first amino acid has been loaded onto a resin (the 
peptide is synthesized from the C-term to the N-term end), subsequent amino acid 
residues are added through repeated cycles of deprotection and coupling steps. In our 
first synthetic strategy, we used the HMPB-ChemMatrix resin (PCAS BioMatrix), which 
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employs a 4-(4-Hydroxymethyl-3-
methoxyphenoxy) butyric acid linker 
and results in a carboxylic acid on the 
C-terminus of the peptide upon final 
cleavage results. However, this 
synthesis scheme resulted in many 
peptide truncations (as shown in Figure 
2.7) and, consequently, in extremely low 
final yield. The final cleaved product 
was also poorly soluble under normal purification methods. 
 Thus, we decided to modify our synthesis by double or triple coupling some 
residues in difficult regions (i.e., after residues that have secondary amines and that 
contain big bulky protecting groups, and also as the peptide got longer) to ensure 
complete coupling, and by introducing an amide on the C-terminal end, a modification 
that had never been tested. We hypothesized that  this modification would simplify (i.e., 
no esterification of the C-terminal residue required) and facilitate synthesis by increasing 
the solubility  of the final product. We also hypothesized that the α-helix formation of 
pHLIP at  low pH and consequently the insertion into the membrane would not be 
effected by  the C-term amide.  Toward this end, we used the H-Rink Amide ChemMatrix 
resin instead of the HMPB-ChemMatrix. This design resulted in less peptide truncations 
and higher yield than obtained with the previous strategy (Figure 2.8). The resulting 
pHLIP amide peptide was purified to >95% via Reverse Phase High Performance Liquid 
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Figure 2.7 HPLC of pHLIP crude final 
cleaved product of pHLIP with carboxy  C-
terminus 
Chromatography (RP-HPLC) on a C8 
preparatory column, eluting at 69% 
acetonitrile. The identity of the peptide 
was established using Matrix Assisted 
Laser Desorption Ionization-Time Of 
Flight Mass Spectrometry (MALDI-
TOF MS) (Appendix 2.1). The sequence 
has since been modified to contain a 
Cys residue at the C-terminus. 
Subsequent synthetic batches with 
further optimization of double and 
triplicate couplings, longer coupling 
steps with meticulous washing steps 
affords final crude peptide with almost 
no t runca t ions and a ids in the 
purification process (Figure 2.9).  Thus, 
synthesis and purification of pHLIP and variants  (Appendix 2.2) are now conducted 
with ease in the laboratory.  
 Far UV circular dichroism (CD) and tryptophan fluorescence measurements in 
presence of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) large unilamellar 
vesicles (LUV) at normal and low pHs were performed to monitor the insertion of 
pHLIP amide into the membrane of lipid vesicles.  CD spectroscopy  measurements show 
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Figure 2.9 HPLC of pHLIP(Cys) crude 
final cleaved product of amidated C-
terminus Cys pHLIP 
Figure 2.8 HPLC of pHLIP Amide crude 
final cleaved product of pHLIP with 
amidated C-terminus 
the typical pH-dependent transition of pHLIP from an unstructured to an α-helical 
structure when the pH is lowered from pH 8.0 to 5.0 (Figure 2.10). Trp fluorescence is 
employed to determine the insertion of pHLIP into the vesicle bilayers based on the 
sensitivity of Trp fluorescence emission to the polarity of the environment. At pH 8, the 
Trp fluorescence emission maxima of pHLIP is centered around 350 nm (Figure 2.10), 
reflecting the exposure of Trp residues to polar, aqueous environments. Lowering the pH 
from 8 to 5 results in a λmax blue shift (~10 nm), which is characteristic for Trp residues 
buried in non-polar environments. This suggests that pHLIP inserts into the membrane at 
pH 4. These findings agree with the pH-responsive changes in secondary  structure 
revealed by CD. Taken together, these results indicate that the presence of an amide at 
the C-term of pHLIP does not  disturb its characteristic shape-shifting behavior. Being 
able to readily synthesize pHLIP (and variants of it) enabled our laboratory  to seek a 
variety of pHLIP-based projects.
Figure 2.10 Biophysical Characterization of pHLIP Amide by (A) 
CD spectroscopy and (B) Trp fluorescence.  The concentration of the 
construct was 7 µM and was in a 1:400 ratio with the POPC lipids. 
(A) (B)
42
2.6 pHLIP Therapeutic Strategies
The research herein focuses on developing new ways to inhibit cancer cell 
growth by delivering therapeutics to cells using pHLIP. Advantageously, when compared 
to other types of targeting and delivery methods, the properties of small peptides can be 
adjusted relatively easily by modifying their amino acid sequence. Moreover, the pH is 
lowest at the surface of cells compared with the bulk extracellular pH and increases with 
distance from the cellular membrane, becoming normal in the vicinity of blood vessels. 
Therefore, the average pH in tumor tissues (~ 6.8) is less informative than the pH at 
cellular surfaces, which needs to be the main target for the development of pH-sensitive 
agents, such as pHLIP.80 Therefore, we hypothesize that the localized targeting 
achievable with pHLIP when combined with potent therapeutics will synergize to create 
an efficacious treatment for cancer.
 The next chapters will focus on our efforts to develop novel strategies to 
specifically target and deliver therapeutics to cancer cells using pHLIP. 
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Appendix 2.1 Molecular Weights and Purities of pHLIP and Variants 
Construct
Calculated
[M + H+]
Found
[M + H+] Purity
pHLIP-Amide 4080 4083 >95%
pHLIP(WT) 4212 4211 >98%
pHLIP(P20G) 4200 4202 >95%
pHLIP(D25E) 4226 4227 >95%
pHLIP(R11Q) 4184 4188 >95%
pHLIP(R11Q;D14Up) 4184 4181 >95%
pHLIP(D14Gla;D25Aad) 4295 4294 >95%
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CHAPTER 3: 
Specific Delivery of Cytotoxic Auristatins
3.1 Abstract
 Localized delivery is vital for the successful development of novel and effective 
therapeutics for the treatment of cancer. In the studies presented in this chapter, we 
investigate the efficacy of pHLIP to target and deliver to cancer cells, highly potent and 
clinically  validated microtubule inhibitors, monomethyl auristatin (MMAs).  We initially 
concentrated our efforts on the monomethyl auristatin E (MMAE) derivative and show 
that pHLIP-MMAE conjugates induce a potent cytotoxic effect (> 90% inhibition of cell 
growth) in a concentration- and pH-dependent manner after only 2-hour incubation 
without any apparent disruption of the plasma membrane. pHLIP-MMAE conjugates 
exhibit between an 11 and 144-fold higher anti-proliferative effect at low pH than at 
physiological pH, and a pronounced pH-dependent cytotoxicity  as compared to free 
drug. Furthermore, we demonstrate that a pHLIP-MMAE drug conjugate effectively 
targets triple negative breast  tumor xenografts in mice.  We extended the study to include 
the less membrane-permeable derivative MMAF and several variants of pHLIP with 
varying pH50 of insertion.  We show pHLIP-MMAF conjugates induce cytotoxicity  in a 
concentration- and pH-dependent manner with varying IC50 values.  Moreover, when 
pHLIP(WT)-MMAF is treated in mice harboring HeLa xenografts modest efficacy  is 
observed. These results indicate pHLIP-based auristatin conjugates may have an 
enhanced therapeutic window as compared to free drug, providing a targeting mechanism 
to attenuate systemic toxicity.
45
3.2 Introduction 
 Auristatins are synthetic analogs of the natural peptide dolastatin 10, a highly  
potent microtubule depolymerization agent originally isolated from the sea organism 
Dolabella auricularia.154 A number of synthetic derivatives have been produced, such as 
monomethyl auristatin E (MMAE), monomethyl auristatin F (MMAF), and monomethyl 
auristatin F-OMe (MMAF-OMe) shown in Figure 3.1, with the goal to optimize 
properties such as solubility, potency, pharmacokinetics, and chemical linkers for 
delivery vehicles.155,156 
 Auristatins have an IC50 that is 52- and 197-fold more toxic than the clinically  
relevant chemotherapies vinblastine and doxorubicin, respectively.155 However, a 
targeting mechanism is necessary to deliver these potent cytotoxic agents to reduce their 
off-target  effects and to increase their concentrations into tumors.157 Antibody drug 
conjugates (ADCs) such as brentuximab vedotin (Adcetris®), have exploited the 
targeting specificity of monoclonal antibodies to selectively deliver auristatins to tumors 
Figure 3.1 Structure of Dolastatin 10 (A, B) Structure of Dolastatin 10 and some of its 
synthetic monomethyl auristatin derivatives: MMAE, MMAF and MMAF-OMe. 
(a)LogPo/w represents the partition coefficient between octanol/water. More hydrophobic 
the compound (more cell permeable), larger the LogPo/w. Values were calculated using 
QikProp  3.0 from the structures of each compound. (b)Data taken from.250 (c)Data taken 
from156
Figure 1
NH R
R'
O
O
N
HOO
N
H
N
O
N
H O
(A) (B)
Compound R R’ Log Po/w (a) IC50 (nM)
Dolastatin 10 H C3H3NS 3.4 0.14(b)
MMAE OH CH3 2.2 0.1 - 2(c)
MMAF H COOH 0.7 105 - 250(c)
MMAF-OMe H COOMe 2.8 0.001(c)
Figure 1.
(B) (a)LogPo/w represents the partition coefficient between octanol/water. More hydrophobic the 
compound (more cell permeable), larger the LogPo/w. Values were calculated using QikProp 3.0 
from the structures of each compound. (b)Data taken from [REF]. (c)Data taken from [REF].
NH H
HOOC
O
O
N
HOO
N
H
N
O
N
H O
O
SS
N
pHLIP-SH NH H
HOOC
O
O
N
HOO
N
H
N
O
N
H O
O
SSpHLIP
Intracellular 
reduction of 
disulfide bond NH H
HOOC
O
O
N
HOO
N
H
N
O
N
H O
O
HS
1 2
3
(C)
46
in an effort to increase their therapeutic window. However, relying on a single cancer 
biomarker as the basis for developing a targeted therapy is flawed and destined to result 
in selection of tumor clones that have lost expression of the target antigen, and 
eventually in therapy resistance and disease progression.158 It is the case for the only  two 
FDA-approved ADCs, brentuximab vedotin and trastuzumab emtansine (Kadcyla®), 
approved for the treatment of Hodgkin’s lymphomas and HER2-positive metastatic 
breast cancer, respectively and with which most treated patients develop acquired drug 
resistance.61,159-162  However, preclinical and clinical evidence demonstrates that therapy 
strategies based on the targeting of specific proteins is significantly hampered by tumor 
heterogeneity, which can promote tumor evolution, and lead to loss of cell surface 
proteins, and eventually, to therapy resistance and disease progression.158  Moreover, 
targeted cancer biomarkers tend to be over-expressed in a tumor-associated, not tumor-
specific manner. While over-expression provides a window of selective targeting, 
targeted uptake into normal tissues is seen163 and has the potential to lead to unacceptable 
toxicity  profiles. Thus, alternatives are desperately needed to circumvent these 
limitations.
 In this study, we investigate the efficacy of pHLIP to deliver the highly potent  
and clinically  validated microtubule inhibitor, Auristatins to cancer cells in vitro in a pH 
dependent manner.  We show that pHLIP and one of its variants chosen to optimize 
targeting, can induce a potent cytotoxic effect in cancer cells, including triple negative 
breast cancer cells when delivering the monomethyl auristatin E (MMAE) derivative. 
Gene expression profiling divides breast cancer into at least five different subtypes164 
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that are broadly classified into three different treatment groups: Hormone responsive165, 
HER2/ERBB2 amplified,166 and triple negative breast cancer.167  Triple negative breast 
cancer (TNBC), so named for its lack of estrogen receptor, progesterone receptor and 
HER2 expression, is over-represented in younger and African-American patient 
populations.168 TNBC has a high rate of early recurrence in response to chemotherapy 
treatment. In contrast to the other treatment groups, there are no effective targeted 
therapies.169,170 Furthermore, with the first auristatin chosen for delivery we demonstrate 
that the pHLIP-MMAE drug conjugates effectively targets human TNBC xenografts in 
mice. This study represents the first demonstrated example of pHLIP-dependent delivery 
of a clinically relevant cytotoxic molecule to tumor cells both in vitro and in vivo.  In the 
subsequent study described in this chapter we investigate a second generation family of 
pHLIP variants with the more cell impermeable auristatin derivative monomethyl 
auristatin F (MMAF).  From six variants studied in vitro we chose a lead compound to 
investigate its translation to an in vivo model.
3.3 Experimental Rationale
 In the present study, with the goal to optimize the selective delivery of 
monomethyl auristatins to cancer cells and tumors, we evaluate the selective cytotoxicity 
of a panel of pHLIP variants with different insertion properties in conjugation with either 
of the two auristatin derivatives, monomethyl auristatin E (MMAE) or monomethyl 
auristatin F (MMAF).  The therapeutics are modified with a succinimide nitrophenyl-
based linker to allow for conjugation to pHLIP via a cleavable disulfide bond upon 
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cytoplasmic delivery  (Figure 3.2).  Here, we 
show that when cells are treated with 
pHLIP-auristatins a pH- and concentration-
dependent selective toxicity is observed. 
The first study concentrated on MMAE 
delivery with two pHLIP variants and 
investigated the targeting of triple negative 
breast xenografts with the lead compound. 
The follow-up study  included six total 
pHLIP variants with the more cell 
impermeable MMAF and the translation of 
the lead molecule into preclinical testing in 
orthotopic models of cervical cancer.
3.4 Results and Discussion
 3.4.A: Inhibition of Cancer Cell Proliferation and Breast Tumor Targeting of 
 pHLIP-Monomethyl Auristatin E Conjugates
  3.4.A.1 Synthesis of pHLIP-MMAE Conjugates
 ADCs have exploited the targeting specificity of monoclonal antibodies to 
selectively deliver MMAE to tumors in an effort to increase the therapeutic window of 
these highly toxic agents.171 Toward this end, we conjugated MMAE, modified with a 
succinimide nitrophenyl-based linker, to the C-terminus of pHLIP and pHLIP(D25E) 
pHLIP
pH
LI
P
Cancer cell 
low pHe
-S-S- Auristatin
-SH
HS- Auristatin
Cancer Cell 
Death
Figure 3.2 Schematic Representation 
o f p H L I P - A u r i s t a t i n s . T h e 
hypothesized cytotoxic effect of the 
pHLIP-Auristatin conjugates.
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(Scheme 3.1) via a cleavable disulfide bond and purified the conjugates by HPLC and 
the molecular weight was determined via MALDI-TOF MS.  This linking strategy allows 
for the release of MMAE into the cytoplasm of cancer cells after translocation and 
reduction of the disulfide bond.133,147 Cleavage of the disulfide bond results in release of 
an N-terminally modified form of MMAE (Scheme 3.1). The resulting MMAE 
derivative and the parental MMAE exhibit IC50 ~ 125 nM and 4 nM  against HeLa cells, 
respectively, when incubated with the cells for 72 hours.
  
3.4.A.2 Biophysical Characterization of the Interaction of pHLIP-MMAE 
  Conjugates with Lipid Bilayers
Scheme 3.1 Conjugation of pHLIP to MMAE (A) Sequences of the pHLIP peptides 
used in this study. The amino acid substitution for the variant  pHLIP(D25E) is shown in 
red, and the cysteine available for disulfide drug conjugation is shown underlined. (B) 
Structure of MMAE with a succinimide nitrophenyl-based linker and conjugation to 
pHLIP via disulfide exchange as well as the structure of MMAE as released 
intracellularly after pHLIP insertion and reduction of the disulfide bond. 
AAEQNPIYWARYADWLFTTPLLLLDLALLVDADEGTCG
AAEQNPIYWARYADWLFTTPLLLLELALLVDADEGTCG
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 Prior to evaluating the pHLIP-mediated translocation of MMAE into cancer cells, 
the interaction of the pHLIP-MMAE conjugates with lipid bilayers was studied (Figure 
3.3). Far-UV circular dichroism spectroscopy (CD) was used to determine the secondary 
structure of pHLIP-MMAE conjugates in the presence of POPC liposomes at both 
normal and low pH. Figure 3.3A shows the typical pH-dependent transition of pHLIP 
from an unstructured configuration at pH 7.4 (blue line) to an α-helical structure when 
the pH is lowered to 5.0 (red line). Tryptophan fluorescence was employed to determine 
the insertion of pHLIP into the vesicle bilayers based on the sensitivity of the 
fluorescence emission of two tryptophan residues present in the sequence of pHLIP to 
the polarity  of the environment. At pH 7.4, the Trp fluorescence emission maxima of 
pHLIP is centered at 348 nm (Figure 3.3B, blue line), reflecting the exposure of Trp 
residues to polar, aqueous environments. Lowering the pH to 5.0 results in a 14 nm λmax 
blue shift  (from 348 nm to 334 nm; red line), which is characteristic of Trp  residues 
buried in hydrophobic environments, suggesting pHLIP’s insertion into the membrane. 
Taken together, these results indicate that the presence of MMAE at the C-term of 
pHLIP does not significantly affect the pH-mediated insertion of pHLIP.
 With the goal of optimizing the targeting and delivery of MMAE by pHLIP, we 
also considered the variant  pHLIP(D25E), which has a higher pH50 of insertion than 
native pHLIP(WT) (6.49 vs. 6.0).103 The higher pH50 of insertion may match better the 
extracellular pH of tumors (i.e., pH 6.5 to 6.9) and favor pHLIP insertion and MMAE 
translocation into cells. Similarly  to pHLIP(WT)-MMAE, CD and tryptophan 
fluorescence measurements indicate that conjugating MMAE to pHLIP(D25E) does not 
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interfere with pHLIP’s characteristic shape-shifting behavior. Indeed, a transition from 
an unstructured conformation to an α-helix, and a clear blue shift  (from 347 nm to 329 
nm) are observed by CD (Figure 3.3C) and Trp fluorescence (Figure 3.3D), respectively. 
 Thus, both pHLIP(WT)-MMAE and pHLIP(D25E)-MMAE conjugates can insert 
in lipid bilayers under acidic conditions to form stable transmembrane α-helices in a 
manner similar to that  of pHLIP alone. The pH50 of insertion of the pHLIP-MMAE 
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Figure 3.3 Interactions of pHLIP−MMAE Constructs with Lipid Bilayers. (A, B) 
pHLIP(WT)−MMAE CD spectroscopy and Trp fluorescence, respectively. (C, D) 
pHLIP(WT)−MMAE CD spectroscopy and Trp fluorescence, respectively. State I 
corresponds to the peptides in an aqueous environment and is shown in black; state II 
corresponds to peptides in the presence of lipid membranes at  pH 7.4 and is shown in 
blue; and state III corresponds to peptides in the presence of lipids at pH 5.0 and is 
shown in red. [peptide] = 7 µM, and peptide/lipid ratio = 1:300 with POPC liposomes. 
conjugates is not expected to differ significantly from pHLIP alone (pH50~6) because 1) 
MMAE has no ionizable group that could influence the pH50 of insertion, and 2) 
conjugation of phalloidoin and amanitin toxin derivatives to pHLIP was shown to not 
change the pK of insertion (6.14 and 5.9, respectively).148,151
  3.4.A.3 Inhibition of Cell Proliferation 
 The ability  of pHLIP to move MMAE across the cell membrane and to inhibit 
cancer cell proliferation in concentration and pH-dependent manners was evaluated. Cell 
treatments for both pHLIP(WT)-MMAE and pHLIP(D25E)-MMAE constructs were 
carried out with conjugate concentrations ranging from 1.25 to 10 µM  at either pH 7.4 or 
5.0. After a 2-hour incubation at  37 ºC, the treatment media was replaced by fresh media, 
and cells were grown for an additional 72 hours at  normal pH before assessing cell 
viability using the MTT assay. This treatment protocol was chosen to prevent cell death 
that may result from prolonged exposure to low pH. It may also better mimic the 
transient exposure of tumor cells to pHLIP-MMAE anticipated to occur in vivo. It  is 
worth noting that this treatment protocol is quite stringent when compared to the typical 
multi-days exposure treatments used with free drugs (Figure 3.4). 
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 When HeLa cells were treated with pHLIP(WT)-MMAE at low pH, cell 
proliferation was severely  disrupted. Up to 93% growth inhibition is observed (Figure 
3.5A). The anti-proliferative effect is concentration-dependent with cell viability  ranging 
from 80% to 7%, with increasing treatment concentration ranging from 1.25 to 10 µM, 
respectively (Figure 3.5A, grey bars). As anticipated, inhibition of cell growth is also pH-
selective: Treatment with pHLIP(WT)-MMAE at pH 7.4 under the same conditions had 
no or a moderate effect on cell proliferation (Figure 3.5A; black bars). This lack of anti-
proliferative effect at normal pH is consistent with the notion that delivery  of MMAE is 
mediated by the pH-dependent insertion of pHLIP across the plasma membrane. It  is 
important to note that the low pH treatment in itself did not have any  detrimental effect 
on the proliferation of HeLa cells, as shown by treatment without pHLIP(WT)-MMAE 
(0 µM treatment). 
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Figure 3.4 MMAE Inhibition of Proliferation in HeLa (A) and MDA-MB-231 (B) cell 
proliferation by free MMAE modified with a succinimide nitrophenyl-based linker 
(MMAE+linker) and by  unmodified MMAE. For each cell assay  3,000 cells/well were 
seeded, allowed to adhere overnight and incubated with either compound for 72 hours in 
complete medium at physiologic pH. Cell viability  was determined with the MTT assay. 
All measurements were normalized to the 1% DMSO controls. Results are shown as 
mean ± SD (n=6). Data were fitted with a sigmoidal doseresponse function in Prism for 
Mac (GraphPad Software, Inc.).
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Figure 3.5 Inhibition of Cell Growth. (A, C, E) HeLa cells treated with 
pHLIP(WT)−MMAE, pHLIP(D25E)−MMAE, and MMAE(linker), respectively. 
(B, D, F) MDA-MB-231 cells treated with pHLIP(WT)−MMAE, pHLIP(D25E)
−MMAE, and MMAE(linker), respectively. Black columns represent cells treated 
at pH 7.4. and cells treated at low pH are shown in gray. For each condition, 3000 
cells/well (96-well plate) were seeded, allowed to adhere overnight, treated for 2 h, 
washed once with media and grown for 72 h in complete medium at physiologic 
pH. Cell viability was assessed with the MTT assay. All measurements were 
normalized to the media control (0 µM, pH 7.4) as 100% cell viability. Results are 
shown as mean ± SD (n = 6−9). To assess statistical significance, two-tailed 
Student’s t test analyses at the 95% confidence level were performed to compare 
the pH 7.4 and 5.0 treatments (****, p  < 0.0001; ***, p = 0.0004; **, p  = 0.0009; 
and *, p = 0.011). For panels E and F, none of the differences between treatment at 
pH 7.4 and 5.0 were statistically different (p > 0.01). 
 We also tested pHLIP(WT)-MMAE with human MDA-MB-231 breast cancer 
cells (Figure 3.5B). A similar concentration and pH-dependent anti-proliferative effect is 
observed: Up to 88% cell growth inhibition is observed with low pH treatment, while no 
significant inhibition of proliferation is observed for cells treated at normal pH. 
However, MDA-MB-231 seem less sensitive to pHLIP(WT)-MMAE treatment, as 
shown by  a higher cell viability  with the 2.5 µM  treatment. This effect may be due to the 
apparent higher resistance of MDA-MB-231 cells to MMAE when compared to HeLa 
cells (Figure 3.4).
 When HeLa and MDA-MB-231 cells were treated with pHLIP(D25E)-MMAE, 
cell proliferation was also disrupted in a concentration- and pH-dependent fashion 
(Figure 3.5C and 3.5D). pHLIP(D25E)-MMAE appears to be more effective at inhibiting 
cell growth than pHLIP(WT)-MMAE. It is especially evident when comparing 
treatments at 1.25 µM  (Figures 3.5C and 3.5D), where greater cell killing is attained with 
pHLIP(D25E)-MMAE than with pHLIP(WT)-MMAE (MDA-MD-231 cells: 49% versus 
100%, respectively). However, while 5 and 10 µM treatment exhibit nearly  100% growth 
inhibition at low pH (Figure 3.5C and 3.5D; grey bars), non-negligible cytotoxicity is 
observed at pH 7.4, with about 75% and 40% cell viability, respectively (Figures 3.5C 
and 3.5D; black bars). This relatively  high cytotoxicity at higher concentrations is not 
due to any intrinsic peptide cytotoxicity or to pHLIP insertion itself, as neither 
pHLIP(WT) or pHLIP(D25E) peptides have any harmful effects on the cell viability  of 
either cell line at  10 µM (Figure 3.6), which is consistent with previous observation that 
pHLIP is minimally toxic.91,148 
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 Cell killing does not seem to be due to instability  of the linker (or any other 
chemical instability) in cell media either, as no degradation products are observed by 
HPLC or mass spectroscopy after low pH treatment with pHLIP(WT)-MMAE or 
pHLIP(D25E)-MMAE (Figure 3.7). We also assessed whether either pHLIP-drug 
constructs may cause cell death through disruption of the plasma membrane: Cells were 
counted after a 2-hour treatment based on the uptake of trypan blue, which can only  be 
taken up by  cells if their plasma membrane is disrupted. Figure 3.8 shows that neither 
conjugates, nor low pH treatment, caused disruption of the membranes of either cell line. 
While pHLIP-mediated translocation of cargo molecules is thought to not be mediated by 
endocytosis, we cannot exclude the possibility that the observed cytotoxicity of 
pHLIP(WT)-MMAE and pHLIP(D25E)-MMAE at higher concentrations might be 
associated with partial endocytotic uptake by the cells promoted by the interaction of 
pHLIP with the plasma membrane at low pH.151
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Figure 3.6 The pHLIP Peptide Variants Are Not Cytotoxic. (A) HeLa cells and (B) 
MDAMB-231 treated with 10 µM of either pHLIP(WT) or pHLIP(D25E) at pH 7.4 
(black bars) or pH 5.0 (grey  bars). Cell viability was assessed with the MTT assay, and 
all measurements were normalized to the media control (0 µM, pH 7.4), as 100% cell 
viability. Results are shown as mean ± SD (n=6-9).
 Nevertheless, our results indicate that pHLIP-mediated translocation of MMAE 
can inhibit the proliferation of cancer cells in a pH-selective fashion, and offers clear 
advantages over treatment with free MMAE: (1) pHLIP prevents the high toxicity of 
MMAE at physiological pH. For instance, in Figure 3.5A, 5 µM  of pHLIP(WT)-MMAE 
shows only marginal cytotoxicity against HeLa whereas MMAE alone exhibits about 
70% cytotoxicity  (Figure 3.5E). Similar results are observed with pHLIP(D25E)-MMAE 
and MDA-MB-231 cells. (2) Conjugation to pHLIP enhances MMAE anti-proliferative 
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Figure 3.7 Purity Check and Chemical Stability of pHLIP-MMAE Conjugates. (A) 
and (B): HPLC traces of pHLIP(WT)-MMAE and pHLIP(D25E)-MMAE, respectively: 
Purified conjugates (upper panels), 10 µM of conjugate in cell media (middle panels) and 
after incubation in cell media for 2h at pH 5.0 and 37 ºC (lower panels). The small peak 
observed around 27 min in (B) upper panel corresponds to some residual free pHLIP 
(<15%), which is known to not be cytotoxic (Figure 3.6). (C) HPLC traces of Alexa750-
pHLIP(WT)-MMAE: Purified conjugate (upper panel), 10 µM Alexa 750-pHLIP(WT)-
MMAE before (upper panel) and after 48h incubation in mouse serum at 37 ºC (lower 
panel). Purity checks and chemical stability runs were performed on different column and 
with different flow rate, explaining the difference in retention times and peak broadness 
(see Experimental Section). Because of the presence of many components in cell medium 
and mouse serum, only portion of the HPLC trace is shown in the middle and lower panel 
traces for clarity. No significant degradation was observed for any of the pHLIP 
conjugates: For each HPLC run, every  peak was collected and checked by mass 
spectroscopy. In all cases, the pHLIP-MMAE conjugate was found intact, while neither 
pHLIP nor MMAE alone was found in any other peaks in the entire retention time range 
by MALDI-TOF.
effects at low concentrations when treated at low pH. It is especially evident when 
comparing cell viability at 2.5 µM: While free MMAE has a marginal cytotoxicity effect 
at these concentrations (20-30%; Figures 3.5E and 3.5F), pHLIP-MMAE conjugates are 
systematically  more toxic than MMAE alone at low pH (up to 87.5% cytotoxicity; 
Figures 3.5A-D).
 Our results suggest that, on one hand, MMAE is effectively sequestered outside 
the cells by pHLIP at  normal pH, preventing its passive diffusion into cells and its 
cytotoxicity. On the other hand, pHLIP improves MMAE potency by actively 
translocating it into the cytoplasm at lower pH in a mechanism more favorable (and/or 
faster) than passive diffusion, likely resulting in a higher effective MMAE concentration 
inside cells. All together, these effects participate in reducing the effective dose of 
MMAE necessary to observe cell death, which may alleviate off-target effect.
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Figure 3.8 pHLIP−MMAE Conjugates Do Not Disrupt The Cell Membrane. The 
integrity  of the plasma membrane is assessed by the uptake of trypan blue dye. HeLa (A) 
and MDA-MB-231 (B) cells were seeded at 3000 cells/well, allowed to adhere overnight, 
and treated with 10 µM conjugates or media alone (no peptide) for 2 h at pH 7.4 (black 
bars) or pH 5.0 (gray bars). Cells were detached and counted based on trypan blue uptake 
with a hemacytometer: % of intact cells corresponds to the number of cells not showing 
any dye uptake over the total number of cells. Results are shown as mean ± SD (n = 4). 
3.4.A.4 In Vivo Targeting 
 The pH-dependent anti-proliferative selectivity observed with pHLIP-MMAE 
and its low cytotoxicity  at higher concentration in comparison with pHLIP(D25E)-
MMAE prompted us to test the hypothesis that pHLIP can selectively deliver MMAE to 
tumors. As seen in Figure 3.9, intravenously  administered Alexa750-pHLIP(WT)-
MMAE is selectively retained in MDA-MB-231 breast cancer xenograft tumors over a 
48 hour imaging time course. As tested, tumors were clearly  visualized by 4 - 6 hours 
post-injection with maximum tumor: background ratios of 2.3 being observed at the 28 
hour post-injection time point (Figure 3.9C). 
 Consistent with a renal clearance mechanism, Alexa750-pHLIP(WT)-MMAE 
rapidly accumulates in kidney with concomitant clearance from the periphery. 
Background levels dropped 4.5-fold by 28 hours and 6-fold by 48 hours (Figure 3.9). 
The conjugation of MMAE to pHLIP did not discernibly alter the tumor targeting 
properties of pHLIP as compared to that seen with other Alexa-pHLIP constructs.116  The 
current imaging studies were carried out with sub-therapeutic doses of Alexa750-
pHLIP(WT)-MMAE to assess its tumor targeting capability and set the stage for in-depth 
studies aimed at determining the therapeutic efficacy and toxicity profiles associated 
with this novel drug conjugate. The clinical efficacy of antibody-drug conjugates (ADCs) 
comprising intact IgG molecules linked to potent  cytotoxics, such as auristatins and 
maytansine, has resulted in significant interest in delineating the pharmacologic 
parameters underlying efficacious ADCs and using that  information to guide 
development of next generation targeting vehicles.172 
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 A comprehensive analysis of tumor and normal tissue exposures to auristatin 
upon SGN-75 (anti-CD70::MMAE) treatment supports selective tumor targeting and 
retention, as well as serum stability, as being critical characteristics.173 Advances in 
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Figure 3.9 Optical Imaging of Alexa705−pHLIP(WT)−MMAE In Vivo Targeting. 
Clearance and tumor targeting of Alexa750−pHLIP(WT)−MMAE in NCr nu/nu mice 
harboring MDA-MB-231 tumor xenografts visualized over a 48 h time course post-
injection. (A) Imaging was performed with the minimum and maximum average radiant 
efficiency set to 1.1×107 and 1.4×108 [p/s/cm2/sr]/[µW/cm2], respectively, for all time 
points. Color intensity reflects absolute levels of probe. Arrow and chevron noted on 28 h 
time point in (A) denote the positions of the tumor and kidney, respectively. The third 
region displaying relatively  high fluorescence corresponds to the epifluorescence 
originating from the region corresponding to the knee joint. (B) Contrast  set in automatic 
scale mode to optimize visualization of tumor targeting at each time point. (C) 
Quantitation of average radiant efficiency [p/s/cm2/sr]/[µW/cm2] for ROIs drawn around 
tumor, kidney, and background (blood pool). Results are shown as mean ± SD. 
antibody engineering techniques have led to development of antibody-based fragments 
that exhibit rapid tumor targeting coupled with rapid systemic clearance. Those antibody-
based molecules have proven to be effective delivery vehicles for other therapeutic 
agents.174-176 The rapid and selective uptake of Alexa750-pHLIP(WT)-MMAE into 
tumors is analogous to that observed with rapidly  cleared antibody-based agents. This 
data, coupled with our demonstration that pHLIP-MMAE is stable in serum over a 
relevant time frame for its systemic clearance rate makes us hypothesize that  appropriate 
dosing of pHLIP(WT)-MMAE will promote tumor control and limit the toxicities 
associated with free MMAE. As detailed above, unlike ADCs, the mechanism of action 
that drives tumor targeting of pHLIP-based constructs is independent of target antigen 
expression. We hypothesize that this makes pHLIP(WT)-MMAE particularly  relevant  to 
diseases such as TNBC, for which efficacious ADC target antigens have not yet been 
established. 
 3.4.B: Therapeutic Efficacy of a Family of pHLIP-MMAF Conjugates in 
 Cancer Cells and Mouse Models
  3.4.B.1 Synthesis of pHLIP-MMAF Conjugates
 In the aforementioned study we demonstrated that the pHLIP provides localized 
delivery of monomethyl auristatin E (MMAE) to cancer cells.177 That study showed that 
pHLIP-mediated translocation of MMAE can inhibit the proliferation of cancer cells in a 
pH-selective and concentration-dependent fashion and that it  offers clear advantages over 
treatment with free MMAE: (1) pHLIP prevents the high toxicity  of MMAE at 
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physiological pH. (2) Conjugation to pHLIP enhances MMAE anti-proliferative effects 
at low concentrations when treated at low pH. The same study  also shows that the pHLP-
MMAE conjugate effectively targets triple-negative breast tumor xenografts in mice, that 
the rapid and selective uptake of pHLIP−MMAE into tumors is analogous to that 
observed with rapidly cleared antibody-based agents, and that pHLIP−MMAE is stable 
in serum over a relevant time frame for its systemic clearance rate. These results indicate 
that pHLIP-based auristatin conjugates may  have an enhanced therapeutic window as 
compared to that of free drug, thus providing a targeting mechanism to attenuate 
systemic toxicity. They also support the further development of pHLIP−monomethyl 
auristatin conjugates as an efficacious treatment of cancer.
 In the succeeding study, with the goal to optimize the selective delivery  of 
monomethyl auristatins to cancer cells and tumors, we evaluate the selective cytotoxicity 
of a panel of pHLIP variants with different insertion properties in conjugation with 
monomethyl auristatin F (MMAF), and translate the lead molecule into preclinical 
testing in orthotopic models of cervical cancer. Since the pHLIP−monomethyl auristatin 
conjugate (pHLIP-MMA) is a two-component system (i.e., targeting/delivery peptide and 
drug cargo), we investigate the effect  of varying both pHLIP and the monomethyl 
auristatin moieties to enhance the potency towards cancer cells and tumors when 
compared to our original pHLIP(WT)-MMAE conjugate 177.
 Advantageously when compared to other type of targeting and delivering 
methods, the properties of small peptides can be adjusted relatively  easily by modifying 
their amino acid sequence. The pHLIP peptides shown in Table 3.1 have been chosen to 
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cover a wide range of properties with the objective to tune/improve selectivity  and 
translocation in cultured cells, and tumor localization in vivo.  
 One criterium for selecting pHLIP variants is their apparent pH50 of insertion in 
lipid membranes (i.e., the pH at which 50% of pHLIP are in the α-helical inserted state). 
Indeed, it is hypothesized that an increased pH50 might be beneficial to pHLIP-based 
drug delivery, as most solid tumors exhibit an average extracellular pH of about 
6.8.79,178-180 For example, the apparent pH50 of insertion across 1-palmitoyl-2-
oleoylphosphatidylcholine (POPC) membrane for pHLIP(WT) is about 6.1 (Table 3.1).
89,103,104,107 Of the 6 pHLIP variants considered here, three have a larger pH50 than 
pHLIP(WT): pHLIP(D25E), where Asp25 is substituted by  the more hydrophobic 
glutamic acid;103 pHLIP(P20G), where the Pro to Gly substitution increases pH50 by 
enhancing the propensity  of the peptide to form an α-helix;93 pHLIP(D14Gla;D25Aad), 
where Asp14 is substituted by an ɣ-carboxyglutamic acid (Gla), which has an additional 
sidechain carboxylic acid, and where Asp25 is substituted for the more hydrophobic α-
aminoadipic acid (Aad). pHLIP(D14Gla;D25Aad) variant not only  shows an increase of 
pH50 (6.79), but also a slight increase in insertion cooperativity (i.e., sharper pH-
response).107 
 While the variants with increased pH50 of insertion might match better the tumor 
microenvironment pH, one cannot exclude that a decreased pH50 of insertion may 
provide better selectivity in vivo by increasing pHLIP’s sensitivity to acidic 
environments, thereby decreasing off-targeted delivery. In addition, variants with 
reduced aggregation tendency may result in a larger pool of conjugate available for 
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targeting.104 For these reasons, two other variants were investigated as well: 
pHLIP(R11Q) and pHLIP(R11Q;D14Up), where substitutions not  only lower pH50 (5.8 
and 5.6, respectively), but also improve response to high ionic strength and reduce 
aggregation tendency.104
 The chemico-physical properties of MMAs can also be exploited to enhance 
pHLIP-MMA conjugate potency.  For instance, MMAF (Figure 3.1A, B) has a higher 
aqueous solubility and lower lipid permeability  than MMAE due to the charged C-
terminal phenylalanine group (Log Po/w = 0.7 vs 2.2, Figure 3.1B), making it of great 
interest for targeted delivery.  Indeed, MMAF would have a lesser tendency to diffuse 
out of the cells after delivery  and thus be more effective than MMAE.  This property 
could also limit side effects associated with possible degradation of conjugate in serum 
with concomitant release of free drug; release of free drug is thought to contribute to 
toxicities associated with ADCs.172  In addition, it has been shown that MMAF (unlike 
MMAE) can sustain significant modification to the N-terminal position (i.e., position of 
conjugation to pHLIP) and still retain its potency.156  For these reasons, we conjugated 
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Table 1
Table 1. Properties of pHLIP peptides used in this study.
pHLIP variants Sequence pH50*
WT AAEQNPIYWARYADWLFTTPLLLLDLALLVDADEGTCG 6.1a
D25E AAEQNPIYWARYADWLFTTPLLLLELALLVDADEGTCG 6.5a
P20G AAEQNPIYWARYADWLFTTGLLLLDLALLVDADEGTCG 6.8b
R11Q AAEQNPIYWAQYADWLFTTPLLLLDLALLVDADEGTCG 5.8c
R11Q / D14Up AAEQNPIYWAQYDAWLFTTPLLLLDLALLVDADEGTCG 5.6c
D14Gla / D25Aad AAEQNPIYWARYAGlaWLFTTPLLLLAadLALLVDADEGTCG 6.8a
*Measured in POPC unless otherwise noted. aData taken from [REF].  bData taken from [REF]. pH50 was determined in 16:1 
phosphatidyl choline (16:1 PC). The pH50 for pHLIP(WT) in 16:1 PC is 6.2. cData taken from [REF].
Figure 1. Biophysical Characterization with lipid bilayers. pHLIP-MMAFs circular dichroism 
spectroscopy and Trp Fluorescence. Spectra were measured in presence of POPC liposomes 
at pH 7.5 (blue line) and at pH 4.0 (red line). [peptide] = 7 µM and peptide- lipid ratio =1:300 
with POPC liposomes. 
Figure 2. Inhibition of cell growth. HeLa cells treated with 4-amino acid  pHLIP-MMAF 
conjugates. Blue lines rep esent cells treated at pH 7.4 and cells treated at low  pH are shown in 
red. For each condition, 3,000 cells/well (96-well plate) were seeded, allowed to adhere 
overnight, treated for 2 hours, washed once with media and grown for 72 hour in complete 
medium at physiologic pH. Cell viability was assessed with the MTT assay. All measurements 
were normalized to the media control (0 µM, pH 7.4), as 100% cell viability. Results are shown 
as mean ± SD (n=9-12). 
Figure 3. Inhibition of tumor growth in vivo. 
3 1 Properties of pHLIP Peptides Used In This Study
*Measured in POPC unless otherwise noted. (a)Data taken from93  (b)Data taken from104 pH50 was determined in 16:1 
phosphatidyl choline (16:1 PC). The pH50 for pHLIP(WT) in 16:1 PC is 6.2. (c)Data taken from107
MMAF, modified with a succinimide nitrophenyl-based linker, to the C-terminus of 
pHLIP variants via a cleavable disulfide bond (Scheme 3.2), to allow for the release of 
MMAF into the cytoplasm of cancer cells upon translocation and reduction of the 
disulfide bond.
  3.4.B.2 Inhibition of Cell Proliferation 
 The ability of pHLIP-MMAF conjugates to inhibit cancer cell proliferation in 
concentration- and pH-dependent manners was evaluated in human cervical cancer HeLa 
cells. Similarly to our previous study,177 cells were treated with pHLIP conjugates for 
only 2 h to prevent cell death that  may result from prolonged exposure to low pH, and to 
possibly better mimic the transient exposure of tumor cells to pHLIP−MMAF anticipated 
to occur in vivo (i.e., pHLIP clears with approximately  a 6-hour half-life).177 
Furthermore, low pH treatments were performed at pH 5.0 to keep the treatment pH 
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Scheme 3.2 Conjugation of pHLIP to MMAF  Structure of MMAF with a succinimide 
nitrophenyl-based linker and conjugation to pHLIP via disulfide exchange as well as the 
structure of MMAF as released intracellularly after pHLIP insertion and reduction of the 
disulfide bond.
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lower than the variants’ pH50 of insertion (Table 3.1) and push the equilibrium toward 
insertion, allowing for direct comparison between conjugates with different pH50. It is 
important to note that  this low pH treatment in itself did not have any significant 
detrimental effect on the proliferation of HeLa cells, as shown by treatment without 
conjugates (Figure 3.10, 0 µM Control).
 Cytotoxicity assays with HeLa show that while all six pHLIP-MMAF conjugates 
display clear pH-selective and concentration-dependent killing, their respective 
cytotoxicity profiles at both low and physiological pHs are remarkably different (Figure 
3.10). The IC50 values at pH 5.0 and 7.4 for each conjugate are reported in Table 3.2. 
Interestingly, the pHLIP(WT)-MMAF conjugate shows the highest and most selective 
killing with IC50 values of 28 nM and 658 nM at pH 5.0 and 7.4, respectively (Figure 
3.10A). It represents a 23-fold higher anti-proliferative effect at  low pH than at 
physiological pH, and a 100-fold improvement over our original pHLIP(WT)-MMAE 
conjugate.177 For example, treating at 40 nM  results in 100% survival at pH 7.4 but leads 
to ~80% cell killing at low pH. It also displays the sharpest  transition at pH 5.0 between 
low and high cytotoxicity. It is also a clear improvement over free MMAF, which 
exhibits a rather modest anti-proliferative effect, with an IC50 value of c.a. 5 µM, likely 
because of its impaired intracellular access (Figure 3.11A).  However, in an attempt to 
compare the activity of pHLIP-MMAF conjugates to that of free MMAF fairly, Figure 
3.11A also shows 72-hour treatments with MMAF. Indeed, our treatment protocol (where 
pHLIP-constructs are removed after a 2-hour treatment) is quite stringent when 
compared to several days exposure typically used with free drugs, from which IC50 
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values are typically derived (including the ones presented in Figure 3.1B). As expected, 
MMAF shows a higher anti-proliferative effect than with 2-hour treatments (IC50 ~ 600 
nM) but it is also exhibits about 50% cytotoxicity  at low concentrations whereas pHLIP-
MMAF conjugates are marginally cytotoxic (Figure 3.10). pHLIP therefore appears to 
improve MMAF potency by facilitating its translocation across the cell membrane into 
the cytoplasm at  lower pH in a mechanism much more favorable than passive diffusion. 
Similar to our previous study with pHLIP-MMAE conjugates,177 pHLIP(D25E)-MMAF 
shows less potency than the pHLIP(WT) conjugate with an IC50 at pH 5.0 of 315 nM. It 
also displays the smallest pH selectivity of all conjugates, with only a 3.7-fold 
improvement at low pH over physiological pH. 
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Figure 3.10 Inhibition of Cell Growth. HeLa cells treated with pHLIP-MMAF 
conjugates. Blue lines represent cells treated at pH 7.4 and cells treated at low pH are 
shown in red. For each condition, 3,000 cells/well (96-well plate) were seeded, allowed 
to adhere overnight, treated for 2 hours, washed once with media and incubated for 72 
hour in complete medium at physiologic pH. Cell viability  was assessed with the MTT 
assay. All measurements were normalized to the media control (0 µM, pH 7.4), as 100% 
cell viability. Results are shown as mean ± SEM (n=9-12). 
Figure 2
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 Even though the other four conjugates are less potent than pHLIP(WT)-MMAF, 
with IC50 values at pH 5.0 ranging from 103 to 613 nM, they exhibit some very 
interesting features. For instance, they all are less cytotoxic at physiological pH than the 
pHLIP(WT) and pHLIP(D25E) conjugates (Table 3.2). These four pHLIP variants may 
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Figure 3.11 Effects of Free MMAF and pHLIP Variants on Cell Proliferation. For 
each cell assay, 3,000 cells/well (96-well plate) were seeded, allowed to adhere 
overnight, treated for either 2 or 72 hours with MMAF at pH 7.4 (A) or for 2 hours with 
10 µM  pHLIP variants (B) at pH 7.4 (black bars) and a low pH (grey bars). After the 2-
hour treatment, cells were washed once with media and cultured for 72 hour in complete 
medium at physiologic pH. Cell viability was assessed with the MTT assay. MMAF 
treated cells were normalized to the 1% DMSO controls and pHLIP variants were 
normalized to the media control (0 µM, pH 7.4), as 100% cell viability.  Results are 
shown as mean ± SEM (n=9)
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possibly interact less with the plasma membrane than pHLIP(WT) and pHLIP(D25E), 
making them less prone to cell uptake. Indeed, while pHLIP-mediated translocation of 
cargo molecules is not thought to be mediated by endocytosis, we cannot exclude the 
possibility that the observed cytotoxicity at physiological pH might be associated with 
partial endocytotic uptake by  the cells promoted by the interaction of pHLIP with the 
plasma membrane at normal pH.133,151Moreover, Weerakkody  and co-workers showed 
that tuning of the biophysical properties of pHLIP–lipid bilayer interactions alters tumor 
targeting, distribution in organs, and blood clearance.98 
 Remarkably, pHLIP(P20G)-MMAF does not show any significant cytotoxicity  at  
physiological pH, and thus represents the most pH-selective conjugate of all constructs 
used in this study. While being 16-fold less potent than pHLIP(WT)-MMAF (IC50, 463 
nM vs. 28 nM), this unique feature may be an advantage in in vivo settings, where it may 
prevent off-target cytotoxicity. This drastic difference in cytotoxicity at  physiological pH 
may be due to the difference in how pHLIP(P20G) interacts with lipid membranes when 
compared to pHLIP(WT).93 However, the exact reasons for this behavior are unknown 
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Table 3.2 In Vitro Cytotoxicity of pHLIP-MMAF Conjugates 2-hour Treatments
Table 2. In Vitro Cytotoxicity of pHLIP-MMAF conjugates.
Conjugate IC50 at pH 5.0 (nM) IC50 at pH 7.4 (nM) Selectivity*
pHLIP(WT)-MMAF 28 658 23
pHLIP(D25E)-MMAF 315 1153 3.7
pHLIP(P20G)-MMAF 463 n.a. n.a.
pHLIP(R11Q)-MMAF 613 3525 5.8
pHLIP(R11Q/D14Up)-MMAF 254 2251 9
pHLIP(D14Gla/D25Aad)-MMAF 103 2637 25
*Selectivity represents the ratio of the IC50 at pH 7.4 over the IC50 at pH 5.0
and are the subjects of current investigations in our group. Additionally, 
pHLIP(D14Gla;D25Aad)-MMAF, while being 3.7-fold less potent than pHLIP(WT)-
MMAF at low pH, shows a remarkable 25-fold improvement at low pH over 
physiological pH, which is similar to that of pHLIP(WT)-MMAF (Table 3.2). However, 
treating at 40 nM results also in 100% survival at pH 7.4 but, unlike pHLIP(WT)-
MMAF, leads to only  ~27% cell killing at low pH (vs. 80% for pHLIP(WT)-MMAF). It 
is important to note that the cytotoxicity observed when cells are treated at higher 
concentrations and at pH 7.4 is not due to any intrinsic peptide cytotoxicity or to pHLIP 
insertion itself, as none of the pHLIP variant peptides have any harmful effects on the 
cell viability  at 10 µM (Figure 3.11B). This is consistent with previous observations that 
pHLIP is minimally  toxic to HeLa cells.177,181 In addition, cell killing does not seem to be 
due to instability of the linker (or any  other chemical instability) in cell media either, as 
no degradation products are observed by HPLC or mass spectroscopy after low pH 
treatment with pHLIP(WT)−MMAF (Figure 3.12).  This result  is consistent with our 
previous observation that the disulfide bond between pHLIP and MMAE is stable in cell 
media over the time frame of the cell treatment.177
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 Although previous studies showed that neither pHLIP-MMAE conjugates, pHLIP 
alone nor low pH treatments disrupt the plasma membrane, including that of MDA-
MB-231 cells,94,177 we also assessed here whether the pHLIP-MMAF conjugates may 
cause cell death through disruption of the plasma membrane. We quantified the uptake of 
Trypan blue, which can be taken up by cells only  if their plasma membrane is disrupted, 
and the release of the intracellular enzyme lactate dehydrogenase (LDH) from potentially 
damaged cells.182 Figure 3.13 shows that neither the conjugates nor low pH treatment 
causes significant update of Trypan blue or release of LDH, confirming that the 
conjugates do not cause dramatic disruption of the cell membrane. 
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Figure 3.12 Chemical Stability of pHLIP(WT)-MMAF. HPLC trace of 10 µM 
pHLIP(WT)-MMAF after incubation in cell media for 2h at pH 5.0 and 37 ºC. No 
significant degradation was observed for either of the pHLIP conjugate: For each HPLC 
run, every  peak was collected and checked by  mass spectroscopy. In all cases, the 
conjugates were found intact.
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 Nevertheless, our results show that all six pHLIP-MMAF conjugates can inhibit  
cancer cell proliferation in a pH-selective and concentration-dependent manner and offer 
clear advantages over treatment with free MMAF, albeit with different efficacy. 
However, pHLIP(WT)-MMAF displays the highest efficacy at low pH and one of the 
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Figure 3.13 Effect of pHLIP-MMAF Variants on Plasma Membrane Integrity and 
Lactate Dehydrogenase (LDH) Release. (A) The integrity of the plasma membrane is 
assessed by the uptake of trypan blue dye. 3,000 cells/well of HeLa cells were seeded, 
incubated until confluent (~72 hours) and treated with 10 µM for 2 hours at pH 7.4 
(black bars) or pH 5.0 (grey bars). Cells were detached and counted based on trypan blue 
uptake with an hemacytometer: % of intact cells corresponds to the number of cells not 
showing any dye uptake over the total number of cells. Results are shown as mean ± SD 
(n=3). (B) LDH release assay.  Cells were seeded at a density of 200,000 cells/well in a 
24 well plate, allowed to adhere overnight and treated with 10 µM  for 2 hours at pH 7.4 
(black bars) or pH 5.0 (grey bars). Cell media supernatant was monitored for the 
presence of LDH following treatment. Results are shown as mean ± SD (n=3).
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largest pH-selectivities of all conjugates. We therefore, selected it as the lead agent for 
further efficacy evaluation in xenograft-based animal studies.
            3.4.B.3 Monitoring therapeutic efficacy of pHLIP(WT)-MMAF in vivo
 To evaluate the therapeutic efficacy of pHLIP(WT)-MMAF in vivo, NCr nu/nu 
mice bearing HeLa xenografts were randomized into cohorts with statistically  similar 
tumor sizes. Agents (pHLIP-MMAF or vehicle control) were administered on days 1, 3, 
5, and 8 post-randomization. Consistent with in vitro data demonstrating that HeLa cells 
are sensitive to pHLIP-MMAF (Figure 3.10), administration of the pHLIP-based 
conjugate slowed tumor growth compared to vehicle control when measured both as a 
fraction of initial tumor size (Figure 3.14A) and as an increase in absolute tumor weight 
(data not shown). By day eight of the study, tumors in pHLIP(WT)-MMAF treated 
animals had grown to sizes that were 168.1 +/-17.5% of initial volumes. This was 
statistically  smaller (P = 0.04) than tumors in vehicle-treated animals, which expanded to 
247.4 +/- 29.9 % of their initial volumes. The statistically significant difference was 
maintained through day  10 (P = 0.01). Although loss of statistical significance (P = 0.24) 
was observed after day 13 (five days after treatment was stopped), the trend in tumor 
growth inhibition was retained. This trend in tumor inhibition was reflected in the overall 
survival of animals treated with pHLIP-MMAF. A tumor weight of 500 mg was 
prospectively  set as a stopping point for this study. As depicted in Figure 3.14B treatment 
of mice with pHLIP-MMAF increased rates of overall survival as compared to the 
vehicle-treated cohort. At the end of the three-week study, four animals in the control 
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cohort had been removed from study due to exceeding the 500 mg tumor weight cut-off. 
This is in contrast  to pHLIP-MMAF were only a single animal had a tumor size that 
required its removal from study. The ability of pHLIP-MMAF to elicit anti-tumor 
activity in vivo was also observed when Ncr nu/nu mice bearing epidermoid carcinoma 
A431 tumors were treated using an intraperitoneal (i.p.) route of delivery. Ki-67 
immunohistochemical staining was used as marker of tumor cell proliferation. A range of 
2016 – 3662 (median = 2513) cells were counted in each of four fields for three tumors 
from each cohort. 
 Tumors from pHLIP-MMAF treated animals displayed a statistically significant 
(P<0.05) decrease in Ki-67 positive cells as compared to those from vehicle-treated 
animals (72.7±1.2%  vs 79.7 ± 1.3% Ki-67 positive). Although pHLIP-MMAF was able 
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Figure 3.14 Inhibition of Tumor Growth In Vivo. HeLa cells were injected 
subcutaneously into the inguinal space of female NCr nu/nu mice. Tumors were allowed 
to develop until they were approximately  75 mm3 in size. On day 0, animals were 
randomized into cohorts with statistically similar tumor sizes; pHLIP(WT)-MMAF (76.8 
+/- 19.3 mm3; n=8) and vehicle control (73 +/- 15.6 mm3; n=9) cohorts. On days 1, 3, 5, 
and 8, animals were injected i.v. with 200 µL of either pHLIP(WT)-MMAF (20 µM in 
PBS + 1% DMSO) or vehicle control (PBS + 1% DMSO). Tumors were measured with 
calipers routinely for approximately 3 weeks.
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to slow cell proliferation in this model, the effect was modest and was unable to slow 
overall tumor growth rates (data not shown). This could be due to inherent resistance of 
A431 to auristatin-based cell killing (Figure 3.15), inefficient dosing, or a combination of 
both. pHLIP-MMAF was dosed at same level through both the i.v. and i.p. routes. It is 
possible that the bolus effect typically observed with i.v. administration resulted in higher 
levels of drug uptake in those tumors. Critical to the hypothesis that pHLIP selectively 
targets tumors, animals receiving either i.p or i.v. administration of pHLIP-MMAF 
exhibited no overt signs of toxicities.
3.5 Conclusions
 The development of tumor-targeting vehicles capable to selectively deliver 
cytotoxic agents hold the promise of being curative cancer therapies. Here, we have 
demonstrated that pHLIP provides localized delivery  of two auristatin derivatives, a 
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Figure 3.15 Effects of Free MMAF on A431 Cell Proliferation. For each cell assay, 
3,000 cells/well (96-well plate) were seeded, allowed to adhere overnight, treated 72 
hours with MMAF pH 7.4 . Cell viability  was assessed with the MTT assay. MMAF 
treated cells were normalized to the 1% DMSO controls, as 100% cell viability.  Results 
are shown as mean ± SEM (n=6)
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clinically  relevant cytotoxic agent. In combination, pHLIP-Auristatin drug conjugates 
synergistically  provide greater selectivity  and inhibit cancer cell proliferation in a 
concentration- and pH-dependent manner in vitro. Moreover, the tumor homing abilities 
of pHLIP-MMAE conjugates were presented in MDA-MB-231 triple negative breast 
cancer xenograft  tumors in vivo. Direct comparisons of the activity  of pHLIP variants 
with the more cell impermeable MMAF were investigated against HeLa cervical cancer 
cells. Importantly, pHLIP(WT)-MMAF was the most  efficacious therapeutic in vitro and 
its therapeutic potential was investigated in vivo.  These studies also highlight that, 
despite, their hypothesized advantages, the other pHLIP variants considered so far are 
not as efficient as pHLIP(WT) in these particular experimental settings. However, it is 
possible that their respective efficacy may differ when tested against different cancer cell 
lines, at different pH, or in combination with other therapeutics. The variants may also 
translate differently to in vivo models and are, therefore, the focus of current 
investigations in our group.   
3.6 Future Directions
 3.6.1 Therapeutic Efficacy
 Future studies with our family of pHLIP-MMAF conjugates will include 
treatment in cultured cells at  each variants respective pH50 of insertion. While our 
experimental conditions used a pH treatment to push the equilibrium to favor mostly 
inserted pHLIP the conjugates could behave differently at pH that may match better the 
tumor environment. It would also be advantageous to test the variants against other cell 
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lines, specifically  MDA-MB-231. While we observed better efficacy with our 
pHLIP(WT)-MMAF conjugate than with our pHLIP(WT)-MMAE they  are compared to 
each other in different cells lines, as seen with the A431 lung cancer cells, each may have 
different resistances to auristatin based therapy.  
 While the animal studies done in this work gave promise towards the 
development of pHLIP-auristatin based therapies, we would like to investigate longer 
experimental settings, more treatment administration and direct comparisons of the 
variants against HeLa xenografts. We would also like to further optimize the treatment 
conditions and compare targeting capabilities and therapeutic efficacies of the pHLIP-
MMAF variants in animal models. It would be favorable to study the conjugates against 
a more prevalent cancer cell line, such as triple negative breast cancer due its challenges 
of targeting by conventional methods.  
 3.6.2 pHLIP variants in mouse models
 In efforts to investigate the differences between the targeting capabilities of 
pHLIP variants, each was labeled  at the N-terminus with AlexaFluor 750, and injected 
into mouse models harboring MDA-MB-231 xenografts. Very  preliminary data (Figure 
3.16) show that despite the strong signal in the bladder in close proximity to the tumor, 
varying degrees of accumulation of the probe is seen with Alexa750-labeled 
pHLIP(WT), pHLIP(RIIQ), pHLIP(D14Gla;D25Aad), and pHLIP(P20G), while no 
tumor accumulation was seen with pHLIP(R11Q;D14Up) (not shown). These results 
highlight the difference in targeting and distribution between pHLIP variants. Future 
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work will include injection of the probe in a fat pad superior to the bladder in order to 
better separate the signals as well as the investigation the potential of pHLIP as a 
theranostic tool by  tethering a fluorescent moiety to the N-terminus and MMAF 
conjugated to the C-terminus for delivery.  
 3.6.3 Pyrrolobenzodiazepines 
 We envision that pHLIP-based delivery  can be extended to another class of 
natural products found to exhibit potent (sub-pM) antibiotic and anti-tumor effects, the 
sequence-specific DNA cross-linkers, pyrrolobenzodiazepines (PBDs). PBDs are capable 
of cross-linking within the minor groove of DNA at specific sites without distorting the 
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Figure 3.16 Imaging of pHLIP Variants in MDA-MB-231/Luc Tumors. Cells mixed 
with matrigel were injected into the first  mammary fat pad of scid mice. Tumors grew to 
a diameter of approximately 5 mm. Mice were injected retro-orbitally with 4 nM of 4 
different AlexaFluor750-pHLIP variants. After acquisition of the fluorescence images 24 
hours post probe injection (left), mice received an injection of 4 mg luciferin i.p., and 
bioluminescence images were taken after 5 minutes (right).
Figure 6
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helix, which may  aid in avoiding therapeutic resistance. PBD monomers bind 
specifically to the exocyclic amino group  of guanine with specificity to 5′-purine-G-
purine sequences.183,184 A dramatic increase in cytotoxicity and sequence selectivity has 
been observed with the larger PBD dimer (PBDD), which  allows for the crosslinking of 
separated guanines on opposite DNA strands.184-188 PBDDs have become another drug of 
choice for investigations with ADCs.  The SGD-1882 derivative has been shown when 
conjugated to the CD33 antibody for the treatment of acute myeloid leukemia (AML), 
with multidrug resistance.189  Therefore, we chose this derivative to focus on as it can be 
modified to contain  a succinimide nitrophenyl based linker for further conjugation to 
pHLIP. The synthesis of SGD-1882 is shown in Scheme 3.3, and will be attempted in our 
laboratory. The efficacy of pHLIP-PBDD can then be tested in cells and investigated in 
combination with pHLIP-MMAF for synergistic activities.  As described in Chapter 1, 
combination therapies are most effective when targeting different cellular activity. 
Therefore, we believe that when combined with the anti-tubulin auristatins, they will 
synergize to create an efficacious therapeutic cocktail as the PBDD can induce cell death 
in both dividing and non-dividing cells.  
80
81
Sc
he
m
e 
3.
3 
Fu
ll 
sy
nt
he
si
s o
f P
B
D
D
: S
G
D
-1
88
2
OH O
HO
O
I(C
H 2
) 3I
TH
F
Na
OH
He
at
48
 hr
s
O
O O
HO
O
O
OH
O
1
ox
aly
l c
hlo
rid
e
M
eO
H
O
O O
O
O
O
O
O
3
Re
flu
x
O/
N
2
Sn
Cl
4
HN
O
3
CH
2C
l 2
-2
0 
o C
20
 m
in
O
O O
O
O
O
O
O
O 2
N
NO
2
4
Na
OH TH
F
40
 o C
6 
ho
ur
s
O
O O
HO
O
O
OH
O
O 2
N
NO
2
5
ox
aly
l c
hlo
rid
e
DM
F
TH
F
RT
16
 h
ou
rs
O
O O
Cl
O
O
Cl
O
O 2
N
NO
2
6
7
O
O O
O
O
O
O 2
N
NO
2
N
O
N
O
HO
O
OH
O
TE
A
TH
F
-3
0 
o C
N 2
 at
m
N H
OO
HO
H-
Cl
O
O O
O
O
O
H N
H N
N
N
Ra
ne
y N
ick
el
M
eO
H
H 6
N 2
O
He
at
HO
O
OH
O
8
O
O O
O
O
O
N
N
N
N
LiB
H 4
TH
F
Et
OH H 2
O
16
RT
N 2
 at
m
NH
2
M
eO
ED
C
DM
AP
DI
EA
CH
2C
l 2
DC
M
N
S
S
OH
O R
T
O
O O
O
O
O
N
N
N
N
17
N H
M
eO
O
S
S
N
O
O O
O
O
O
H N
H N
N
N
TB
SC
l
im
ida
zo
le
DM
F
N 2
 at
m
TB
SO
O
OT
BS
O
9
O
O O
O
O
O
N
N
N
N
n-
Bu
Li
TH
F
DM
F
SE
M
Cl
TB
SO
O
OT
BS
O
10
SE
M
SE
M
-3
0 
o C
N 2
 at
m
O
O O
O
O
O
N
N
N
N
TB
AF
TH
F
O
O
11
SE
M
SE
M
OH
HO
RT
82
O
O O
O
O
O
N
N
N
N
TC
CA
TE
M
PO
DC
M
O
O
12
SE
M
SE
M
O
O
0 
o C
N 2
 at
m
O
O O
O
O
O
N
N
N
N
2,
6-
lut
idi
ne
tri
flic
 a
nh
yd
rid
e
DC
M
O
O
13
SE
M
SE
M
-4
5 
o C
N 2
 at
m
Tf
O
OT
f
O
O O
O
O
O
N
N
N
N
Pd
(P
Ph
3) 4
Na
2C
O
3
to
lue
ne
Et
OH H 2
O
O
O
14
SE
M
SE
M
N 2
 at
m
Tf
O
NH
2
NH
2
B
O O
O
O O
O
O
O
N
N
N
N
Pd
(P
Ph
3) 4
Na
2C
O
3
to
lue
ne
Et
OH H 2
O
O
O
15
SE
M
SE
M
RT
N 2
 at
m
NH
2
OM
e
B
HO HO
M
eO
O
O O
O
O
O
N
N
N
N
LiB
H 4
TH
F
Et
OH H 2
O
16
RT
N 2
 at
m
NH
2
M
eO
ED
C
DM
AP
DI
EA
CH
2C
l 2
DC
M
N
S
S
OH
O R
T
O
O O
O
O
O
N
N
N
N
17
N H
M
eO
O
S
S
N
Appendix 3.1 Molecular Weights and Purities of pHLIP-MMAE Constructs
Construct Calculated [M + H+] Found [M + H+] Purity
pHLIP(WT)-MMAE 5046 5047 >98%
pHLIP(D25E)-MMAE 5031 5032 >85%
Alexa750-pHLIP(WT)-MMAE ~5915 5912 >95%
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Appendix 3.2 Molecular Weights and Purities of pHLIP-MMAF Constructs
Construct Calculated [M + H+] Found [M + H+] Purity
pHLIP(WT)-MMAF 5030 5030 >98%
pHLIP(D25E)-MMAF 5045 5053 >98%
pHLIP(P20G)-MMAF 4991 5018* >98%
pHLIP(R11Q)-MMAF 5003 5004 >98%
pHLIP(R11Q;D14Up)-MMAF 5003 5008 >98%
pHLIP(D14Gla;D25Aad)-MMAF 5515 5113 >98%
*pHLIP(P20G)-MMAF calculated [M + Na+] = 5013
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CHAPTER 4: 
Down-Regulation of PAR1 Activity with a pHLIP-based Allosteric Antagonist 
Induces Cancer Cell Death
4.1 Abstract
 Even though abnormal expression of G protein-coupled receptors (GPCRs) and of 
their ligands is observed in many cancer cells of various origins, only a few anti-cancer 
compounds directly act  on their signaling. One promising approach to modulate their 
activity consists of targeting the receptor cytoplasmic surfaces interacting with the 
associated G proteins using peptides mimicking the intracellular loops of the receptor. 
Thus, to be fully  effective, the peptide mimics must be selectively targeted to the tumor 
while sparing healthy tissues, translocated across the cell membrane and stay anchored to 
the cytoplasmic leaflet of the plasma membrane. Here, we introduce a novel way to 
selectively target and inhibit the activity of a GPCR in cancer cells under acidic 
conditions, such as those found in solid tumors. We find that the conjugation of a peptide 
fragment derived from the third intracellular loop of the Protease Activated Receptor 1 
(PAR1) to a peptide that can selectively  target tumors solely based on their acidity 
(pHLIP), produces a construct capable of effectively  down-regulating PAR1 activity in a 
concentration - and pH-dependent manner, and of inducing a potent cytotoxic effect in a 
panel of cancer cells that is proportional to the relative level of receptor expression at the 
cell surface. This strategy not only  allows for a more selective targeting and specific 
intracellular delivery than current approaches, but also offers new possibilities for 
developing novel anti-cancer drugs targeting GPCRs.
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4.2. Introduction
G-Protein Coupled Receptors (GPCRs) represent the largest family of cell surface 
receptors and are encoded by nearly 1,000 of the ~22,000 genes in the human genome. 
Consequently, they are involved in almost every aspect of cell biology  and physiology 
(e.g., sensory systems, neurotransmission, inflammation pathways, hormone signaling, 
cell-cell communication) by mediating a plethora of cellular signals across the cell 
plasma membrane in response to an array  of ligands. Despite exhibiting striking diversity 
in primary sequence and biological function, GPCRs share the same fundamental 
architecture, consisting of a hydrophobic core of seven- transmembrane α-helices joined 
by extracellular and intracellular loops that interact to form a three-dimensional barrel 
within the cell membrane. They transduce extracellular signals by coupling to hetero-
trimeric guanine nucleotide binding proteins (G-proteins), consisting of α, β and γ 
subunits (Figure 4.1). G-proteins are associated to the cytoplasmic face of the receptor 
through interactions with the intracellular loops.190 Upon ligand binding, the receptor 
undergoes conformational changes that stimulate exchange of guanosine triphosphate 
(GTP) to guanosine diphosphate (GDP) on Gα subunits, dissociating Gα and Gβγ 
subunits that, in turn, trigger biological responses by  binding to effector proteins that 
regulate processes (e.g., second messenger production, protein kinase cascades, gene 
transcription and ion channel activity).
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 1
Figure 4.1 Schematic Representation of GPCR Signaling 
 Due to their critical role in physiological processes and links to numerous 
diseases, GPCRs are prime pharmaceutical drug targets. Currently 30-40% of marketed 
drugs target GPCRs, generating annual worldwide drug sales exceeding $70 billion.191 
Most drugs developed against GPCRs bind to the extracellular orthosteric ligand domain 
and are small molecules. However, these binding sites across members within a receptor 
subfamily are often highly conserved, making it difficult  to achieve high selectivity for a 
specific GPCR.192 Therefore, the ability to modulate signaling through an allosteric site 
may provide novel drug target opportunities.191-193 Allosteric modulation provides greater 
selectivity as it can perturb the signaling cascade irrespective of the presence or absence 
of the orthosteric ligand.194 While most allosteric modulators act extracellularly, 
intracellular domains of GPCRs are key sites for allosteric regulation due to multiple 
regions in the cytoplasmic domains of GPCRs to which G proteins can make contact.193 
Mutagenesis studies have demonstrated that the third intracellular loop (i3) mediates a 
large part of the coupling between receptor and G protein.195-197 Importantly, intracellular 
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modulation of GPCRs increases the number of pharmaceutical targets as there are still 
many without known endogenous ligands, making drug development for these “orphan” 
GPCRs challenging.191
 In the late 1990s scientists Kuliopulos and Covic at Tufts Medical Center began 
researching ways in which GPCR activity  could be modulated intracellularly. They 
developed peptide modulators based on the i3 loops of GPCRs to exploit the coupling 
relationship  between the i3 loop, shown in Figure 4.2 and the G protein to modify the 
signaling pathway, hence the activity of the receptor. This technique was first described 
in a report by Covic et al. as an entirely novel approach to modulate GPCR activity at the 
cytosolic plasma membrane interface using palmitoylated peptides (Figure 4.2), termed 
“Pepducins”.195,198
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breast cancer cells both in vitro and in animals. The data presented
here suggest that PAR1 blockade by P1pal-7 may be a viable
approach to affect PAR1-mediated survival pathways and may
synergistically enhance cytotoxicity and apoptosis with antitumor
agents, as exemplified by Taxotere, in models of breast cancer.
Combination treatment of breast tumors with P1pal-7 and
Taxotere significantly inhibited tumor growth and caused massive
apoptosis. Our present study characterizes the involvement of
the prominent cell survival mediator, Akt, in the context of
PAR1 blockade and combination therapy. While investigating the
role of PAR1 in growth and survival, we observed that breast
cancer cells expressing PAR1 have increased proliferative
potential but are simultaneously vulnerable to PAR1 blockade.
In fact, stable expression of PAR1 (MCF7-PAR1/N55) is sufficient
in rendering P1pal-7 sensitivity to the MCF7 cell line. PAR1
blockade also had cytotoxic effects against MDA-MB-231 and
Bt549 breast cancer cell lines naturally expressing high levels of
PAR1, representing an advanced, endocrine therapy-resistant form
of breast cancer (43, 44). PAR1, hence, provides a novel mode of
attack against advanced breast cancer models with aggressive
phenotypes.
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Figure 6. MMP-1/PAR1 blockade inhibits breast tumor
metastasis to the lung. A, MDA-MB-231/GFP cells
(2 ! 106) were introduced via the tail vein of female nude
mice (n = 5-10 mice per group). Vehicle (10% DMSO),
P1pal-7 (10 mg/kg), or FN439 (5 mg/kg) were administered
6 d/wk for 6 wk. Lungs were photographed (left column )
and sectioned for H&E staining (right column ;
magnification, !4). T, tumor nodule. B, number of
metastatic tumor nodules per lung as counted under a
light microscope. ***, P < 0.001.
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breast cancer cells both in vitro and in animals. The data presented
here suggest that PAR1 blockade by P1pal-7 may be a viable
approach to affect PAR1-mediated survival pathways and may
synergistically enhance cytotoxicity and apoptosis with antitumor
agents, as exemplified by Taxotere, in models of breast cancer.
Combination treatment of breast tumors with P1pal-7 and
Taxotere significantly inhibited tumor growth and caused massive
apoptosis. Our present study characterizes the involvement of
the prominent cell survival mediator, Akt, in the context of
PAR1 blockade and combination therapy. While investigating the
role of PAR1 in growth and survival, we observed that breast
cancer cells expressing PAR1 have increased proliferative
potential but are simultaneously vulnerable to PAR1 blockade.
In fact, stable expression of PAR1 (MCF7-PAR1/N55) is sufficient
in rendering P1pal-7 sensitivity to the MCF7 cell line. PAR1
blockade also had cytotoxic effects against MDA-MB-231 and
Bt549 breast cancer cell lines naturally expressing high levels of
PAR1, representing an advanced, endocrine therapy-resistant form
of breast cancer (43, 44). PAR1, hence, provides a novel mode of
attack against advanced breast cancer models with aggressive
phenotypes.
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Figure 6. MMP-1/PAR1 blockade inhibits breast tumor
metastasis to the lung. A, DA-MB-231/GFP cells
(2 ! 106) were introduced via the tail vein of female nude
mice (n = 5-10 mice per group). Vehicle (10% DMSO),
P1pal-7 (10 mg/kg), or FN439 (5 mg/kg) were administered
6 d/wk for 6 wk. Lungs were photographed (left column )
and sectioned for H&E staining (right column ;
magnification, !4). T, tumor nodule. B, number of
metastatic tumor nodules per lung as counted under a
light microscope. ***, P < 0.001.
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• Promotes tumorigenicity, invasion, and metastasis in breast and 
ovarian carcinoma.
• High expression levels in invasive breast cancer cell lines.
• Palmitoylated peptide fragments based on the i3 :
- Induce toxicity in breast cancer cells by blocking PAR1 signaling. 
- Suppress breast tumor survival in MD-MB-231 xenografts.
- Inhibit metastasis to the lungs in mice.
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breast cancer cells both in vitro and in animals. The data presented
here suggest that PAR1 blockade by P1pal-7 may be a viable
approach to affect PAR1-mediated survival pathways and may
synergistically enhance cytotoxicity and apoptosis with antitumor
agents, as exemplified by Taxotere, in models of breast cancer.
Combination treatment of breast tumors with P1pal-7 and
Taxotere significantly inhibited tumor growth and caused massive
apoptosis. Our present study characterizes the involvement of
the prominent cell survival mediator, Akt, in the context of
PAR1 blockade and combination therapy. While investigating the
role of PAR1 in growth and survival, we observed that breast
cancer cells expressing PAR1 have increased proliferative
potential but are simultaneously vulnerable to PAR1 blockade.
In fact, stable expression of PAR1 (MCF7-PAR1/N55) is sufficient
in rendering P1pal-7 sensitivity to the MCF7 cell line. PAR1
blockade also had cytotoxic effects against MDA-MB-231 and
Bt549 breast cancer cell lines naturally expressing high levels of
PAR1, representing an advanced, endocrine therapy-resistant form
of breast cancer (43, 44). PAR1, hence, provides a novel mode of
attack against advanced breast cancer models with aggressive
phenotypes.
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Figure 6. MMP-1/PAR1 blockade inhibits breast tumor
metastasis to the lung. A, MDA-MB-231/GFP cells
(2 ! 106) were introduced via the tail vein of female nude
mice (n = 5-10 mice per group). Vehicle (10% DMSO),
P1pal-7 (10 mg/kg), or FN439 (5 mg/kg) were admini tered
6 d/wk for 6 wk. Lungs were photographed (left column )
and sectioned for H&E staining (right column ;
magnification, !4). T, tumor nodule. B, number of
metastatic tumor nodules per lung as counted under a
light microscope. ***, P < 0.001.
References
1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ.
Cancer statistics, 2007. CA Cancer J Clin 2007;57:43–66.
2. Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD,
Frye DK, Buzdar AU. Long-term follow-up of patients
with complete remission following combination che-
motherapy for metastatic breast cancer. J Clin Oncol
1996;14:2197–205.
3. Orlando L, Colleoni M, Fedele P, et al. Management of
advanced breast cancer. Ann Oncol 2007;18 Suppl 6:
vi74–6.
4. Ihemelandu CU, Leffall LD, Jr., Dewitty RL, et al.
Molecular breast cancer subtypes in premenopausal and
postmenopausal African-American women: age-specific
prevalence and survival. J Surg Res 2007;143:109–18.
5. Dalerba P, Cho RW, Clarke MF. Cancer stem cells:
models and concepts. Annu Rev Med 2007;58:267–84.
6. Granovsky-Grisaru S, Zaidoun S, Grisaru D, et al. The
pattern of protease activat d recepto 1 (PAR1)
expression in endometrial carcinoma. Gynecol Oncol
2006;103:802–6.
7. Grisaru-Granovsky S, Salah Z, Maoz M, Pruss D, Beller
U, Bar-Shavit R. Differential expression of protease
activated receptor 1 (Par1) and pY397FAK in benign and
malignant human ovarian tissue samples. Int J Cancer
2005;113:372–8.
8. Heider I, Schulze B, Oswald E, Henklei P, Scheele J,
Kaufmann R. PAR1-type thrombin recepto stimul tes
migration and matrix adhesion of human c lon
carcinoma cells by a PKCq-dependent mech nism.
Oncol R s 2004;14:475–82.
9. Greenberg DL, Mize GJ, Takayama TK. Protease-
activated receptor mediated RhoA signaling and cyto-
skeletal reorganization in LNCaP cells. Biochemistry
2003;42:702–9.
Cancer Research
Cancer Res 2009; 69: (15). August 1, 2009 6230 www.aacrjournals.org
 American As ociation for anc r Research Copyright © 2009 
 on February 23, 2011cancerres.aacrjournals.orgDownloaded from 
Published OnlineFirst July 21, 2009; DOI:10.1158/0008-5472.CAN-09-0187
breast cancer cells both in vitro and in animals. The data presented
here suggest that PAR1 blockade by P1pal-7 may be a viable
approach to affect AR1-mediated survival pathways and may
synergistically enhance cytotoxicity and apoptosis with antitumor
agents, as exemplified by Taxotere, in models of breast cancer.
Combination treatment of breast tumors with P1pal-7 and
Taxotere significantly inhibited tumor growth and caused massive
apoptosis. Our present study characterizes the involvement of
the prominent cell survival mediator, Akt, in the context of
PAR1 blockade and combination therapy. While investigating the
role of PAR1 in growth and survival, we observed that breast
cancer cells expressing PAR1 have increased proliferative
potential but are simultaneously vulnerable to PAR1 blockade.
In fact, stable expression of PAR1 (MCF7-PAR1/N55) is sufficient
in rendering P1pal-7 sensitivity to the MCF7 cell line. PAR1
blockade also had cytotoxic effects against MDA-MB-231 and
Bt549 breast cancer cell lines naturally expressing high levels of
PAR1, representing an advanced, endocrine therapy-resistant form
of breast cancer (43, 44). PAR1, hence, provides a novel mode of
attack against advanced breast cancer models with aggressive
phenotypes.
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Figure 6. MMP-1/PAR1 blockade inhibits breast tumor
metastasis to the lung. A, DA-MB-231/GFP cells
(2 ! 106) were introduced via the tail vein of female nude
mice (n = 5-10 mice per group). Vehicle (10% DMSO),
P1pal-7 (10 mg/kg), or FN439 (5 mg/kg) were administered
6 d/wk for 6 wk. Lungs were photographed (left column )
and sectioned for H&E staining (right column ;
magnification, !4). T, tumor nodule. B, number of
metastatic tumor nodules per lung as counted under a
light microscope. ***, P < 0.001.
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• Promote  tumorigenicity, invasion, and metastasis in breast and 
ovarian carcinoma.
• High expression levels in invasive breast cancer cell lines.
• Palmitoylated peptide fragments based on the i3 :
- Induce toxicity in breast cancer cells by blocking PAR1 signaling. 
- Suppress breast tumor survival in MD-MB-231 xenografts.
- Inhibit metastasis to the lungs in mice.
Figure 4.2 Pepducins and Representative GPCR Pepducins are membrane 
anchored peptide mimics of the 3rd intracellular loop of the target GPCR
 In that study it was shown that the protease-activated receptors 1 and 2 (PAR 1 
and 2) could be activated or antagonized based on the peptide mimic sequence used. 
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Subsequent studies showed that certain pepducins based on the i1, i2, and i3 loops could 
also act as either agonists or antagonists of several GPCRs, including protease-activated 
receptors (PAR1, PAR2 and PAR4), chemokine receptors (CXCR1, CXCR2 and 
CXCR4), sphingosine 1-phosphate receptor-3 (S1P3), melanocortin-4 receptor, and 
formyl peptide receptor 2.174,191,195,198-201 Biochemical and pharmacologic studies 
indicated that the lipid moiety of pepducins facilitates translocation across the lipid 
bilayer and serves to anchor the peptide mimic at the cytosolic interface of the plasma 
membrane in the vicinity of the target receptor. 198 Confirmation of the pepducins’ ability 
to traverse the plasma membrane was first  provided by Wielders et al. who employed a 
FRET based assay using NBD labeled phospholipids distributed across the plasma 
membrane, and monitored the energy transfer with combined treatment of the acceptor 
rhodamine labeled PAR1 pepducin, it was shown that the pepducin is able to come in 
close proximity to the labeled  phosphotidylserine located on the inner leaflet of the 
plasma membrane.198,201,202  In another study, it  was shown with confocal microscopy 
that a fluorescently  labeled pepducin associated with the intracellular region of the target 
Smoothened receptor and subsequently  inhibited its signaling198,203. Taken together, these 
studies show sufficient evidence that the lipid moiety mediates the delivery and 
membrane anchorage of the receptor modulating peptides. Even though the exact 
mechanism of action remains unclear, it  is proposed that the peptide moiety directly 
interacts with its cognate receptor, and stabilizes the active or inactive conformation of 
the receptor.191
89
 Specifically, the PAR receptors are tethered-ligand receptors that are activated 
through the proteolytic cleavage of their extracellular domains by  serine proteases such 
as thrombin, activated protein C, plasmin and factor Xa.204 Within the PAR subfamily, 
PAR1, PAR2 and PAR4 have been shown to be modulated effectively by pepducins.
195,201,205,206 PAR4 pepducins have been investigated for the treatment of ulcerative 
colitis, irritable bowel syndrome, and rhematoid arthritis.200,201,207-209 PAR2 pepducins 
have been shown to successfully suppress signaling in vitro and effectively block PAR2-
dependent inflammatory response in mouse models.198,205 PAR1 (Figure 4.2) has proven 
to be an attractive target for oncogenic treatment because of its involvement in the 
invasive and metastatic processes of various cancers, including breast, ovary, lung, colon 
and prostate cancers as well as melanoma.16,191,199,200,206,210-214 For instance, PAR1 has 
shown to promote tumorigenicity, invasion, and metastasis in breast and ovarian 
carcinoma xenograft models.199,200,206,210,215-218 Therefore, the inhibition of PAR1 
signaling should potentially abate cancer progression.  Several pepducins for the 
modulation of PAR1 have been investigated with varying lengths (from 7-19) with 
sequences based on the i3 intacellular loop.  Of particular interest, the pepducin P1pal-7 
(7 amino acid residue peptide mimic of PAR1 i3 KKSRALF, with a palmatate lipid tail) 
developed to modulate the PAR1/G-protein signaling was first shown to shut down the 
amount of intracellular calcium flux activity as well as phospholipase Cβ-dependent 
inositol triphosphate, effectively inhibiting PAR1 signaling pathways.206 The efficacy of 
P1pal-7 was treated in nude mice containing PAR1-expressing human breast cancer 
xenografts and > 60% decrease in tumor volume was observed when compared to 
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vehicle-treated mice.198,206 In another animal study, it was shown that  treatment with 
P1pal-7 strikingly inhibited angiogenesis of peritoneal ovarian cancer.198,199 In a 
succeeding investigation of P1pal-7 it was shown to block PAR1 signaling and cause 
cytotoxic effects against PAR1 expressing breast cancer cell lines proportional to 
expression levels, such as MCF7, MDA-MB-231 and Bt549 cells.  Importantly, 
treatment of P1pal-7 attenuated the metastatic propensity of breast cancer cells in vivo to 
the lungs.200  Moreover, combination therapy  with P1-pal7 and docetaxel (the standard-
of-care chemotherapeutic agent for the treatment of metastatic breast cancer) showed 
strong cytotoxic synergy in inhibiting growth, invasion and metastasis of breast cancer 
and ovarian cancer xenografts in nude mice, providing a significant  improvement over 
treatment with docetaxel alone.199,200
 Targeting an intracellular loop of GPCRs using a peptide mimic of the loop such 
as pepducins, shows promising therapeutic potential.  While lipidation enhances the 
potency of peptide inhibitors by  stabilizing the peptide folding through interactions with 
the membrane, enables cell permeability and increases the effective concentration in 
receptor vicinity the targeting specificity relies solely on the over-expression of PAR1 in 
cells.  It, therefore, lacks specificity to cancer cells, and would likely result in off-target 
toxicity  in an in vivo setting if used as a treatment modality.  Nevertheless, pepducins 
attain some specificity, but it  relies on the over-expression of the GPCRs of interest (e.g., 
PAR1) in the tumor relatively to healthy tissues.  As explained previously, this type of 
targeting approach is destined to result in therapy resistance.  
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 4.3 Experimental Rationale
 In the present study, we hypothesized that higher selectivity  towards cancer cells 
and a more controlled intracellular delivery  can be achieved by replacing the lipid 
vehicle with the pHLIP. Therefore, upon insertion, the modulating peptide will remain 
membrane anchored, if conjugated to the C-terminal end of pHLIP through a non-labile 
linker.  Here, we show that a peptide fragment derived from the third intracellular (i3) 
loop of PAR1, induces cytotoxicity from the down-regulation of PAR1 cell signaling 
pathway when conjugated to the C-terminus of pHLIP, as shown in Figure 4.3. This 
study represents not only the first demonstrated example of using pHLIP to modulate a 
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Figure 4.3 Schematic Representation of pHLIP-P1AP: The hypothesized antagonistic 
effect of the pHLIP-PAR1 Inhibitory Peptide conjugate (pHLIP-P1AP) on the activity  of 
the Protease-Activated Receptor 1 (PAR1). The peptide sequences of pHLIP and P1AP 
are shown. 
GPCR, but also a new way to selectively modulate the activity of this important class of 
membrane receptors in cancer cells. 
4.4 Results and Discussion
 4.4.1 Synthesis of pHLIP-P1AP conjugate. 
 Peptides that  mimic the residues of the intracellular loops of GPCRs have been 
shown to allosterically modulate receptor conformation and signaling. Particularly, the 
pepducin P1pal-7, which consists of a palmitoyl and a seven-residue peptide 
(KKSRALF; named in this study, PAR1 Allosteric Peptide or P1AP) that mimics i3 of 
PAR1, was shown to induce toxicity in breast  cancer cells expressing PAR1 by blocking 
its signaling. It was also shown to suppress breast tumor survival in MD-MB-231 
xenografts to inhibit  93metastasis to the lungs and inhibit  progression and metastasis of 
ovarian cancer in mice.195,200,206 P1AP was synthesized by standard Fmoc solid-phase 
synthesis using H-Rink Amide resin. A non-cleavable linker (chloro-acetylchloride) was 
added to the peptide mimic still on resin in an acyl substitution reaction, as shown in 
Scheme 4.1. Further conjugation to pHLIP was performed through a SN2 reaction, the 
nucleophilic thiol of pHLIP displaces the halogen present on P1AP, yielding a non-
reducible thioether linkage between the two peptides (Scheme 4.1).  The construct was 
purified by  HPLC and its identity determined with MALDI-TOF mass spectrometry 
(Appendix 4.1). This linking strategy  should anchor P1AP to the cytosolic face of the 
plasma membrane of cancer cells upon translocation by  pHLIP in an acidic environment, 
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allowing for P1AP to stabilize PAR1 in its non-active conformation, effectively down-
regulating its signaling cascade.
 4.4.2 Biophysical Characterization of the Interaction of pHLIP-P1AP 
 Conjugates with Lipid Bilayers. 
 Before evaluating pHLIP-mediated translocation of P1AP into cancer cells, the 
conjugates interaction with lipid bilayers was investigated using far UV circular 
dichroism (CD) spectroscopy  and tryptophan fluorescence to monitor the process of 
insertion at  low pH (Figure 4.4). CD was used to determine the secondary structure of 
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Scheme 4.1 Synthesis of pHLIP-P1AP.  P1AP (KKSRALF) was prepared using 
standard Fmoc solid-phase synthesis on H-Rink amide resin.  At the completion of the 
peptide sequence, the N-terminal protecting Fmoc group was removed and the non-labile 
linker chloro-acetylchloride was coupled on resin in the presence of DIEA for 3 hours. 
The resulting modified peptide was cleaved from resin, purified and conjugated to 
pHLIP via disulfide exchange.  The same synthesis scheme was used for obtaining the 
scrambled version of P1AP (AFKLKSR).
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pHLIP-P1AP in the presence of POPC LUVs at both normal and low pH. Results in 
Figure 4.4A show the typical pH-dependent transition of pHLIP from an unstructured 
conformation to an α-helical structure when the pH is lowered from pH 7.4 (blue line) to 
4.0 (red line). Tryptophan fluorescence was employed to determine the insertion of 
pHLIP into the vesicle bilayers based on the sensitivity of Trp  fluorescence emission to 
the polarity of the environment. 
 At pH 7.4, the Trp fluorescence emission maximum of pHLIP is centered at 340 
nm (Figure 4.4B, blue line), reflecting the relative exposure of Trp residues to polar, 
aqueous environments. Lowering the pH to 4.0 results not only in λmax blue shift  (albeit 
a small one, ~ 3 nm), but also in a large increase in fluorescence emission intensity. 
These observations are characteristic for Trp residues buried in more hydrophobic 
environments upon peptide folding, and are consistent  with the conformational change 
observed by  CD.  All together, these results demonstrate that the presence of P1AP at the 
Figure 4.4 Interaction of pHLIP-P1AP with Lipid Bilayers. (A-B) pHLIP-P1AP 
circular dichroism spectroscopy and Trp Fluorescence, respectively. Spectra were 
measured in presence of POPC liposomes at pH 7.5 (blue line) and at pH 4.0 (red line). 
[peptide] = 7 µM and peptide- lipid ratio =1:300 with POPC liposomes. 
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C-term of pHLIP, does not disrupt significantly the pH-mediated shape-shifting behavior 
of pHLIP.
 4.4.3 The anti-proliferative effect of pHLIP-P1AP correlates with the level of 
 PAR1 cell surface expression. 
 The efficacy  of pHLIP-P1AP to down-regulate PAR1 signaling and inhibit cell 
proliferation in a concentration- and pH-dependent manner was investigated across a 
panel of cell lines with varying expression levels of PAR1. Relative PAR1 membrane 
surface expression levels were determined by flow cytometry in several cell lines: HeLa, 
MCF7, MCF7-PAR1/N55 and MDA-MB-231. Little PAR1 cell surface expression was 
observed in the PAR1 ‘null’ MCF7 and HeLa cell lines (Figure 4.5). The MCF7 breast 
cancer cell line that was transfected to stably express PAR1, MCF7-PAR1/N55 (MCF7/
PAR1+; kind gift of Lidija Covic, Tufts University)200,201,206, exhibited a 2-fold increase 
in PAR1 expression compared to MCF7; while MDA-MB-231, a breast cancer cell line 
that constitutively expresses high levels of PAR1200,206,219, showed the highest level of 
PAR1 surface expression (4-fold increase compared to MCF7). We reasoned that the cell 
lines with the highest relative level of PAR1 membrane surface expression levels would 
be those that respond the most to pHLIP-P1AP treatments. Importantly, the invasive 
MDA-MB-231 cells classified as triple negative breast cancer (TNBC) cells due to their 
lack of estrogen receptor, progesterone receptor and HER2 expression, all of which are 
crucial cellular receptors for targeted cancer therapeutics. Thus, in contrast to the other 
treatment groups, there are no effective targeted therapies against TNBC.169,170 
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Cell treatments were conducted from concentrations ranging from 1.25 to 10 µM at 
either pH 7.4 or 5.0. After a 2 h incubation at  37 °C, the treatment media was replaced by 
fresh media, and cells were grown for an additional 72 h at  normal pH before assessing 
cell viability using the MTT assay. This treatment protocol is quite stringent  when 
compared to the typical multi-days exposure treatments used with pepducins.200 As 
hypothesized, treatments with pHLIP-P1AP at either normal or low pHs had no 
Figure 4.5 PAR1 Expression Levels. (A) HeLa, (B) MCF7, (C) MCF7/PAR1+ and (D) 
MDA- MB-231 cells were analyzed for PAR1 surface expression levels employing 
mouse anti-PAR1 and goat anti-mouse IgG-FITC antibodies. After incubation with 
antibodies cells were fixed and analyzed using BDFacs Canto II flow cytometer. Cells 
treated with secondary antibody alone are shown in grey, and primary plus secondary 
antibodies are shown in black.  Relative expression levels are obtained by normalizing 
the fluorescence intensity of samples exposed to both antibodies to that of the samples 
only exposed to secondary antibody.  Results are normalized shown in the graph (E) and 
table (F) as mean ± SEM (n=3). 
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significant effect  on cell viability  of HeLa and MCF7 cells (Figure 4.6A-B), consistent 
with their low level of PAR1 membrane expression. On the other hand, when MDA-
MB-231 cells were treated with pHLIP-P1AP, cell proliferation was drastically 
disrupted. Up to 77% growth inhibition is observed (Figure 4.6C). 
(A) (B)
(C) (D)
Figure 4.6 Inhibition of Cancer Cell Growth. pHLIP-P1AP treated in (A) HeLa, (B) 
MCF7, (C) MDA-MB-231 and (D) MCF7/PAR1+ cells. Blue columns represent  cells 
treated at pH 7.4 and cells treated at low pH are shown in red. For each cell line, 3,000 
cells/well (96-well plate) were seeded, allowed to adhere overnight, treated for 2 hours, 
washed once with media and grown for 72 hour in complete medium at physiologic pH. 
Cell viability was assessed with the MTT assay. All measurements were normalized to 
the media control (0 µM, pH 7.4), as 100% cell viability. Results are shown as mean ± 
SEM (n=9-12). To assess statistical significance two-tailed Student’s t test analyses at 
95% confidence level were performed for the comparison of pH 7.4 and pH 5.0 
treatments. For Figures (A) and (B), none of the differences between treatment at pH 7.4 
and pH 5.0 were statistically different (p > 0.05). 
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 The antiproliferative effect is concentration-dependent, with cell viability ranging 
from 65 to 23%, with increasing treatment concentration ranging from 1.25 to 10 µM, 
respectively (Figure 4.6C, red bars). Noteworthy, similar growth inhibition is seen when 
MDA-MB-231 cells are treated with the pepducin P1pal-7, albeit for an extended 72 
hour treatment and at  pH 7.4 (Figure 4.9B). As expected, inhibition of cell growth is also 
pH-selective: Treatment with pHLIP-P1AP at pH 7.4 under the same conditions had no 
significant effect on cell proliferation (Figure 4.6D, blue bars). This is consistent with the 
notion that P1AP delivery is mediated by the pH-dependent insertion of pHLIP across 
the plasma membrane. When MCF7/PAR1+ cells were treated with pHLIP-P1AP a 
concentration and pH-dependent disruption of cell proliferation (51% cell death) was 
also observed (Figure 4.6D). However, MCF7/PAR1+ cells seem to be less sensitive to 
pHLIP-P1AP treatment than MDA-
MB-231 cells, as shown by a 
higher cell viability  at all treatment 
concentrations (Figure 4.6D). 
These results are consistent with 
the lower PAR1 surface expression 
in MCF7/PAR1+ cells. Notably, the 
antiproliferative effect of pHLIP-
P1AP is directly correlated to the 
level of PAR1 expression at the cell 
surface (Figure 4.7). 
99
Figure 4.7 PAR1 Expression Correlates to 
Inhibition of Cell Growth. Viability of cells after 
treatment of 10 µM pHLIP-P1AP correlates to 
relative PAR1 expression. Cell viability  (n=9-12) 
was determined as shown in Figure 4.6, and PAR1 
expression (n=3) was analyzed by flow as shown 
in Figure 4.5. Results are shown as mean ± SEM 
(R2 = 0.9985). 
 The relatively high cytotoxicity observed at higher concentrations is not due to 
any intrinsic peptide cytotoxicity or to pHLIP insertion itself, as neither pHLIP nor 
P1AP has any  harmful effects on the cell viability  of any cell line at  10 µM (Figure 4.8). 
This is consistent with previous observation that pHLIP is minimally  toxic,177 and that 
P1AP is unlikely to cross the plasma membrane on its own based on its physical 
properties (MW = 924 g.mol-1 and octanol/water partition coefficient [Log Po/w] = 
-2.93; calculated with QikProp 3.0).220 Importantly, our results also showed that the 
inhibitory effect of P1AP appears to be sequence specific, as a scrambled version of 
P1AP (AFKLKSR) does not affect significantly  cell growth when conjugated to either 
pHLIP (Figure 4.9A) or a palmitoyl (Figure 4.9B). It is also important to note that there 
are no detrimental contribution of the low pH treatment in itself on proliferation of any 
of the cell lines studied, as shown by treatment without pHLIP-P1AP (Figure 4.6, 0 µM 
treatments). 
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Figure 4.8 Neither P1AP or pHLIP Peptides Are Cytotoxic. For each peptide, all cell 
lines were seeded at 3,000 cells/well (96 well plate) and allowed to adhere overnight. Cell 
media was removed and replaced with 10 µM of either (A) P1AP or (B) pHLIP at  pH 7.4 
(black bars) or pH 5.0 (grey bars) for 2 hours, washed once with media and grown for 72 
hours in complete medium at physiologic pH. Cell viability was assessed with the MTT 
assay, and all measurements were normalized to the media control (0 µM, pH 7.4), as 
100% cell viability. Results are shown as mean ± SEM (n=9-12). None of the differences 
between treatment at  pH 7.4 and pH 5.0 were statistically  different (p  > 0.05) using the 
Student’s t test.
 To ensure that pHLIP-P1AP was not causing cell death through disruption of the 
plasma membrane, we assessed the percentage of intact membrane after treatments based 
on the uptake of trypan blue. Membrane disruption was not observed in any of the cell 
lines after treatment with neither pHLIP-P1AP nor low pH environments (Figure 4.10). 
All together, these results suggest  that the antiproliferative effect of pHLIP-P1AP is due 
to the pH-selective translocation of P1AP across the plasma membrane and to the 
inhibition of PAR1 activity.
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(A) (B)
Figure 4.9 pHLIP-Scrambled P1AP and Pepducin P1pal-7 Cell Growth Inhibition. 
All cell lines were seeded at 3,000 cells/well (96 well plate) and allowed to adhere 
overnight. Cell media was removed and replaced with (A) 10 µM  of pHLIP-Scrambled 
P1AP at pH 7.4 (black bars) or pH 5.0 (grey bars) for 2 hours, washed once with media 
and grown for 72 hours in complete medium at physiologic pH. (B) Cell media was 
removed and replaced with 10 µM pepducins in DMEM  for 72 hours.  Cell viability 
was assessed with the MTT assay, and all measurements were normalized to the media 
control (0 µM, pH 7.4), as 100% cell viability. Results are shown as mean ± SEM 
(n=9-12). None of the differences between treatment at pH 7.4 and pH 5.0 were 
statistically different (p > 0.05) using the Student’s t test. 
4.4.4 pHLIP-P1AP Down-Regulates PAR1-Mediated Calcium Mobilization. 
 To determine whether pHLIP-P1AP inhibits PAR1 activity, we conducted 
functional activity assays of PAR1 by  monitoring changes in intracellular calcium fluxes 
in response to serine protease activation. Upon activation by thrombin, PAR1 stimulates 
phospholipase Cβ via Gαq/11 and/or βɣ(Gi), which causes production of inositol 
triphosphate and mobilization of Ca2+ from intracellular stores.219 This mobilization can 
be monitored by  using the calcium sensitive indicator fura-2 (Life Technologies) that 
fluoresces when bound to calcium. P1AP was previously shown to inhibit  Ca2+ by 
specifically blocking PAR1 activity and not another downstream component in the Ca2+ 
flux pathway.195 
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Figure 4.10 pHLIP-P1AP Does Not Disrupt the Cell Membrane. The integrity  of the 
plasma membrane was assessed by the uptake of trypan blue dye. All cell lines were 
seeded at 3,000 cells/well, allowed to adhere. Upon confluency  (~72 hours) cells were 
treated with 10 µM pHLIP-P1AP or media alone (no peptide) for 2 hours at pH 7.4 (black 
bars) or pH 5.0 (grey  bars). Cells were detached and counted based on trypan blue uptake 
with an hemacytometer: % of intact cells corresponds to the number of cells not showing 
any dye uptake over the total number of cells. Results are shown as mean ± SEM (n=3). 
None of the differences between treatment at pH 7.4 and pH 5.0 were statistically 
different (p > 0.05) using the Student’s t test.
 As shown in Figures 4.11, MDA-MB-231 cells showed a sharp increase in 
fluorescence signal that quickly falls back to baseline levels when cells were treated with 
thrombin after treatments at both normal (Figure 4.11A) and low pH (Figure 4.11B), 
indicating robust intracellular Ca2+ fluxes and that PAR1 is functionally active. 
Conversely, cells not exposed to thrombin do not exhibit any increase in fluorescence. 
Treating cells with pHLIP-P1AP at normal pH before thrombin activation elicited a sharp 
increase in intracellular Ca2+ similar to that of the one observed with thrombin alone 
(Figure 4.11C). However, as hypothesized, the Ca2+ response was greatly reduced (58%) 
when cells were treated with pHLIP-P1AP at lower pH, indicating that PAR1 activity is 
down-regulated even after activation with thrombin. It  is important to note that a shorter 
pHLIP-P1AP treatment time was implemented to avoid unwanted effects on intracellular 
Ca2+ due to a prolonged exposure to an acidic environment. We thus believe that the 
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Figure 4.11 PAR1-Mediated Calcium Mobilization. MDA-MB-231 cells were seeded 
at a density of 40,000 cells/well and allowed to adhere overnight. Cells were treated at 
(A) pH 7.4, (B) pH 5.0 or (C) with pHLIP-P1AP at both pH. After 10 min incubation at 
37ºC, the treatment media was removed, and the calcium indicator fura-2, NM was 
added. Cells were incubated for 30 min at 37ºC and then for 30 min at  room temperature. 
10 nM thrombin was then added (A, B; black lines and C; black and dashed lines) or not 
(A, B; dotted lines), and fluorescence emission intensity  at 530 nm (excitation at 485 nm) 
was immediately measured. 
inhibition of PAR1 is more robust during the 2-hour treatment used in the anti-
proliferative assay. 
4.5 Conclusion
 In summary, we have demonstrated that pHLIP provides localized delivery and 
membrane anchorage of a polar, conformationally flexible allosteric peptide inhibitor of 
a GPCR. In combination, the pHLIP-P1AP conjugate inhibits cancer cell proliferation in 
a concentration- and pH-dependent manner by specifically  down-regulating PAR1 
activity, allowing for a more selective targeting and specific intracellular delivery  than 
current approaches. To our knowledge, it is the first study to employ pHLIP to deliver a 
membrane receptor modulating peptide. 
4.6 Future Directions
 Studies have shown that dual treatment with P1pal-7 and docetaxel synergistically 
inhibits cell viability and promotes apoptosis in PAR1-expressing breast carcinoma cells.
200 MDA-MB-231 cells treated with 1 µmol/L P1pal-7 and 0.3 µmol/L docetaxel for 72 
hours yielded ~5% viable cells.  This combination therapy also showed synergistic 
inhibition of tumor growth in MDA-MB-231 xenografts in mice. This dual treatment 
approach can be applied to a combination therapy of docetaxel with pHLIP-P1AP. This 
combinatorial approach can be extended to not  only free docetaxel drug but also to a 
pHLIP-docetaxel construct or ultimately a single pHLIP peptide containing both the 
P1AP peptide and the docetaxel drug. As the majority of oncological treatments in the 
clinical setting are chemotherapeutic cocktails (a mixture of different cancer therapies 
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with differing targets and mechanism of action) it would be advantageous to develop 
dual combination therapies at the early stages of cancer therapeutic design. 
 There are several pepducins that have shown to antagonize PAR1 receptor.  P1pal-7 
was chosen as our first pepducin to start with due to the small length of PAR1 mimic 
peptide (P1AP). However, there are varying lengths (7-19 amino acid residues) of PAR1 
antagonistic pepducins that have shown to inhibit PAR1 activity in vitro.198 Therefore, 
we have an arsenal of potential peptides that could be investigated.  
 While this work focused on PAR1, we believe that  this approach can be applied to 
a broad range of GPCRs. Currently, pepducins have been identified for more than 20 
receptors, including PAR1, 2, and 4; chemokine receptors CXCR1, 2 and 4; 5-
hydroxytryptamine receptors; and several class A orphan receptors.191 With over 800 
members in the human genome, which includes more than a hundred orphan receptors, 
there is an abundance of opportunities for directly  targeting GPCRs expressed on tumor 
cells. 
 We expect this strategy can be extended to the modulation of other membrane 
receptors that rely  on intracellular regions for their signaling processes.  For example, the 
lab is currently focusing efforts on disrupting the oligomerization of the Epidermal 
Growth Factor Receptor (EGFR), which relies on its juxtamembrane (JM) regions for 
this interaction. Similarly to the pHLIP-P1AP construct, a JM  peptide mimic consisting 
of seven amino acid residues is conjugated to pHLIP for targeting and membrane 
anchorage is used to associate with EGFR JM region to stabilize it as a monomer and 
consequently attenuate its signaling.  We thus envision that our strategy will enable the 
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discovery  and development of a potentially important class of therapeutic peptides in 
oncology.
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Appendix 4.1 Molecular Weights and Purities of pHLIP-P1AP Constructs
Construct Calculated [M + H+] Found [M + H+] Purity
P1AP-linker 925.5 926.7 > 95%
pHLIP-P1AP 5101.9 5101.2 > 95%
Scrambled P1AP-
linker 925.5 928.5 > 95%
pHLIP-Scrambled 
P1AP 5101.9 5101.9 > 95%
P1pal-7 1087.5 1087.6 > 95%
Scrambled 
P1pal-7 1087.5 1085.3 > 95%
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CHAPTER 5: 
pH-Selective Cytotoxicity of pHLIP-Antimicrobial Peptide Conjugates
5.1 Abstract
 Positively charged antimicrobial peptides have become promising agents for the 
treatment of cancer by inducing apoptosis though their preferential binding and 
disruption of negatively charged membranes, such as the mitochondrial membrane. 
(KLAKLAK)2 is such a peptide but due to its polarity, it  cannot cross the cellular 
membrane and therefore relies on the use of a delivery agent. For targeted delivery, 
previous studies have relied on cell penetrating peptides, nanoparticles or specific 
biomarkers. Herein, we investigated the first  use of pHLIP to selectively target  and 
directly  translocate (KLAKLAK)2  into the cytoplasm of breast cancer cells, based on the 
acidic tumor micro-environment. With the goal of identifying a lead conjugate with 
optimized selective cytotoxicity towards cancer cells, we analyzed a family of 
(KLAKLAK)2 analogs with varying size, polarity  and charge. We present a highly 
efficacious pHLIP conjugate that selectively  induces concentration- and pH-dependent 
toxicity in breast cancer cells.
5.2 Introduction
 In search for novel and more efficacious anticancer therapeutics, many positively 
charged antimicrobial peptides (AMPs) have surfaced as promising agents because they 
can kill cancer cells by  preferentially  disrupting mitochondrial membranes while sparing 
plasma membranes. Indeed, while mitochondrial membranes maintain large 
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transmembrane potentials and have a high content of anionic phospholipids, the outer 
leaflet of eukaryotic plasma membrane is almost exclusively  composed of zwitterionic 
phospholipids and has a low membrane potential.221-225 Thus, upon cytoplasmic delivery, 
an AMP would induce cell death by preferential mitochondrial membrane disruption, 
while remaining non-toxic outside the cells.225 Therapeutic strategies that induce 
mitochondrial depolarization are attractive because they  bypass apoptosis resistance 
mechanisms that act upstream of the mitochondria.226,227 
 AMPs have been proposed to have several mechanistic modes in which they can 
disrupt membranes. In the carpet mechanism, peptides are absorbed parallel to the 
bilayer to produce a detergent like effect. The barrel-stave pore model is when the 
peptide inserts into the membrane perpendicularly  forming a pore parallel to the 
phospholipid chains.  Similarly, the toroidal pore model induces a curvature to the 
membrane after the perpendicular peptide insertion so that the lumen is partly  lined by 
peptide and partly  phospholipid head groups. Lastly  the disordered toroidal pore model 
modifies the aforementioned that less-rigid peptide confirmations and orientations are 
observed and the lumen is lined with phospholipid head groups.  
 (KLAKLAK)2 is a cationic AMP that forms an amphipathic α-helix when bound 
to negatively charged lipid membranes, with the charged and nonpolar residues on 
opposite faces,228-230 and that can induce cell death in a variety  of cell lines upon cell 
internalization.230-235 The amphipathic nature of (KLAKLAK)2 is shown in Figure 5.1, 
the helical wheel representation.  Here the purple pentagons represent the positively 
charged polar lysine residues, the green triangles represent the hydrophobic leucine 
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residues and the orange circles represent the 
lesser hydrophobic alanine residues. Even though 
it has been shown to be able to accumulate on, 
disrupt and depolarize the mitochondrial 
membrane, contrasting mechanisms of cell death 
have been proposed for (KLAKLAK)2-based 
cancer therapeutics. While some reports indicate 
that these peptides induce apoptosis due to their 
ability  to depolarize mitochondrial membranes,
230-234 others have reported that they induce 
plasma membrane lysis leading to oncotic/
necrotic death in cancer cells in caspase-dependent and caspase-independent pathways.
234,235 This discrepancy in mechanisms of action is very likely due to the difference in the 
methods used to target and translocate (KLAKLAK)2 conjugates to and into cancer cells.
230-235 Indeed, the efficacy of (KLAKLAK)2 is challenged by its poor ability  to permeate 
the plasma membrane,230 and it therefore requires the use of a delivery agent to facilitate 
its cellular uptake. Several methods have been implemented for the delivery of 
(KLAKLAK)2 including, membrane receptor ligands, antibodies, cell penetrating 
peptides232, and nanoparticles.236 However, these strategies either are effective at rather 
high concentration (~ 100 µM),230 lack specificity  for cancer cells (e.g, cell penetrating 
peptides), or rely on the over-expression of biomarkers on the surface of cancer cells to 
achieve their targeting.  While over-expression provides a window of selective targeting, 
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Figure 5 .1 . He l i ca l Whee l 
Representation of (KLAKLAK)2. 
Here the purple pentagons represent 
the positively  charged polar lysine 
residues, the green triangles 
represent the hydrophobic leucine 
residues and the orange circles 
represent the lesser hydrophobic 
alanine residues.
uptake into normal tissues is seen and has the potential to lead to unacceptable toxicity 
profiles. Moreover, it is not  clear how lytic peptides internalized through endocytosis and 
how they escape the endosome to reach the mitochondrial membrane.  Thus, there is a 
need for a delivery agent capable of enhancing the selectivity, potency and spectrum of 
the malignant cells that can be targeted by AMPs and (KLAKLAK)2, specifically.
5.3 Experimental Rationale
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Figure 5.2. Schematic Representation of pHLIP-KLAKs the 
hypothesized effect of the pHLIP–KLAKs on apoptosis and cell 
viability. The peptide sequences of pHLIP is shown.
 In the present study, with the goal of inducing selective toxicity in cancer cells, 
we employ  the tumor-targeting pHLIP for the specific targeting and delivery of a family 
of (KLAKLAK)2 derivatives directly into the cytoplasm. Here, we show that 
(KLAKLAK)2 derivatives, when conjugated to the C-terminus of pHLIP, induce a pH-
selective toxicity effect in breast  cancer cells from mitochondrial membrane disruption 
(Figure 5.2). This study is the first not only to employ pHLIP to deliver antimicrobial 
peptides into cancer cells but also to test the size, polarity and charge of the cargo peptide 
systematically. We thus anticipate that this approach could be applied to a broad range of 
therapeutic peptides with intracellular targets.
5.4 Results and Discussion
 5.4.1 Synthesis of pHLIP-KLAK Conjugates
 While (KLAKLAK)2 has been shown to be efficacious at inducing cell death 
when transported into cells, its relatively  large size and high polarity  were a concern, as 
the properties of cell-impermeable cargo molecules that can be delivered into cells by 
pHLIP are not fully defined. Indeed, even though pHLIP has been shown previously to 
be capable of translocating across membrane highly polar peptides (octanol/water 
partition coefficient [Log Po/w] ~ 3) in a pH-dependent manner, these peptides were 
cyclic and substantially  smaller than (KLAKLAK)2 (molecular weight ~ 800 g.mol-1)147. 
Thus, with the goal of optimizing delivery by pHLIP and toxicity towards cancer cells, 
we tested, in addition to (KLAKLAK)2, smaller peptide analogs ranging in size and 
polarity (Table 5.1). The four-amino acid peptide analogues, KAAK, KKKK, KLLK and 
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KGGK have been shown previously to exhibit, when covalently linked to a fatty acid 
(lipopeptide), potent broad-spectrum antimicrobial activity  against a range of fungi, 
Gram-positive and Gram-negative bacteria, albeit with varying specificity237-239. We also 
tested the activity of the 4-amino acid KLAK as well as of the 7-amino acid KLAKLAK 
peptide because its size and polarity make it an attractive compromise to the long and 
polar (KLAKLAK)2 and the short four-amino acid peptides. Importantly, these six 
shorter analogues have never been tested for their activity against mitochondrial 
membranes upon intracellular delivery.
 (KLAKLAK)2 and its six peptide derivatives (subsequently designated KLAKs) 
were synthesized and conjugated to the C-terminus of pHLIP through a disulfide bond 
(Scheme 5.1), allowing for the antimicrobial peptides to act on the mitochondrial 
membranes upon cytoplasmic entry and disulfide reduction. KLAKs, pHLIP and 
conjugates were purified by  RP-HPLC and identified by MALDI-TOF MS (Appendices 
5.1-5.2).
Table 5.1. Properties of cargo peptides attached to the C-terminus of 
C-terminal cargo MWa Log Po/w a
KGGK 490.6 -4.22
KAAK 518.7 -3.66
KLAK 560.8 -2.28
KLLK 602.8 -1.81
KKKK 632.9 -4.78
KLAKLAK 873.2 -3.49
(KLAKLAK)2 1625.1 -5.69
aOctanol/water partition coefficients (Log Po/w) and molecular weight (MW) were calculated using 
QikProp 3.0 (Schrödinger, LLC).
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 5.4.2 Cell Viability of pHLIP-KLAK Analogues
 The efficacy of the pHLIP-KLAKs constructs to inhibit cell proliferation in a 
concentration- and pH-dependent was investigated in MDA-MB-231 breast cancer cells. 
Cell treatments were conducted from 10 µM down to 2.5 nM  of pHLIP-KLAKs at either 
pH 7.4 or 5.0 for 2 hours at 37ºC, after which constructs were removed and cells were 
recovered for 72 hours at normal pH in complete media before assessing cell viability 
using the MTT assay. Noteworthy, this treatment protocol, which was chosen to prevent 
any unwanted effects to the cells due to the prolonged exposure to a low pH 
environment, is much shorter and stringent than the 72-hour treatments typically used 
with (KLAKLAK)2.230,234,235,240 We have previously shown that this treatment protocol 
and pHLIP alone have no effect on MDA-MB-231 cell viability.177,181
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Scheme 5.1 Conjugation of pHLIP-(KLAKLAK)2.  Peptides were prepared using 
standard Fmoc solid-phase synthesis on H-Rink amide resin.  At completion peptides 
were cleaved from resin, purified and conjugated to pHLIP via disulfide exchange.  The 
same synthesis and conjugation conditions were used to obtain all pHLIP-KLAK 
analogues
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Figure 5.3. Inhibition of cell  growth. MDA-MB-231 cells treated with 4-amino acid 
pHLIP-KLAKS conjugates. Black columns represent cells treated at pH 7.4 and cells 
treated at low pH are shown in grey. For each condition, 3,000 cells/well (96-well plate) 
were seeded, allowed to adhere overnight, treated for 2 hours, washed once with media 
and cultured for 72 hour in complete medium at physiologic pH. Cell viability  was 
assessed with the MTT assay. All measurements were normalized to the media control (0 
µM, pH 7.4), as 100% cell viability. Results are shown as mean ± SEM (n=9-12). 
 Treatments with the tetrapeptide pHLIP-KLAKs conjugates were carried out from 
1.25 µM to 10 µM. As hypothesized, little to no effect on MDA-MB-231 cell viability 
was observed when cells were treated with these constructs at normal physiological pH 
(Figure 5.3, black bars). On the other hand, cell proliferation was drastically  disrupted 
when cells were treated at low pH (up to 95% growth inhibition) (Figure 5.3, grey bars). 
The anti-proliferative effect is also concentration-dependent, with cell viability ranging 
from 69% to 5%, with increasing treatment  concentration ranging from 1.25 to 10 µM, 
respectively. Consistent with the fact that the palmitoyl-KGGK lipopeptide had the 
highest relative antimicrobial activity of all KXXK peptides when tested by Makovitzki 
et al. against bacteria, fungi and yeast,237 pHLIP-KGGK showed the most overall cell 
proliferation inhibition of all the 4-amino acid pHLIP-KLAKs conjugates (Figure 5.3A). 
Indeed, while pHLIP-KKKK, pHLIP-KAAK and pHLIP-KLLK showed also high 
proliferation inhibition at 10 µM  (from 80% to 95%), their overall activity is lower than 
pHLIP-KGGK (Figures 5.3B, C and D). The pHLIP-KLAK construct exhibited similar 
activity to that of pHLIP-KLLK with growth inhibition up to 80% with 10 µM 
treatments (Figure 5.3E). Noteworthy, the anti-proliferative effect observed is not due to 
any intrinsic peptide cytotoxicity or to cell membrane disruption, as neither pHLIP(WT) 
nor the tetrapeptides has any  significant harmful effects on the cell viability or plasma 
membrane integrity at 10 µM (Figure 5.4)
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Figure 5.4 Effect of Free Peptides on Cell Viability and Plasma Membrane 
Integrity.  For each condition, 3,000 cells/well (96-well plate) were seeded, incubated 
until confluent (~72 hours) and treated for 2 hours with 10 µM of free pHLIP(WT) or 
free tetrapeptides at pH 7.4 (black bars) and a low pH (grey bars). (A) Cell viability 
assay. After the 2-hour treatment, cells were washed once with media and cultured for 72 
hour in complete medium at physiologic pH. Cell viability was assessed with the MTT 
assay. All measurements were normalized to the media control (0 µM, pH 7.4), as 100% 
cell viability.  Results are shown as mean ± SEM (n=9-12).  (B) After the 2-hour 
treatment, cells were detached and counted based on trypan blue uptake with an 
hemacytometer: % of intact cells corresponds to the number of cells not showing any  dye 
uptake over the total number of cells. Results are shown as mean ± SD (n=3).
 When cells were treated with pHLIP-(KLAKLAK)2 or pHLIP-KLAKLAK, 
concentration- and pH-dependent cell growth inhibitions were also observed, with little 
to no significant decrease in cell viability at pH 7.4 and up to 85% and 90% inhibition 
with pHLIP-(KLAKLAK)2 and pHLIP-KLAKLAK treatments, respectively (Figure 
5.5A and 5.5B).  However, these pHLIP-(KLAKLAK)2 and pHLIP-KLAKLAK are 
significantly more cytotoxic than the 4-amino acid pHLIP-KLAKs conjugates, with IC50 
values of 1 µM  and 0.5 µM  for pHLIP-(KLAKLAK)2 and pHLIP-KLAKLAK, 
respectively. We thus subsequently focused our efforts on these two conjugates.
 It is important to point out that, while using short treatment time, the pHLIP-
(KLAKLAK)2 and pHLIP-KLAKLAK constructs achieve greater cell growth inhibition 
at much lower concentrations when compared to most reported delivery methods. For 
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Figure 5.5 Inhibition of Cell Growth MDA-MB-231 cells treated with pHLIP-
(KLAKLAK)2 (A), pHLIP-KLAKLAK (B),  Black circles represent cells treated at pH 
7.4 and cells treated at low pH are shown in grey. For each condition, 3,000 cells/well 
(96-well plate) were seeded, allowed to adhere overnight, treated for 2 hours, washed 
once with media and cultured for 72 hour in complete medium at physiologic pH. Cell 
viability was assessed with the MTT assay. All measurements were normalized to the 
media control (0 µM, pH 7.4), as 100% cell viability. Results are shown as mean ± SEM 
(n=9-12). Data at pH 5.0 (A and B) were fitted with a sigmoidal dose-response using 
Prism 6 for Macintosh (GraphPad, Inc).
instance, (KLAKLAK)2, when conjugated to the cyclic tumor-homing peptide CNGRC, 
achieved ~75% cell proliferation inhibition after 96 hours at  60 µM.230  In another study, 
30 µM of (KLAKLAK)2 conjugated to a monoclonal antibody targeting the prostate-
specific membrane antigen were needed to induce 75% cell growth inhibition LnCaP 
prostate cancer cells.234 Finally, another approach, which relies on the formation of 
peptide amphiphile nanofibers that can be internalized by cancer cells, achieved IC50 
values of ~6 µM in MDA-MB-231 and SKBR-3 breast cancer cell lines, though after 24 
hour treatment times.235  Noticeably, Sioud et al. showed that (KLAKLAK)2  when 
conjugated to a cancer-cell binding peptides induces rapid killing in breast cancer cells 
(10-20% cell viability in 1 h treatment), albeit through a very different apparent 
mechanism (i.e., disruption of the cytoplasmic membrane).240
 5.4.3 pHLIP-KLAK Mechanism of Action
 Although some reports indicate that (KLAKLAK)2 induces apoptosis due to its 
ability  to depolarize mitochondrial membranes,230,234,235,241 others have reported that it 
induces plasma membrane lysis leading to necrotic death in cancer cells.240 We therefore 
investigated the possible mechanism(s) of cell death induced by  the pHLIP-
(KLAKLAK)2 and pHLIP-KLAKLAK constructs.
 First, we assessed the effect of the conjugates on the integrity of cell membranes 
based on the uptake of Trypan Blue, which can be taken up by cells only if their plasma 
membrane is disrupted. Figure 5.6A shows that neither the conjugates nor free peptides 
causes disruption of cell membranes. We also measured the release of the intracellular 
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enzyme lactate dehydrogenase (LDH) after peptide treatment, as another method to 
evaluate plasma membrane damage.182 
The results presented in Figure 5.6B and 5.6C show that no significant LDH release is 
observed 2 and 24 hours after treatment. Importantly, it  was previously shown that 
neither pHLIP alone nor low pH treatments disrupts membranes, including that of MDA-
MB-231 cells94,177 (Figure 5.4). Thus, these results indicate that pHLIP-(KLAKLAK)2 
and pHLIP-KLAKLAK do not  cause cell death through dramatic disruption of the 
plasma membrane. 
 However, it  is interesting to note that  some LDH release is observed 24 hours 
post-treatment for cells treated with (KLAKLAK)2 or KLAKLAK at low pH (Figure 
5.6C), indicating that these two peptides have a tendency to disrupt the plasma 
membrane at lower pH. Therefore, while pHLIP-mediated translocation of cargo 
molecules is not thought to be mediated by endocytosis or passive diffusion through the 
membrane, we cannot exclude the possibility  that the observed cytotoxicity of pHLIP-
(KLAKLAK)2 and pHLIP-KLAKLAK might be associated to enhanced membrane 
permeability  and/or membrane-disruptive ability of (KLAKLAK)2 and KLAKLAK at 
low pH. Indeed, acidification and subsequent formation of a pH-gradient across lipid 
membranes have been shown to facilitate membrane translocation of cationic cell 
penetrating peptides such as penetratin.242,243 We thus also assessed the cytotoxicity of 
free (KLAKLAK)2 and KLAKLAK peptides against MDA-MB-231 cells.
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Figure 5.6 Effect of Free Peptides and pHLIP-Conjugates on Plasma Membrane 
Integrity and Lactate Dehydrogenase (LDH) Release. (A) The integrity of the plasma 
membrane is assessed by the uptake of trypan blue dye. 3,000 cells/well of MDA-
MB-231 cells were seeded, incubated until confluent (~72 hours) and treated with 10 
µM for 2 hours at pH 7.4 (black bars) or pH 5.0 (grey bars). Cells were detached and 
counted based on trypan blue uptake with an hemacytometer: % of intact cells 
corresponds to the number of cells not showing any dye uptake over the total number of 
cells. Results are shown as mean ± SD (n=3). (B) LDH release assay.  Cells were seeded 
at a density  of 200,000 cells/well in a 24 well plate, allowed to adhere overnight and 
treated with 10 µM for 2 hours at pH 7.4 (black bars) or pH 5.0 (grey bars).  Cell media 
supernatant was monitored for the presence of LDH following treatment. Results are 
shown as mean ± SD (n=3). 
Figure 5.7 shows that while (KLAKLAK)2 and KLAKLAK are not significantly toxic at 
physiological pH, consistent with previous observations in MDA-MB-231 cells,235,240 
both peptides exhibit enhanced cytotoxicity at low pH when used at  10 µM, albeit at 
different levels. (KLAKLAK)2 shows the greatest enhancement and KLAKLAK shows 
only a modest one, consistent with the number of ionizable groups and the enhanced 
permeability  of such peptides at low pH. However, it is important to note that the pH-
dependent cytotoxicity observed with pHLIP-(KLAKLAK)2 and pHLIP-KLAKLAK 
(Figure 5.5) is unlikely  due to free (KLAKLAK)2 and KLAKLAK, as no degradation 
products are observed by HPLC or mass spectroscopy after low pH treatment with 
pHLIP-(KLAKLAK)2 and pHLIP-KLAKLAK (Figure 5.8).   
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Figure 5.7 Effect of Free Peptides on Cell  Viability. MDA-MB-231 cells were treated 
with 10 µM of either (KLAKLAK)2 (A) or KLAKLAK (B) at pH 7.4 (black circles) or 
pH 5.0 (grey squares) for 2 hours, washed once with media and cultured for 72 hours in 
complete medium at physiologic pH. Cell viability was assessed with the MTT assay, and 
all measurements were normalized to the media control (0 µM, pH 7.4), as 100% cell 
viability. Results are shown as mean ± SEM (n=9). 
Moreover, the lack of activity when cells are treated at physiologic pH provides further 
evidence that the mechanism of entry is likely not endocytosis. Nevertheless, the 
significant killing of free (KLAKLAK)2 is an obvious concern in moving this conjugate 
forward, and we thus focused our subsequent effort solely  on the pHLIP-KLAKLAK 
conjugate.
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Figure 5.8 Chemical Stability of pHLIP Conjugates. HPLC traces of 10 µM  pHLIP-
(KLAKLAK)2 (A) and pHLIP-KLAKLAK (B) after incubation in cell media for 2h at 
pH 5.0 and 37 ºC.  No significant degradation was observed for either of the pHLIP 
conjugates: For each HPLC run, every peak was collected and checked by mass 
spectroscopy. In all cases, the conjugates were found intact.
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Figure 5.9 Induction of Apoptosis Due to Mitochondrial Membrane Disruption. 
Annexin V and MitoTracker Red dual staining was performed and measured by flow 
cytometry  in MDA-MB-231 cells by pHLIP-KLAKLAK, (KLAKLAK)2 and 
KLAKLAK. (A-H)  Cells were treated with either no peptide or with 10 µM peptides at 
pH 7.4 (A-D) or at  pH 5.0 (E-H) for 2 hours, washed once with media and cultured for 24 
hours in complete medium at  physiologic pH. Quantification of mitochondrial 
depolarization and phosphatidyl serine externalization for cell samples was determined 
based on their fluorescence intensities at both 530 (Annexin V Alex Fluor 488) and 633 
(MitoTracker Red) nm.  Cells were gated as two populations based on high MitoTracker/
low Annexin V and low MitoTracker/high Annexin V.  (I) For all measurements the 
percentage of cells in each population was normalized to the media control (0 µM, pH 
7.4).  A minimum of 10,000 events were counted for each data point. The data was 
analyzed using the FACSDiva version 6.1.1 software. Results are shown as mean ± SD 
(n=3). 
 To ensure that pHLIP-KLAKLAK exerts its activity by disrupting the 
mitochondrial membrane, we determined the extent of phosphatidylserine (PS) 
externalization and change in mitochondrial membrane potential, two of the hallmarks of 
(KLAKLAK)2 mechanism of action. These processes can be monitored by flow 
cytometry  using Alexa Fluor 488-labeled Annexin V, which binds to cells based on their 
membrane composition and the MitoTracker Red that only binds to intact  mitochondrial 
membrane.234,244 Thus, live cells with intact mitochondrial membrane and low PS 
externalization should exhibit  high MitoTracker Red and low Annexin V staining. This is 
the case, for example, with non-treated cells at pH 7.4 (Figure 5.9A and 5.9I, Bar Set #1). 
On the other hand, cells ongoing cell death would exhibit increased green fluorescence 
(increase of PS externalization) and decreased red fluorescence (disruption of 
mitochondrial membrane) when compared to live cells. A clear shift in cell population 
should then be observed by flow cytometry. This is case, for example, when cells are 
treated with the staurosporine, a known inducer of apoptosis (Figure 5.10).
 As hypothesized and consistent with the results from the anti-proliferation assay  
(Figure 5.5B), little to no effect on apoptosis markers was observed when MDA-MB-231 
cells were treated with pHLIP-KLAKLAK at normal physiological pH (Figure 5.9B and 
5.9I, Bar Set  #3). On the other hand, a significant increase in Annexin V signal and 
decrease in MitroTracker Red signal are observed when cells were treated with pHLIP-
KLAKLAK at low pH, resulting in clear shift  in cell population (Figure 5.9F and 5.9I, 
Bar Set #4). 
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Increase in Annexin V signal and decrease in MitroTracker Red signals are also 
indicative of the apoptotic process, which is often associated to the activation of 
caspases. Thus, to probe the possible involvement of a caspase-mediated apoptotic 
pathway, we monitored the activity  of the apoptotic effector caspases 3 and 7 after 
treatment.Remarkably, our results (Figure 5.11) show that neither treatments with 
pHLIP-KLAKLAK or KLAKLAK induces any significant caspase activation. These 
results may be appear contradictory, as apoptosis resulting from mitochondrial 
membrane permeabilization is usually believed to be a caspase-dependent process. 
However, apoptosis can be mediated in caspase-independent manners as well. For 
instance, the release of the mitochondrial proteins Apotosis-inducing factor and 
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Figure 5.10 Staurosporine Apoptosis Positive Control. Annexin V -AlexaFluor 488 
and MitoTracker Red dual staining was performed and measured by flow cytometry to 
evaluate the induction of apoptosis in MDA-MB-231 cells by  Staurosporine.  Cells were 
treated with either no compound (A-B) or with 1 µM Staurosporine (C-D) for either 6 (A 
and C) or 24 hours (B and D). The relative amount of cells in each population is shown in 
(E). A minimum of 6,000-10,000 events  were counted for each data point. The data was 
analyzed using the FACSDiva version 6.1.1 software. Results are shown as mean ± SD 
(n=3). 
endonuclease G have been shown to mediate programmed cell death in a caspase-
independent manner after mitochondrial membrane permeabilization.245,246 
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Figure 5.11 Caspase Activity Assay. Cells were seeded at a density  of 3,000 cells/well in 
a 96 well plate, allowed to adhere overnight and treated with either 10 µM peptides for 2 
hours at pH 7.4 (black bars) or pH 5.0 (grey  bars) or 1 µM Staurosporine. Cells treated 
with pHLIP-KLAKLAK or free KLAK peptides were recovered in complete medium and 
cells treated with Staurosporine were treated in the presence of CellEvent Caspase-3/7 
Green Detection Reagent.  Cells were monitored for the presence of active caspase at 24, 
48 and 72 hours, A-C respectively. Results are shown as mean ± SD (n=3).
Moreover, Rege and colleagues showed that their KLAK conjugate can induce prostate 
cancer cell death through mitochondrial damage independently  of caspase activation.234. 
Nevertheless, our results clearly indicate that pHLIP-KLAKLAK toxicity  results from 
disruption of the mitochondrial membrane potential in a pH-mediated manner. 
 Importantly, the low pH treatment has little to no effect on either MitoTracker 
Red and low Annexin V staining (Figure 5.9E and 5.9I, Bar Set #2). Interestingly and 
also consistent with the levels of LDH release and cytotoxicity  observed when cells are 
treated with free peptides (Figures 5.6B, 5.6C and 5.7), (KLAKLAK)2 and KLAKLAK 
appear to induce PS externalization and loss of mitochondrial membrane potential in a 
pH-mediated manner, with (KLAKLAK)2 exhibiting the largest effect and KLAKLAK 
only a modest one (Figure 5.9I, Bar Sets #6 vs #8). The effect of free KLAKLAK is 
significantly lower than with pHLIP-KLAKLAK when cells are treated at low pH. 
Noteworthy, there is no evidence of these effects 6 hours post-treatment with either 
constructs (Figure 5.12), which is consistent with the reported delayed action of the 
KLAK peptide on apoptosis upon its active translocation inside cells.230,235
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 Thus, all together, our results indicate that  the anti-proliferative effect of pHLIP–
KLAKLAK is due to the pH-selective translocation of KLAKLAK across the plasma 
membrane and to mitochondrial membrane disruption. It is crucial to note that pHLIP 
greatly potentiates the activity of KLAKLAK at lower pH, indicating a synergistic effect 
pH 7.4 pH 5.0 pH 7.4 pH 5.0 pH 7.4 pH 5.0 pH 7.4 pH 5.0
no peptide pHLIP-KLAKLAK (KLAKLAK)2 KLAKLAK
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Figure 5.12 Peptides Do Not Induce Apoptosis Within 6 Hours Post-Treatment. 
Annexin V -AlexaFluor 488 and MitoTracker Red dual staining was performed and 
measured by flow cytometry  to evaluate the induction of apoptosis in MDA-MB-231 
cells by pHLIP-KLAKLAK, (KLAKLAK)2 and KLAKLAK. (A-H)  Cells were treated 
with either no peptide or with 10 µM  peptides at pH 7.4 (A-D) or at pH 5.0 (E-H) for 2 
hours, washed once with media and cultured for 6 hours in complete medium at 
physiologic pH. The relative amount of cells in each population is shown in (I). A 
minimum of 10,000 events were counted for each data point. The data was analyzed 
using the FACSDiva version 6.1.1 software. Results are shown as mean ± SD (n=3). 
Multiple comparisons analyses using either the Dunnett (at 95% confidence intervals) or 
the Holm-Ŝidák tests (Prism 6 for Macintosh) show no statistically  significant 
differences between the treatment conditions and the pH 7.4 no peptide control.
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between pHLIP-mediated insertion and enhanced ‘permeability’ of KLAKLAK at low 
pH, which may contribute to the high activity of pHLIP-KLAKLAK and may be 
advantageous in animal settings. 
 
 5.5 Conclusion
 The use of AMPs have become more prevalent for the treatment of cancer but  a 
lack of efficient and selective delivery system has limited their use and impact. Herein, 
we presented a family  of cell-impermeable (KLAKLAK)2 derivatives that  exhibit a wide 
range of physical properties to determine the most efficacious therapeutic cargo peptide 
for targeting and translocation using pHLIP.  Together, our results indicate that this 
family of (KLAKLAK)2 analogs can inhibit  cancer cell growth in a concentration- and 
pH-dependent manner upon pHLIP-mediated translocation. In addition, we identified 
pHLIP-KLAKLAK as a lead conjugate because of its low cytotoxicity at physiological 
pH, chemical stability, high anti-proliferation potency and specific induction of 
mitochondrial membrane disruption at lower pH. 
5.6 Future Directions
 Due to the overlap  of cytotoxic pathways, further studies investigating the exact  
mechanism of action for these constructs could be of particular interest. As 
externalization of PS is observed for cells going through both necrosis and apoptosis, the 
integrity  of the membrane can be monitored simultaneously with use of cell impermeant 
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nucleic dyes such as propidium dye as a marker for necrosis. While we observed no 
presence of active caspase 3 and 7 independent cell death, we could turn our sights to a 
more upstream effector that does not require activation in the apoptotic signaling 
pathway. For example, cytochrome C initiates the caspase-mediated apoptotic pathway 
upon its release from mitochondria. We could also look for the presence of apoptosis-
inducing factor (AIF), which triggers DNA fragmentation and chromatin condensation 
upon entry into the cytoplasm in a caspase-independent manner. Many of these effectors 
can be detected using fluorescent based assays or western blot. As the mechanism of cell 
death of (KLAKLAK)2 varies based on the delivery method, it  is conceivable that the 
tetrapeptides may also utilize a separate distinct mechanism. Identifying this process 
could give us insight into how to optimize and develop a larger library  of small 
therapeutic peptides.
 Observing the morphological changes the cells undergo upon treatment of the 
pHLIP-KLAKs could be of great interest. Towards this end, we could monitor the 
disruption of mitochondrial membrane over several time points using confocal 
microscopy. We could also monitor the morphologies of isolated mitochondria after 
treatments using electron microscopy.  
 The efficacies of the current library could be compared to their D-amino acid 
counterparts. Indeed, KLAK has been shown to be effective when consisting of only  D-
amino acids instead of the naturally occurring L-amino acids, as it disrupts membranes in 
a chiral-independent manner.247,248 This substitution makes the peptide less susceptible to 
proteolytic cleavage, which could be affecting the activity of our current construct. 
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 Eventually, we expect to be able to test the efficacy of our pHLIP-KLAK 
construct in vivo. Certainly, KLAK has proved to be an efficacious therapy in tumor 
therapy in mice with breast cancer xenografts, and we believe that our construct with 
robust tumor targeting ability would provide a more advantageous therapy against a 
panel of cancer types.  
 KLAK belongs to a very  large and diverse class of peptides, with more than 
1,200 peptides identified or predicted to be AMPs.249 Thus, there is a large set of peptides 
from which to choose. Furthermore, with greater knowledge gained about the 
translocation capabilities of pHLIP, efforts can be extended to include a myriad of 
therapeutic peptides with varying activities. For example, the pro-apoptotic peptide 
Smac/DIABLO which antagonizes inhibitors of apoptosis proteins, thus activating 
caspases and apoptosis. Another therapeutic peptide that has always been of great interest 
is PNC-28, which is a 9 amino acid p53 peptide from the mdm-2-binding domain that 
utilizes penetratin for cellular entry that has been shown to induce necrosis and blocks 
tumor growth in vivo. Therefore, we anticipate that our approach could be applied to a 
broad range of therapeutic peptides with intracellular targets.
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Appendix 5.1 Molecular Weights and Purities of Free Peptides
Construct Calculated [M + H+] Found [M + H+] Purity
(KLAKLAK)2 1627 1627 > 98%
KLAKLAK 874 896* >98%
KLAK 562 561 > 98%
KAAK 520 541* > 98%
KLLK 604 604 > 98%
KKKK 634 632 > 98%
KGGK 492 513* > 98%
*KLAKLAK calculated [M + Na+] = 896
*KAAK calculated [M + Na+] = 542
*KGGK calculated [M + Na+] = 514
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Appendix 5.2 Molecular Weights and Purities of pHLIP constructs
Construct Calculated [M + H+] Found [M + H+] Purity
pHLIP-(KLAKLAK)2 5839 5837 > 98%
pHLIP-KLAKLAK 5085 5085 >98%
pHLIP-KLAK 4773 4775 > 98%
pHLIP-KAAK 4731 4728 > 98%
pHLIP-KLLK 4815 4849 > 98%
pHLIP-KKKK 4845 4866 > 98%
pHLIP-KGGK 4703 4710 > 98%
*pHLIP-KLLK calculated [M + Na+] = 4837
*pHLIP-KKKK calculated [M + Na+] = 4866
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CHAPTER 6: 
Materials and Methods
6.1 Materials
 N-Hydroxybenzotriazole (HOBt), o-benzotriazol-N, N, N, N’, N’-
tetramethyluronium hexafluorophosphate (HBTU), and all N-fluorenyl-9-
methoxycarbonyl (Fmoc) protected L-amino acids were purchased from GL Biochem 
Ltd. H-Rink Amide-ChemMatrix solid support  resin was from PCAS BioMatrix Inc. 
Diisopropylehtylamine (DIEA), piperazine, N, N-dimethylformamide (DMF), 
dichloromethane (DCM), trifluoroacetic acid (TFA), methanol, acetonitrile, dimethyl 
sulfoxide (DMSO) and Dulbecco’s modified Eagle’s medium (DMEM) were all from 
Thermo Fisher Scientific Inc. Fetal Bovine Serum (FBS) was purchased from Atlanta 
Biologicals Inc. Penicillin-Streptomycin was purchased from Sigma-Aldrich. 
monomethylauristatin E (MMAE), pyridyldithiol-activated MMAE (Py-ds-Prp-MMAE) 
pyridyldithiol-activated MMAF (Py-ds-Prp-MMAE) were from Concortis. 1-
palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) was from Avanti Polar Lipids 
Inc. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was purchased 
from EMD Millipore. AlexaFluor 750 NHS ester was purchased from Life Technologies. 
Anti-PAR1 mouse and goat anti-mouse IgG-FITC was purchased from Life 
Technologies. Fluo-4 NW Calcium Assay  Kit was purchased from Life Technologies. 
Mitochondrial Membrane Potential/Annexin V Apoptosis Kit, Pierce LDH Cytotoxicity 
Assay Kit, and CellEvent™ Caspase-3/7 Green Detection Reagent were all purchased 
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from Thermo Fisher Scientific.  Noncanonical amino acids (Gla and Aad) were 
purchased from ChemImpex.  
6.2 Solid-Phase Peptide Synthesis 
 Peptides were prepared by  Fmoc solid-phase synthesis, using H-Rink Amide 
resin affording an amidated C-terminus and purified via reverse-phase high performance 
liquid chromatography  (RP-HPLC) (Phenomenex Luna prep 10 µ 250 x 21.20 mm C8; 
flow rate 10mL/min; phase A: water 0.1% TFA; phase B: acetonitrile 0.1% TFA; 
gradient 60 min from 95/5 A/B to 0/100 A/B). The purity of the peptides was determined 
by RP-HPLC (Agilent Zorbax Eclipse 5 µm 4.6 x 50 mm XDB-C8; flow rate 1 mL/min; 
phase A: water 0.01% TFA; phase B: acetonitrile 0.01% TFA; gradient 45 min from 95/5 
A/B to 0/100 A/B) and their identity  was confirmed via matrix-assisted laser desorption 
ionization time of flight (MALDI-TOF) mass spectrometry. 
6.3 Preparation of Conjugates
 Each pHLIP peptide was dissolved in DMSO to a concentration of 1 mM, 
followed by the addition of 1.5 eq. of Peptide in DMSO. To facilitate disulfide exchange, 
100 µL of 1 M Tris buffer, pH 8.0 was added to the solution and allowed to mix at room 
temperature for 2-3 hours. For the N-terminally modified AlexaFluor 750 conjugates, 
was obtained by  dissolving 1 mg of the NHS activated AlexaFluor 750 in 200 µL of 
DMF followed by  the addition of 1 equiv of pHLIP construct  in DMF in the presence of 
DIEA, affording amide bond conjugation to the N-terminal amine of pHLIP. The desired 
pHLIP conjugates were isolated using the same techniques described for the pHLIP 
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peptides. The purity  of the peptide-drug conjugates was determined by RP-HPLC as 
listed, and their identity was confirmed by MALDI-TOF MS.
6.4 Preparation of POPC Liposomes
Ten milligrams of POPC in chloroform were dried and then held under vacuum 
overnight. The dried lipid film was rehydrated with 1 ml of 5 mM sodium phosphate, pH 
8.0, and mixed by vigorous vortex. The resulting multilamellar vesicle solution was 
freeze-thawed in liquid nitrogen for seven cycles and were extruded through a 
polycarbonate membrane with 100 mm diameter pores using a mini extruder (Avanti 
Polar Lipids) to produce large unilamellar vesicles. Liposomes were used immediately 
following their preparation. Lipid concentration was checked using the Marshall’s assay 
and the size distribution was verified by dynamic light scattering analysis performed at a 
scattering angle of 90° using an ALV/GSC-3 goniometer system equipped with ALV/
ALV-7004 correlator (ALV-GmbH, Langen, Germany).
6.5 Sample Preparation for Circular Dichroism and Tryptophan Fluorescence 
Measurements
Prior to CD or fluorescence measurements, lyophilized aliquots of pHLIP constructs 
were resuspended to 20 µM with 5 mM sodium phosphate, pH 8.0, and incubated for 1 
hour at  room temperature. This stock solution was diluted to a final concentration of 7 
µM and, when appropriate, incubated with POPC liposomes at a 1:300 peptide-to-lipid 
molar ratio for 30 minutes at room temperature. Subsequently, samples were adjusted to 
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the desired experimental pH values with the addition of aliquots of a HCl solution to 
elicit  pH-dependent insertion. Samples were allowed to equilibrate at the desired pH for 
30 minutes at room temperature before spectroscopic measurements.
6.6 Tryptophan Fluorescence Spectroscopy
All measurements were carried out using a Cary  Eclipse Fluorescence 
Spectrophotometer (Varian), and performed at 25 ºC with pHLIP construct 
concentrations equal to 7 µM. Samples were excited at 295 nm and the emission spectra 
were taken from 300 to 500 nm, with the slit  widths for emission and excitation both set 
5 nm. 
6.7 Circular Dichroism Spectroscopy 
Far-UV CD spectra of pHLIP constructs were recorded on Jasco J-815 CD spectrometer 
equipped with a Peltier thermal-controlled cuvette holder (Jasco, Inc.). All measurements 
were performed in 0.1 mm quartz cuvette at 25 ºC with pHLIP constructs concentrations 
equal to 7 µM. CD intensities are expressed in mean residue molar ellipticity  [θ] 
calculated from the following equation: where, θobs is the observed ellipticity  in 
millidegrees, l is the optical path length in centimeters, c is the final molar concentration 
of the peptides, and n is the number of amino acid residues. Samples were measured in a 
0.1 cm path length quartz cuvette and raw data were acquired from 260 nm to 190 nm at 
θ
θ
×
[ ] =
10 l.c.n
(in degrees cm .dmol )obs 2 -1
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1 nm intervals with a 100 nm/min scan rate, and at least five scans were averaged for 
each sample. The spectrum of POPC liposomes was subtracted out from all construct 
samples. 
6.8 Cell Culture
 Human cervical adenocarcinoma HeLa cells and human breast adenocarcinoma 
MDA-MB-231and MCF7 cells (kind gifts from Matthew Robinson, Fox Chase Cancer 
Center) and MCF7- PAR1/N55 stably  transfected to express PAR1 (kind gift  from the 
Lidija Covic, Tufts University) cells were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM  supplemented with 10% FBS, 100 U/mL penicillin, and 0.1 mg/mL 
streptomycin in a humidified atmosphere of 5% CO2 at 37 °C.
6.9 Anti-proliferation Assay
 HeLa and MDA-MB-231 cells were seeded in 96-well plates at a density  of 3,000 
cells/well and incubated overnight. Before treatment, construct aliquots were solubilized 
in an appropriate volume of DMEM without FBS (pH 7.4) - so that upon pH adjustment 
the desired treatment concentration is obtained - and gently sonicated for 30-60 seconds 
using a bath sonicator (Branson Ultrasonics). After removal of cell media, this treatment 
solution was added to each well and incubated at 37 °C for 5-10 minutes. The pH was 
then adjusted to the desired value using a pre-established volume of DMEM, pH 2.0 
buffered with citric acid (final volume = 50 µL) and the plate was incubated at 37 °C for 
2 hours. After treatment, the media was removed, cells were washed once with 100 µL of 
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complete DMEM, and 100 µL of complete medium was added to each well before 
returning the plate to the incubator. Treatment solutions were collected and their pH 
values measured using a micro-combination pH probe (Microelectrodes, Inc.). For 
physiologic pH treatments a small down-drift (~0.2 pH unit) was usually  observed, 
whereas an up-drift  was observed for low pH treatments (e.g., pH 7.4 → pH 7.2, and pH 
5.0 → pH 5.2). Cell viability was determined after 72 hours using the colorimetric MTT 
assay. Briefly, 10 µL of a 5 mg/mL MTT stock solution was added to the treated cells and 
incubated for 2 hours at 37 ºC. The resulting formazan crystals were solubilized in 200 
µL DMSO and the absorbance measured at 580 nm using an Infinite 200 PRO microplate 
reader (Tecan). Cell viability was calculated against control cells treated with media at 
physiologic pH. 
6.10 Cell Membrane Integrity Assay
 Cells were seeded in 96-well plates at a density of 3,000 cells/well and incubated 
until confluent (~ 72 hours). For the Lactate Dehydrogenase (LDH) assay cells were seed 
in 24-well plates at a density of 200,000 cells/well and incubated until confluent  (~24 
hours). Before treatment, construct aliquots were solubilized in an appropriate volume of 
DMEM  without FBS (pH 7.4) so that upon pH adjustment 10 µM is obtained. Cell media 
was removed, the treatment solution was added to each well and cell were incubated at 
37 °C for 5-10 minutes. The pH was then adjusted to the desired value using a pre-
established volume of DMEM, pH 2.0 buffered with citric acid (final volume = 50 µL). 
The plate was incubated at 37 °C for 2 hours. After treatment, the media was removed, 
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cells were detached using trypsin and counted based on trypan blue uptake using an 
hemacytometer. For the LDH assay cell media supernatant was collected in a 96 well 
plate in triplicate after treatment and LDH reaction mixture was added to each well 
recommended by the manufacturer protocol.  After a 30 minute incubation at room 
temperature stop  solution was added to each well and the absorbance at 490 and 680 nm 
of each well was determined using an Infinite 200 PRO microplate reader (Tecan). 
Percent LDH release was calculated against control cells treated with media at 
physiologic pH.
6.11 Construct Stability HPLC in Cell Media and Mouse Serum
 pHLIP constructs were solubilized in DMEM  without FBS (pH 7.4) to obtain a 
10 µM solution, and gently sonicated for 30-60 seconds using a bath sonicator. Peptide 
solutions were incubated at either pH 7.4 or pH 5.0 (37 °C and 5% CO2) and 100 µL 
aliquots were monitored via RP-HPLC at various time points (Agilent Eclipse XDB-C18 
5 µM 9.4 x 250 mm; flow rate 2 mL/min; phase A: water 0.01% TFA; phase B: 
acetonitrile 0.01% TFA; gradient 45 min from 95/5 A/B to 0/100 A/B). HPLC peaks 
were collected and identified via MALDI-TOF MS. The stability of Alexa750-
pHLIP(WT)-MMAE was determined in mouse serum by solubilizing the construct to 10 
µM, incubating it at 37 °C and monitoring via RP-HPLC at specific time points.
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6.12 Tumor Targeting in Vivo
 Tumor targeting of Alexa750-pHLIP(WT)-MMAE was evaluated in NCr nu/nu 
mice harboring MDA-MB-231 tumor xenografts (n = 3). Tumor cells were implanted 
subcutaneously (3 x 106 / animal) and allowed to grow until tumors reached volumes of 
approximately  100 mm3. Alexa750-pHLIP(WT)-MMAE was then administered 
intravenously (100 µL, 5 µM  in PBS pH 7.2) and its uptake in tumor and normal tissues 
was monitored over time by optical imaging on an IVIS Spectrum (Perkin Elmer). 
Average Radiant Efficiency (ARE, expressed as [p/s/cm2/sr] / [µW/cm2]) was calculated 
for regions of interest (ROIs) drawn around regions encompassing tumor, kidney, and 
background blood pool. 
6.13 In Vivo Efficacy. 
 HeLa cells (ATCC#: CCL-2) were grown using ATCC recommended conditions, 
harvested by trypsin-treatment, and 5x106 viable cells/mouse were injected 
subcutaneously (s.c.) into the inguinal space of 20, 6 - 8 week old female NCr nu/nu 
mice (Taconic Biosciences). Tumor-bearing mice (n = 17) were injected intravenously 
(i.v.) with 200 µL of either pHLIP-MMAF (20 µM in PBS + 1% DMSO) or vehicle 
control. Tumor volume was calculated using caliper measurements and the formula 
Volume = Length x Width x (Height  x 0.5). A tumor weight of 500 mg was prospectively 
set as a stopping point for this study. An analogous study was carried out with NCRr nu/
nu mice bearing A431 (ATCC#: CRL-1555) tumors. A431 tumor-bearing mice (n = 10/
cohort) were treated intraperitoneally (i.p.) with either pHLIP(WT)-MMAF or vehicle 
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control and evaluated by  immunohistochemistry (IHC) using Ki-67 as a biomarker of 
efficacy. Sections were evaluated, in a blinded manner, for Ki-67 staining by the FCCC 
animal histopathology core facility and a Wilcoxon ranked-sum analysis was used to 
evaluate statistical difference between treatment groups. 
6.14 PAR1 Cell-Surface Expression
 Cells were detached using trypsin and pelleted, resuspended and washed with 100 
µL PBS 3 times. Cells were then incubated at 4 oC for 30 minutes with PAR1 mouse 
monoclonal antibody (Invitrogen), and washed 3 times with PBS. Cells were then 
incubated with goat anti-mouse IgG-FITC antibody (Invitrogen) for 30 minutes at 4 oC, 
and washed 3 times with PBS. Cells were then fixed in 2% formaldehyde and cells were 
analyzed using a BDFacs Canto II flow cytometer (BD Biosciences, San Jose, CA) 
equipped with a 488 nm argon laser and a 530 bandpass filter (FL1). A minimum of 
10,000 events were counted for each data point. The data was analyzed using the 
FACSDiva version 6.1.1 software. Fluorescence data is expressed as mean arbitrary 
fluorescence units and were gated to include all healthy cells. 
6.15 PAR1-Mediated Calcium Mobilization Assay
 Cells were seeded in 96-well plates at a density of 40,000 cells/well and 
incubated overnight. Before treatment, construct aliquots were solubilized in an 
appropriate volume of DMEM without FBS (pH 7.4) so that upon pH adjustment 10 µM 
is obtained. Cell media was removed and the treatment solution was added to each well 
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and incubated at 37 °C for 5 minutes. The pH was then adjusted to the desired pH using a 
pre-established volume of DMEM, pH 2.0 buffered with citric acid (final volume 50 µL). 
The plate was incubated at 37 °C for 10 minutes, shorter pHLIP-P1AP treatment time 
was implemented to avoid unwanted effects on intracellular Ca2+ due to a prolonged 
exposure to an acidic environment. After treatment the media was removed and the 
calcium indicator fura-2, NW (Life Technologies) was added according to the 
manufacturer’s protocols. After incubation for 30 min at 37 oC and then for 30 min at 
room temperature, 10 nM thrombin was added to each well. Fluorescence emission 
intensity at 530 nm (Excitation = 485 nm) was immediately measured with an Infinite 
200 PRO microplate reader (Tecan) after a brief shaking. 
6.16 Apoptosis Assay
 Apoptosis was investigated by flow cytometry using the Mitochondrial 
Membrane Potential Apoptosis Kit with Alexa Fluor 488 Annexin V and  MitoTracker 
Red (ThermoFisher Scientific). Cells were seeded in 24-well plates at a density of 
200,000 cells/well and incubated until confluent (~24 hours). Before treatment, construct 
aliquots were solubilized in an appropriate volume of DMEM without FBS (pH 7.4) so 
that upon pH adjustment 10 µM  is obtained. Cell media was removed and the treatment 
solution was added to each well and incubated at 37 °C for 5 minutes. The pH was then 
adjusted to the desired pH using a pre-established volume of DMEM, pH 2.0 buffered 
with citric acid (final volume 200 µL). The plate was incubated at 37 °C for 2 hours. 
After treatment, the media was removed, cells were washed once with 500 µL of 
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complete DMEM, and recovered for 24 hours in complete DMEM. Cells were then 
pelleted, resuspended in 1 mL of complete DMEM  and MitoTracker Red dye was added 
to the suspended cells following the manufacturer’s protocols and incubated for 30 min 
at 37 °C. The cells were then washed and incubated at room temperature with Alexa 488 
Annexin V. The cells were then analyzed using a BDFacs Canto II flow cytometer (BD 
Biosciences, San Jose, CA) equipped with a 488 nm argon laser, and 530/633 bandpass 
filters. A minimum of 10,000 events were counted for each data point. Cells were gated 
as two populations (non-apoptotic and apoptotic cells) based on fluorescence intensity  at 
both 530 nm and 633 nm wavelengths. The data was analyzed using the FACSDiva 
version 6.1.1 software.
6.17 Caspase Activity Assay
 To probe the possible involvement of the caspase-mediated apoptotic pathway, 
we use the CellEvent™ Caspase-3/7 Green Detection Reagent (ThermoFisher 
Scientific). Cells were seeded at a density of 3,000 cells/well in a 96 well plate and 
allowed to adhere overnight.  Before treatment, construct aliquots were solubilized in an 
appropriate volume of DMEM without FBS (pH 7.4) so that upon pH adjustment 10 µM 
is obtained. Cell media was removed and the treatment solution was added to each well 
and incubated at 37 °C for 5 minutes. The pH was then adjusted to the desired pH using a 
pre-established volume of DMEM, pH 2.0 buffered with citric acid (final volume 50 µL). 
The plate was incubated at 37 °C for 2 hours.  After treatment, the media was removed, 
cells were washed once with 100 µL of complete DMEM, and recovered complete 
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DMEM. As a positive control cells were also treated with 1 µM Staurosporine. Cells 
treated with pHLIP-KLAKLAK or free KLAK peptides were recovered and cells treated 
with Staurosporine were done so in the presence of CellEvent Caspase-3/7 Green 
Detection Reagent.  Cells were monitored for the presence of active caspase at 24, 48 
and 72 hours, based on the fluorescence intensity at excitation/emission at  485/530 nm 
using an Infinite 200 PRO microplate reader (Tecan). Caspase activity was normalized to 
control cells treated with media at physiologic pH.  
146
REFERENCES
(1) Cancer Facts & Figures - 2013. 2013.
(2) Seyfried, T. N.; Shelton, L. M. Cancer as a Metabolic Disease. Nutr Metab 
(Lond) 2010, 7 (7), 269–270.
(3) Hanahan, D.; Weinberg, R. A. The Hallmarks of Cancer. Cell 2000, 100 (1), 57–
70.
(4) Hanahan, D.; Weinberg, R. A. Hallmarks of Cancer: the Next Generation. Cell 
2011, 144 (5), 646–674.
(5) Anand, P.; Kunnumakkara, A. B.; Kunnumakara, A. B.; Sundaram, C.; 
Harikumar, K. B.; Tharakan, S. T.; Lai, O. S.; Sung, B.; Aggarwal, B. B. Cancer 
Is a Preventable Disease That Requires Major Lifestyle Changes. Pharm. Res. 
2008, 25 (9), 2097–2116.
(6) Bailar, J. C.; Gornik, H. L. Cancer Undefeated. New England Journal of 
Medicine 1997.
(7) Society, A. C. Cancer Facts & Figures 2016. cancer.org.
(8) CDC - Expected New Cancer Cases and Deaths in 2020. cdc.gov.
(9) Siegel, R. L.; Miller, K. D.; Jemal, A. Cancer Statistics, 2016. CA: A Cancer 
Journal for Clinicians 2016, 66 (1), 7–30.
(10) Krumbhaar, E. B.; Krumbhaar, H. The Blood and Bone Marrow in Yellow Cross 
Gas (Mustard Gas) Poisoning. Changes Produced in Bone Marrow in Fatal Cases. 
J. Mater. Res. 1919, No. 40, 497–508.
(11) DeVita, V. T.; Chu, E. A History of Cancer Chemotherapy. Cancer Res. 2008, 68 
(21), 8643–8653.
(12) Marshall, E. Historical Perspectives in Chemotherapy. Advances in 
Chemotherapy. Vol. I. 1964, 1, 1–8.
(13) Payne, S.; Miles, D. Mechanisms of Anticancer Drugs. 2008.
(14) Shewach, D. S.; Kuchta, R. D. Introduction to Cancer Chemotherapeutics. Chem. 
Rev. 2009, 109 (7), 2859–2861.
(15) Gascoigne, K. E.; Taylor, S. S. How Do Anti-Mitotic Drugs Kill Cancer Cells? J. 
Cell. Sci. 2009, 122 (Pt 15), 2579–2585.
(16) Pàez-Ribes, M.; Allen, E.; Hudock, J.; Takeda, T.; Okuyama, H.; Viñals, F.; 
Inoue, M.; Bergers, G.; Hanahan, D.; Casanovas, O. Antiangiogenic Therapy 
Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant 
Metastasis. Cancer Cell 2009, 15 (3), 220–231.
(17) Wong, R. S. Y. Apoptosis in Cancer: From Pathogenesis to Treatment. J. Exp. 
Clin. Cancer Res. 2011, 30, 87.
(18) Housman, G.; Byler, S.; Heerboth, S.; Lapinska, K.; Longacre, M.; Snyder, N.; 
Sarkar, S. Drug Resistance in Cancer: an Overview. Cancers (Basel) 2014, 6 (3), 
1769–1792.
(19) Sauna, Z. E.; Ambudkar, S. V. Characterization of the Catalytic Cycle of ATP 
Hydrolysis by Human P-Glycoprotein. the Two ATP Hydrolysis Events in a 
147
Single Catalytic Cycle Are Kinetically Similar but Affect Different Functional 
Outcomes. J. Biol. Chem. 2001, 276 (15), 11653–11661.
(20) Olaussen, K. A.; Dunant, A.; Fouret, P.; Brambilla, E.; André, F.; Haddad, V.; 
Taranchon, E.; Filipits, M.; Pirker, R.; Popper, H. H.; Stahel, R.; Sabatier, L.; 
Pignon, J.-P.; Tursz, T.; Le Chevalier, T.; Soria, J.-C.; IALT Bio Investigators. 
DNA Repair by ERCC1 in Non-Small-Cell Lung Cancer and Cisplatin-Based 
Adjuvant Chemotherapy. N. Engl. J. Med. 2006, 355 (10), 983–991.
(21) Selvakumaran, M.; Pisarcik, D. A.; Bao, R.; Yeung, A. T.; Hamilton, T. C. 
Enhanced Cisplatin Cytotoxicity by Disturbing the Nucleotide Excision Repair 
Pathway in Ovarian Cancer Cell Lines. Cancer Res. 2003, 63 (6), 1311–1316.
(22) Wijesinghe, D.; Engelman, D. M.; Andreev, O. A.; Reshetnyak, Y. K. Tuning a 
Polar Molecule for Selective Cytoplasmic Delivery by a pH (Low) Insertion 
Peptide. Biochemistry 2011, 50 (47), 10215–10222.
(23) Tsutsumi, S.; Neckers, L. Extracellular Heat Shock Protein 90: a Role for a 
Molecular Chaperone in Cell Motility and Cancer Metastasis. Cancer Sci 2007, 
98 (10), 1536–1539.
(24) Wang, J. L.; Zhang, Z. J.; Choksi, S.; Shan, S.; Lu, Z.; Croce, C. M.; Alnemri, E. 
S.; Korngold, R.; Huang, Z. Cell Permeable Bcl-2 Binding Peptides: a Chemical 
Approach to Apoptosis Induction in Tumor Cells. Cancer Res. 2000, 60 (6), 
1498–1502.
(25) Sun, J.; Blaskovich, M. A.; Jain, R. K.; Delarue, F.; Paris, D.; Brem, S.; 
Wotoczek-Obadia, M.; Lin, Q.; Coppola, D.; Choi, K.; Mullan, M.; Hamilton, A. 
D.; Sebti, S. M. Blocking Angiogenesis and Tumorigenesis with GFA-116, a 
Synthetic Molecule That Inhibits Binding of Vascular Endothelial Growth Factor 
to Its Receptor. Cancer Res. 2004, 64 (10), 3586–3592.
(26) Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and 
Computational Approaches to Estimate Solubility and Permeability in Drug 
Discovery and Development Settings. Adv. Drug Deliv. Rev. 2001, 46 (1-3), 3–26.
(27) Kobayashi, H.; Watanabe, R.; Choyke, P. L. Improving Conventional Enhanced 
Permeability and Retention (EPR) Effects; What Is the Appropriate Target. 
Theranostics 2014.
(28) Tiwari, G.; Tiwari, R.; Bannerjee, S.; Bhati, L.; Pandey, S.; Pandey, P.; 
Sriwastawa, B. Drug Delivery Systems: an Updated Review. Int J Pharma 
Investig 2012, 2 (1), 2.
(29) Ranganathan, R.; Madanmohan, S.; Kesavan, A.; Baskar, G.; Krishnamoorthy, Y. 
R.; Santosham, R.; Ponraju, D.; Rayala, S. K.; Venkatraman, G. Nanomedicine: 
Towards Development of Patient-Friendly Drug-Delivery Systems for 
Oncological Applications. International journal of nanomedicine. January 1, 
2012.
(30) Matsumura, Y.; Maeda, H. A New Concept for Macromolecular Therapeutics in 
Cancer Chemotherapy: Mechanism of Tumoritropic Accumulation of Proteins 
and the Antitumor Agent Smancs. Cancer Res. 1986, 46 (12 Pt 1), 6387–6392.
148
(31) Siemann, D. W. The Unique Characteristics of Tumor Vasculature and Preclinical 
Evidence for Its Selective Disruption by Tumor-Vascular Disrupting Agents. 
Cancer Treat. Rev. 2011, 37 (1), 63–74.
(32) Hori, K.; Suzuki, M.; Tanda, S.; Saito, S.; Shinozaki, M.; Zhang, Q. H. 
Fluctuations in Tumor Blood Flow Under Normotension and the Effect of 
Angiotensin II-Induced Hypertension. Jpn. J. Cancer Res. 1991, 82 (11), 1309–
1316.
(33) Yin, H.; Liao, L.; Fang, J. Enhanced Permeability and Retention (EPR) Effect 
Based Tumor Targeting: the Concept, Application and Prospect. JSM Clin Oncol 
Res. January 30, 2014, p 1010.
(34) Vicent, M. J.; Ringsdorf, H.; Duncan, R. Polymer Therapeutics: Clinical 
Applications and Challenges for Development. Adv. Drug Deliv. Rev. 2009, 61 
(13), 1117–1120.
(35) Duncan, R. The Dawning Era of Polymer Therapeutics. Nat Rev Drug Discov 
2003, 2 (5), 347–360.
(36) Fang, J.; Nakamura, H.; Maeda, H. The EPR Effect: Unique Features of Tumor 
Blood Vessels for Drug Delivery, Factors Involved, and Limitations and 
Augmentation of the Effect. - PubMed - NCBI. Adv. Drug Deliv. Rev. 63, 136–
151.
(37) Iyer, A. K.; Khaled, G.; Fang, J.; Maeda, H. Exploiting the Enhanced 
Permeability and Retention Effect for Tumor Targeting. Drug Discov Today 2006, 
11 (17), 812–818.
(38) Greish, K. Enhanced Permeability and Retention of Macromolecular Drugs in 
Solid Tumors: a Royal Gate for Targeted Anticancer Nanomedicines. Journal of 
Drug Targeting 2008, 15 (7-8), 457–464.
(39) Maeda, H.; Bharate, G. Y.; Daruwalla, J. Polymeric Drugs for Efficient Tumor-
Targeted Drug Delivery Based on EPR-Effect. Eur J Pharm Biopharm 2009, 71 
(3), 409–419.
(40) Cho, K.; Wang, X.; Nie, S.; Chen, Z. G.; Shin, D. M. Therapeutic Nanoparticles 
for Drug Delivery in Cancer. Clin. Cancer Res. 2008, 14 (5), 1310–1316.
(41) Allen, T. M.; Cullis, P. R. Liposomal Drug Delivery Systems: From Concept to 
Clinical Applications. Adv. Drug Deliv. Rev. 2013, 65 (1), 36–48.
(42) Gregoriadis, G.; Ryman, B. E. Liposomes as Carriers of Enzymes or Drugs: a 
New Approach to the Treatment of Storage Diseases. Biochem. J. 1971, 124 (5), 
58P–58P.
(43) Gregoriadis, G. Drug Entrapment in Liposomes. FEBS Lett. 1973.
(44) Gregoriadis, G. The Carrier Potential of Liposomes in Biology and Medicine. N. 
Engl. J. Med. 1976, 295 (13), 704–710.
(45) Gregoriadis, G. The Carrier Potential of Liposomes in Biology and Medicine. N. 
Engl. J. Med. 1976, 295 (14), 765–770.
(46) Pillai, G. Nanomedicines for Cancer Therapy: an Update of FDA Approved and 
Those Under Various Stages of Development. SOJ Pharm Pharm Sci 2014.
149
(47) Fan, Y.; Zhang, Q. Development of Liposomal Formulations: From Concept to 
Clinical Investigations. Asian Journal of Pharmaceutical Sciences 2013, 8 (2), 
81–87.
(48) Oerlemans, C.; Bult, W.; Bos, M.; Storm, G.; Nijsen, J. F. W.; Hennink, W. E. 
Polymeric Micelles in Anticancer Therapy: Targeting, Imaging and Triggered 
Release. Pharm. Res. 2010, 27 (12), 2569–2589.
(49) Matsumura, Y. Poly (Amino Acid) Micelle Nanocarriers in Preclinical and 
Clinical Studies. Adv. Drug Deliv. Rev. 2008, 60 (8), 899–914.
(50) Matsumura, Y. Polymeric Micellar Delivery Systems in Oncology. Jpn J Clin 
Oncol 2008, 38 (12), 793–802.
(51) Hamaguchi, T.; Kato, K.; Yasui, H.; Morizane, C.; Ikeda, M.; Ueno, H.; Muro, 
K.; Yamada, Y.; Okusaka, T.; Shirao, K.; Shimada, Y.; Nakahama, H.; 
Matsumura, Y. A Phase I and Pharmacokinetic Study of NK105, a Paclitaxel-
Incorporating Micellar Nanoparticle Formulation. Br. J. Cancer 2007, 97 (2), 
170–176.
(52) Wilson, R. H.; Plummer, R.; Adam, J.; Eatock, M. M.; Boddy, A. V.; Griffin, M.; 
Miller, R.; Matsumura, Y.; Shimizu, T.; Calvert, H. Phase I and Pharmacokinetic 
Study of NC-6004, a New Platinum Entity of Cisplatin-Conjugated Polymer 
Forming Micelles. ASCO Meeting Abstracts 2008, 26 (15_suppl), 2573.
(53) Kim, T.-I.; Ou, M.; Lee, M.; Kim, S. W. Arginine-Grafted Bioreducible 
Poly(Disulfide Amine) for Gene Delivery Systems. Biomaterials 2009, 30 (4), 
658–664.
(54) Kim, D. W.; Kim, S. Y.; Kim, H. K.; Kim, S. W.; Shin, S. W.; Kim, J. S.; Park, K.; 
Lee, M. Y.; Heo, D. S. Multicenter Phase II Trial of Genexol-PM, a Novel 
Cremophor-Free, Polymeric Micelle Formulation of Paclitaxel, with Cisplatin in 
Patients with Advanced Non-Small-Cell Lung Cancer. Ann. Oncol. 2007, 18 (12), 
2009–2014.
(55) Kim, T.-Y.; Kim, D.-W.; Chung, J.-Y.; Shin, S. G.; Kim, S.-C.; Heo, D. S.; Kim, 
N. K.; Bang, Y.-J. Phase I and Pharmacokinetic Study of Genexol-PM, a 
Cremophor-Free, Polymeric Micelle-Formulated Paclitaxel, in Patients with 
Advanced Malignancies. Clin. Cancer Res. 2004, 10 (11), 3708–3716.
(56) Rajora, A. K.; Ravishankar, D.; Osborn, H.; Greco, F. Impact of the Enhanced 
Permeability and Retention (EPR) Effect and Cathepsins Levels on the Activity 
of Polymer-Drug Conjugates. Polymers 2014.
(57) Duncan, R. Polymer Conjugates as Anticancer Nanomedicines. - PubMed - 
NCBI. Nat. Rev. Cancer 2006, 9, 688–701.
(58) Larson, N.; Ghandehari, H. Polymeric Conjugates for Drug Delivery. Chem 
Mater 2012, 24 (5), 840–853.
(59) Scott, A. M.; Allison, J. P.; Wolchok, J. D. Monoclonal Antibodies in Cancer 
Therapy. Cancer Immun. 2012, 12, 14.
(60) Younes, A.; Gopal, A. K.; Smith, S. E.; Ansell, S. M.; Rosenblatt, J. D.; Savage, 
K. J.; Ramchandren, R.; Bartlett, N. L.; Cheson, B. D.; de Vos, S.; Forero-Torres, 
A.; Moskowitz, C. H.; Connors, J. M.; Engert, A.; Larsen, E. K.; Kennedy, D. A.; 
150
Sievers, E. L.; Chen, R. Results of a Pivotal Phase II Study of Brentuximab 
Vedotin for Patients with Relapsed or Refractory Hodgkin's Lymphoma. J. Clin. 
Oncol. 2012, 30 (18), 2183–2189.
(61) Verma, S.; Miles, D.; Gianni, L.; Krop, I. E.; Welslau, M.; Baselga, J.; Pegram, 
M.; Oh, D.-Y.; Diéras, V.; Guardino, E.; Fang, L.; Lu, M. W.; Olsen, S.; 
Blackwell, K. Trastuzumab Emtansine for HER2-Positive Advanced Breast 
Cancer. N. Engl. J. Med. 2012, 367 (19), 1783–1791.
(62) Slamon, D.; Clark, G.; Wong, S.; Levin, W.; Ullrich, A.; McGuire, W. Human 
Breast Cancer: Correlation of Relapse and Survival with Amplification of the 
HER-2/Neu Oncogene. Science 1987, 235 (4785), 177–182.
(63) Ross, J. S.; Slodkowska, E. A.; Symmans, W. F.; Pusztai, L.; Ravdin, P. M.; 
Hortobagyi, G. N. The HER-2 Receptor and Breast Cancer: Ten Years of Targeted 
Anti-HER-2 Therapy and Personalized Medicine. Oncologist 2009, 14 (4), 320–
368.
(64) Dawood, S.; Broglio, K.; Buzdar, A. U.; Hortobagyi, G. N.; Giordano, S. H. 
Prognosis of Women with Metastatic Breast Cancer by HER2 Status and 
Trastuzumab Treatment: an Institutional-Based Review. J. Clin. Oncol. 2010, 28 
(1), 92–98.
(65) Slamon, D. J.; Leyland-Jones, B.; Shak, S. Use of Chemotherapy Plus a 
Monoclonal Antibody Against HER2 for Metastatic Breast Cancer That 
Overexpresses HER2. … England Journal of … 2001.
(66) Marty, M.; Cognetti, F.; Maraninchi, D.; Snyder, R.; Mauriac, L.; Tubiana-Hulin, 
M.; Chan, S.; Grimes, D.; Antón, A.; Lluch, A.; Kennedy, J.; O'Byrne, K.; Conte, 
P.; Green, M.; Ward, C.; Mayne, K.; Extra, J.-M. Randomized Phase II Trial of 
the Efficacy and Safety of Trastuzumab Combined with Docetaxel in Patients 
with Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast 
Cancer Administered as First-Line Treatment: the M77001 Study Group. J. Clin. 
Oncol. 2005, 23 (19), 4265–4274.
(67) Seyfried, T. N.; Mukherjee, P. Targeting Energy Metabolism in Brain Cancer: 
Review and Hypothesis. Nutr Metab (Lond) 2005, 2, 30–30.
(68) Semenza, G. L.; Artemov, D.; Bedi, A.; Bhujwalla, Z.; Chiles, K.; Feldser, D.; 
Laughner, E.; Ravi, R.; Simons, J.; Taghavi, P.; Zhong, H. “The Metabolism of 
Tumours”: 70 Years Later. In onlinelibrary.wiley.com; Novartis Foundation 
Symposia; John Wiley & Sons, Ltd: Chichester, UK, 2001; Vol. 240, pp 251–264.
(69) Ristow, M. Oxidative Metabolism in Cancer Growth. Current Opinion in Clinical 
Nutrition & Metabolic Care 2006, 9 (4), 339–345.
(70) Gatenby, R. A.; Gillies, R. J. Why Do Cancers Have High Aerobic Glycolysis? 
Nat. Rev. Cancer 2004, 4 (11), 891–899.
(71) Gogvadze, V.; Orrenius, S.; Zhivotovsky, B. Mitochondria in Cancer Cells: What 
Is So Special About Them? Trends in Cell Biology 2008, 18 (4), 165–173.
(72) Warburg, O. On the Origin of Cancer Cells. Science 1956, 123 (3191), 309–314.
(73) Kim, J.-W.; Dang, C. V. Cancer's Molecular Sweet Tooth and the Warburg Effect. 
Cancer Res. 2006, 66 (18), 8927–8930.
151
(74) Pavlides, S.; Whitaker-Menezes, D.; Castello-Cros, R.; Flomenberg, N.; 
Witkiewicz, A. K.; Frank, P. G.; Casimiro, M. C.; Wang, C.; Fortina, P.; Addya, 
S.; Pestell, R. G.; Martinez-Outschoorn, U. E.; Sotgia, F.; Lisanti, M. P. The 
Reverse Warburg Effect: Aerobic Glycolysis in Cancer Associated Fibroblasts 
and the Tumor Stroma. Cell Cycle 2009, 8 (23), 3984–4001.
(75) Cairns, R.; Papandreou, I.; Denko, N. Overcoming Physiologic Barriers to 
Cancer Treatment by Molecularly Targeting the Tumor Microenvironment. Mol 
Cancer Res 2006, 4 (2), 61–70.
(76) Chiche, J.; Brahimi-Horn, M. C.; Pouysségur, J. Tumour Hypoxia Induces a 
Metabolic Shift Causing Acidosis: a Common Feature in Cancer. J. Cell. Mol. 
Med. 2010, 14 (4), 771–794.
(77) Griffiths, J. R. Are Cancer Cells Acidic? Br. J. Cancer 1991, 64 (3), 425–427.
(78) Vaupel, P.; Kallinowski, F.; Okunieff, P. Blood Flow, Oxygen and Nutrient 
Supply, and Metabolic Microenvironment of Human Tumors: a Review. Cancer 
Res. 1989, 49 (23), 6449–6465.
(79) Wike-Hooley, J. L.; Haveman, J.; Reinhold, H. S. The Relevance of Tumour pH 
to the Treatment of Malignant Disease. Radiother Oncol 1984, 2 (4), 343–366.
(80) Reshetnyak, Y. K. Imaging Tumor Acidity: pH-Low Insertion Peptide Probe for 
Optoacoustic Tomography. Clin. Cancer Res. 2015, 21 (20), 4502–4504.
(81) Rofstad, E. K.; Mathiesen, B.; Kindem, K.; Galappathi, K. Acidic Extracellular 
pH Promotes Experimental Metastasis of Human Melanoma Cells in Athymic 
Nude Mice. Cancer Res. 2006, 66 (13), 6699–6707.
(82) Gillies, R. J.; Robey, I.; Gatenby, R. A. Causes and Consequences of Increased 
Glucose Metabolism of Cancers. J. Nucl. Med. 2008, 49 Suppl 2, 24S–42S.
(83) Estrella, V.; Chen, T.; Lloyd, M.; Wojtkowiak, J.; Cornnell, H. H.; Ibrahim-
Hashim, A.; Bailey, K.; Balagurunathan, Y.; Rothberg, J. M.; Sloane, B. F.; 
Johnson, J.; Gatenby, R. A.; Gillies, R. J. Acidity Generated by the Tumor 
Microenvironment Drives Local Invasion. Cancer Res. 2013, 73 (5), 1524–1535.
(84) Liu, J.; Huang, Y.; Kumar, A.; Tan, A.; Jin, S.; Mozhi, A.; Liang, X.-J. pH-
Sensitive Nano-Systems for Drug Delivery in Cancer Therapy. Biotechnol. Adv. 
2014, 32 (4), 693–710.
(85) Shao, Y.; Huang, W.; Shi, C.; Atkinson, S. T.; Luo, J. Reversibly Crosslinked 
Nanocarriers for on-Demand Drug Delivery in Cancer Treatment. Ther Deliv 
2012, 3 (12), 1409–1427.
(86) Li, W.; Nicol, F.; Szoka, F. C. GALA: a Designed Synthetic pH-Responsive 
Amphipathic Peptide with Applications in Drug and Gene Delivery. Adv. Drug 
Deliv. Rev. 2004, 56 (7), 967–985.
(87) Hunt, J. F. J.; Earnest, T. N. T.; Bousché, O. O.; Kalghatgi, K. K.; Reilly, K. K.; 
Horváth, C. C.; Rothschild, K. J. K.; Engelman, D. M. D. A Biophysical Study of 
Integral Membrane Protein Folding. Biochemistry 1997, 36 (49), 15156–15176.
(88) Fendos, J.; Engelman, D. pHLIP and Acidity as a Universal Biomarker for 
Cancer. Yale J Biol Med 2012, 85 (1), 29–35.
152
(89) Reshetnyak, Y. K.; Segala, M.; Andreev, O. A.; Engelman, D. M. A Monomeric 
Membrane Peptide That Lives in Three Worlds: in Solution, Attached to, and 
Inserted Across Lipid Bilayers. Biophys. J. 2007, 93 (7), 2363–2372.
(90) Reshetnyak, Y. K.; Andreev, O. A.; Segala, M.; Markin, V. S.; Engelman, D. M. 
Energetics of Peptide (pHLIP) Binding to and Folding Across a Lipid Bilayer 
Membrane. Proc. Natl. Acad. Sci. U.S.A. 2008, 105 (40), 15340–15345.
(91) Reshetnyak, Y. K.; Andreev, O. A.; Lehnert, U.; Engelman, D. M. Translocation 
of Molecules Into Cells by pH-Dependent Insertion of a Transmembrane Helix. 
Proc. Natl. Acad. Sci. U.S.A. 2006, 103 (17), 6460–6465.
(92) Barrera, F. N.; Weerakkody, D.; Anderson, M.; Andreev, O. A.; Reshetnyak, Y. 
K.; Engelman, D. M. Roles of Carboxyl Groups in the Transmembrane Insertion 
of Peptides. J. Mol. Biol. 2011, 413 (2), 359–371.
(93) Barrera, F. N.; Fendos, J.; Engelman, D. M. Membrane Physical Properties 
Influence Transmembrane Helix Formation. Proceedings of the National 
Academy of Sciences 2012, 109 (36), 14422–14427.
(94) Zoonens, M.; Reshetnyak, Y. K.; Engelman, D. M. Bilayer Interactions of pHLIP, 
a Peptide That Can Deliver Drugs and Target Tumors. Biophys. J. 2008, 95 (1), 
225–235.
(95) Reshetnyak, Y. K.; Burstein, E. A. Decomposition of Protein Tryptophan 
Fluorescence Spectra Into Log-Normal Components. II. the Statistical Proof of 
Discreteness of Tryptophan Classes in Proteins. Biophys. J. 2001, 81 (3), 1710–
1734.
(96) Andreev, O. A.; Karabadzhak, A. G.; Weerakkody, D.; Andreev, G. O.; Engelman, 
D. M.; Reshetnyak, Y. K. pH (Low) Insertion Peptide (pHLIP) Inserts Across a 
Lipid Bilayer as a Helix and Exits by a Different Path. Proceedings of the 
National Academy of Sciences 2010, 107 (9), 4081–4086.
(97) Deacon, J.; Engelman, D. M.; Barrera, F. N. Targeting Acidity in Diseased 
Tissues: Mechanism and Applications of the Membrane-Inserting Peptide, pHLIP. 
Arch. Biochem. Biophys. 2014.
(98) Weerakkody, D.; Moshnikova, A.; Thakur, M. S.; Moshnikova, V.; Daniels, J.; 
Engelman, D. M.; Andreev, O. A.; Reshetnyak, Y. K. Family of pH (Low) 
Insertion Peptides for Tumor Targeting. Proceedings of the National Academy of 
Sciences 2013, 110 (15), 5834–5839.
(99) Andreev, O. A.; Dupuy, A. D.; Segala, M.; Sandugu, S.; Serra, D. A.; Chichester, 
C. O.; Engelman, D. M.; Reshetnyak, Y. K. Mechanism and Uses of a Membrane 
Peptide That Targets Tumors and Other Acidic Tissues in Vivo. Proc. Natl. Acad. 
Sci. U.S.A. 2007, 104 (19), 7893–7898.
(100) Hessa, T.; Kim, H.; Bihlmaier, K.; Lundin, C.; Boekel, J.; Andersson, H.; Nilsson, 
I.; White, S. H.; Heijne, von, G. Recognition of Transmembrane Helices by the 
Endoplasmic Reticulum Translocon. Nature 2005, 433 (7024), 377–381.
(101) Kyrychenko, A.; Vasquez-Montes, V.; Ulmschneider, M. B.; Ladokhin, A. S. 
Lipid Headgroups Modulate Membrane Insertion of pHLIP Peptide. Biophys. J. 
2015, 108 (4), 791–794.
153
(102) Scott, H. L.; Nguyen, V. P.; Alves, D. S.; Davis, F. L.; Booth, K. R.; Bryner, J.; 
Barrera, F. N. The Negative Charge of the Membrane Has Opposite Effects on the 
Membrane Entry and Exit of pH-Low Insertion Peptide. Biochemistry 2015, 54 
(9), 1709–1712.
(103) Musial-Siwek, M.; Karabadzhak, A.; Andreev, O. A.; Reshetnyak, Y. K.; 
Engelman, D. M. Tuning the Insertion Properties of pHLIP. Biochim. Biophys. 
Acta 2010, 1798 (6), 1041–1046.
(104) Fendos, J.; Barrera, F. N.; Engelman, D. M. Aspartate Embedding Depth Affects 
pHLIP's Insertion pH50. Biochemistry 2013.
(105) Vostrikov, V. V.; Hall, B. A.; Greathouse, D. V.; Koeppe, R. E.; Sansom, M. S. P. 
Changes in Transmembrane Helix Alignment by Arginine Residues Revealed by 
Solid-State NMR Experiments and Coarse-Grained MD Simulations. J. Am. 
Chem. Soc. 2010, 132 (16), 5803–5811.
(106) Killian, J. A.; Heijne, von, G. How Proteins Adapt to a Membrane-Water 
Interface. Trends Biochem. Sci. 2000, 25 (9), 429–434.
(107) Onyango, J. O.; Chung, M. S.; Eng, C.-H.; Klees, L. M.; Langenbacher, R.; Yao, 
L.; An, M. Noncanonical Amino Acids to Improve the pH Response of pHLIP 
Insertion at Tumor Acidity. Angew. Chem. Int. Ed. Engl. 2015, 54 (12), 3658–
3663.
(108) Andreev, O. A.; Engelman, D. M.; Reshetnyak, Y. K. Targeting Acidic Diseased 
Tissue: New Technology Based on Use of the pH (Low) Insertion Peptide 
(pHLIP). Chim Oggi 2009, 27 (2), 34–37.
(109) Segala, J.; Engelman, D. M.; Reshetnyak, Y. K.; Andreev, O. A. Accurate 
Analysis of Tumor Margins Using a Fluorescent pH Low Insertion Peptide 
(pHLIP). Int J Mol Sci 2009, 10 (8), 3478–3487.
(110) Reshetnyak, Y. K.; Yao, L.; Zheng, S.; Kuznetsov, S.; Engelman, D. M.; Andreev, 
O. A. Measuring Tumor Aggressiveness and Targeting Metastatic Lesions with 
Fluorescent pHLIP. Mol Imaging Biol 2011, 13 (6), 1146–1156.
(111) Adochite, R.-C.; Moshnikova, A.; Golijanin, J.; Andreev, O. A.; Katenka, N. V.; 
Reshetnyak, Y. K. Comparative Study of Tumor Targeting and Biodistribution of 
pH (Low) Insertion Peptides (pHLIP(®) Peptides) Conjugated with Different 
Fluorescent Dyes. Mol Imaging Biol 2016.
(112) Serganova, I.; Rizwan, A.; Ni, X.; Thakur, S. B.; Vider, J.; Russell, J.; Blasberg, 
R.; Koutcher, J. A. Metabolic Imaging: a Link Between Lactate Dehydrogenase a, 
Lactate, and Tumor Phenotype. Clin. Cancer Res. 2011, 17 (19), 6250–6261.
(113) Tao, K.; Fang, M.; Alroy, J.; Sahagian, G. G. Imagable 4T1 Model for the Study 
of Late Stage Breast Cancer. BMC Cancer 2008, 8, 228.
(114) Yang, J.; Mani, S. A.; Donaher, J. L.; Ramaswamy, S.; Itzykson, R. A.; Come, C.; 
Savagner, P.; Gitelman, I.; Richardson, A.; Weinberg, R. A. Twist, a Master 
Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis. Cell 
2004, 117 (7), 927–939.
(115) Eckhardt, B. L.; Parker, B. S.; van Laar, R. K.; Restall, C. M.; Natoli, A. L.; 
Tavaria, M. D.; Stanley, K. L.; Sloan, E. K.; Moseley, J. M.; Anderson, R. L. 
154
Genomic Analysis of a Spontaneous Model of Breast Cancer Metastasis to Bone 
Reveals a Role for the Extracellular Matrix. Mol Cancer Res 2005, 3 (1), 1–13.
(116) Adochite, R.-C.; Moshnikova, A.; Carlin, S. D.; Guerrieri, R. A.; Andreev, O. A.; 
Lewis, J. S.; Reshetnyak, Y. K. Targeting Breast Tumors with pH (Low) Insertion 
Peptides. Mol Pharm 2014, 11 (8), 2896–2905.
(117) Andreev, O. A.; Engelman, D. M.; Reshetnyak, Y. K. pH-Sensitive Membrane 
Peptides (pHLIPs) as a Novel Class of Delivery Agents. Mol Membr Biol 2010, 
27 (7), 341–352.
(118) Kellum, J. A.; Song, M.; Li, J. Science Review: Extracellular Acidosis and the 
Immune Response: Clinical and Physiologic Implications. Critical care (London, 
England) 2004, 8 (5), 331–336.
(119) Xiong, Z.-G.; Pignataro, G.; Li, M.; Chang, S.-Y.; Simon, R. P. Acid-Sensing Ion 
Channels (ASICs) as Pharmacological Targets for Neurodegenerative Diseases. 
Curr Opin Pharmacol 2008, 8 (1), 25–32.
(120) Holzer, P. Acid-Sensitive Ion Channels and Receptors. Handb Exp Pharmacol 
2009, No. 194, 283–332.
(121) Sosunov, E. A.; Anyukhovsky, E. P.; Sosunov, A. A.; Moshnikova, A.; 
Wijesinghe, D.; Engelman, D. M.; Reshetnyak, Y. K.; Andreev, O. A. pH (Low) 
Insertion Peptide (pHLIP) Targets Ischemic Myocardium. Proceedings of the 
National Academy of Sciences 2013, 110 (1), 82–86.
(122) Li, N.; Yin, L.; Thévenin, D.; Yamada, Y.; Limmon, G.; Chen, J.; Chow, V. T.; 
Engelman, D. M.; Engelward, B. P. Peptide Targeting and Imaging of Damaged 
Lung Tissue in Influenza-Infected Mice. Future Microbiol 2013, 8 (2), 257–269.
(123) Vāvere, A. L.; Biddlecombe, G. B.; Spees, W. M.; Garbow, J. R.; Wijesinghe, D.; 
Andreev, O. A.; Engelman, D. M.; Reshetnyak, Y. K.; Lewis, J. S. A Novel 
Technology for the Imaging of Acidic Prostate Tumors by Positron Emission 
Tomography. Cancer Res. 2009, 69 (10), 4510–4516.
(124) Daumar, P.; Wanger-Baumann, C. A.; Pillarsetty, N.; Fabrizio, L.; Carlin, S. D.; 
Andreev, O. A.; Reshetnyak, Y. K.; Lewis, J. S. Efficient (18)F-Labeling of Large 
37-Amino-Acid pHLIP Peptide Analogues and Their Biological Evaluation. 
Bioconjug Chem 2012, 23 (8), 1557–1566.
(125) Macholl, S.; Morrison, M. S.; Iveson, P.; Arbo, B. E.; Andreev, O. A.; 
Reshetnyak, Y. K.; Engelman, D. M.; Johannesen, E. In Vivo pH Imaging with 
(99m)Tc-pHLIP. Mol Imaging Biol 2012, 14 (6), 725–734.
(126) Emmetiere, F.; Irwin, C.; Viola-Villegas, N. T. 18F-Labeled-Bioorthogonal 
Liposomes for in Vivo Targeting. Bioconjugate … 2013.
(127) Li, J.; Liu, S.; Lakshminarayanan, R.; Bai, Y.; Pervushin, K.; Verma, C.; 
Beuerman, R. W. Molecular Simulations Suggest How a Branched Antimicrobial 
Peptide Perturbs a Bacterial Membrane and Enhances Permeability. Biochim. 
Biophys. Acta 2013, 1828 (3), 1112–1121.
(128) Loja, M. N.; Luo, Z.; Greg Farwell, D.; Luu, Q. C.; Donald, P. J.; Amott, D.; 
Truong, A. Q.; Gandour-Edwards, R. F.; Nitin, N. Optical Molecular Imaging 
155
Detects Changes in Extracellular pH with the Development of Head and Neck 
Cancer. Int. J. Cancer 2013, 132 (7), 1613–1623.
(129) Yao, L.; Daniels, J.; Wijesinghe, D.; Andreev, O. A.; Reshetnyak, Y. K. 
pHLIP(®)-Mediated Delivery of PEGylated Liposomes to Cancer Cells. J 
Control Release 2013.
(130) Cruz-Monserrate, Z.; Roland, C. L.; Deng, D.; Arumugam, T.; Moshnikova, A.; 
Andreev, O. A.; Reshetnyak, Y. K.; Logsdon, C. D. Targeting Pancreatic Ductal 
Adenocarcinoma Acidic Microenvironment. Sci Rep 2014, 4, 4410.
(131) Viola-Villegas, N. T.; Carlin, S. D.; Ackerstaff, E.; Sevak, K. K.; Divilov, V.; 
Serganova, I.; Kruchevsky, N.; Anderson, M.; Blasberg, R. G.; Andreev, O. A.; 
Engelman, D. M.; Koutcher, J. A.; Reshetnyak, Y. K.; Lewis, J. S. Understanding 
the Pharmacological Properties of a Metabolic PET Tracer in Prostate Cancer. 
Proceedings of the National Academy of Sciences 2014, 111 (20), 7254–7259.
(132) Luo, Z.; Loja, M. N.; Farwell, D. G.; Luu, Q. C.; Donald, P. J.; Amott, D.; 
Truong, A. Q.; Gandour-Edwards, R.; Nitin, N. Widefield Optical Imaging of 
Changes in Uptake of Glucose and Tissue Extracellular pH in Head and Neck 
Cancer. Cancer Prev Res (Phila) 2014, 7 (10), 1035–1044.
(133) Karabadzhak, A. G.; An, M.; Yao, L.; Langenbacher, R.; Moshnikova, A.; 
Adochite, R.-C.; Andreev, O. A.; Reshetnyak, Y. K.; Engelman, D. M. pHLIP-
FIRE, a Cell Insertion-Triggered Fluorescent Probe for Imaging Tumors 
Demonstrates Targeted Cargo Delivery in Vivo. ACS Chem. Biol. 2014.
(134) Cheng, C. J.; Bahal, R.; Babar, I. A.; Pincus, Z.; Barrera, F.; Liu, C.; Svoronos, 
A.; Braddock, D. T.; Glazer, P. M.; Engelman, D. M.; Saltzman, W. M.; Slack, F. 
J. MicroRNA Silencing for Cancer Therapy Targeted to the Tumour 
Microenvironment. Nature 2015, 518 (7537), 107–110.
(135) Kimbrough, C. W.; Khanal, A.; Zeiderman, M.; Khanal, B. R.; Burton, N. C.; 
McMasters, K. M.; Vickers, S. M.; Grizzle, W. E.; McNally, L. R. Targeting 
Acidity in Pancreatic Adenocarcinoma: Multispectral Optoacoustic Tomography 
Detects pH-Low Insertion Peptide Probes in Vivo. Clin. Cancer Res. 2015, 21 
(20), 4576–4585.
(136) Andreev, O. A.; Engelman, D. M.; Reshetnyak, Y. K. Targeting Diseased Tissues 
by pHLIP Insertion at Low Cell Surface pH. Front Physiol 2014, 5, 97.
(137) Davies, A.; Lewis, D. J.; Watson, S. P.; Thomas, S. G.; Pikramenou, Z. pH-
Controlled Delivery of Luminescent Europium Coated Nanoparticles Into 
Platelets. Proceedings of the National Academy of Sciences 2012, 109 (6), 1862–
1867.
(138) Wijesinghe, D.; Arachchige, M. C. M.; Lu, A.; Reshetnyak, Y. K.; Andreev, O. A. 
pH Dependent Transfer of Nano-Pores Into Membrane of Cancer Cells to Induce 
Apoptosis. Sci Rep 2013, 3, 3560.
(139) Yao, L.; Daniels, J.; Danniels, J.; Moshnikova, A.; Kuznetsov, S.; Ahmed, A.; 
Engelman, D. M.; Reshetnyak, Y. K.; Andreev, O. A. pHLIP Peptide Targets 
Nanogold Particles to Tumors. Proceedings of the National Academy of Sciences 
2013, 110 (2), 465–470.
156
(140) Hainfeld, J. F.; Dilmanian, F. A.; Slatkin, D. N.; Smilowitz, H. M. Radiotherapy 
Enhancement with Gold Nanoparticles. J. Pharm. Pharmacol. 2008, 60 (8), 977–
985.
(141) Mahmoud, M. A.; El-Sayed, M. A. Gold Nanoframes: Very High Surface 
Plasmon Fields and Excellent Near-Infrared Sensors. J. Am. Chem. Soc. 2010, 
132 (36), 12704–12710.
(142) Glazer, E. S.; Zhu, C.; Massey, K. L.; Thompson, C. S.; Kaluarachchi, W. D.; 
Hamir, A. N.; Curley, S. A. Noninvasive Radiofrequency Field Destruction of 
Pancreatic Adenocarcinoma Xenografts Treated with Targeted Gold 
Nanoparticles. Clin. Cancer Res. 2010, 16 (23), 5712–5721.
(143) Antosh, M. P.; Wijesinghe, D. D.; Shrestha, S.; Lanou, R.; Huang, Y. H.; 
Hasselbacher, T.; Fox, D.; Neretti, N.; Sun, S.; Katenka, N.; Cooper, L. N.; 
Andreev, O. A.; Reshetnyak, Y. K. Enhancement of Radiation Effect on Cancer 
Cells by Gold-pHLIP. Proceedings of the National Academy of Sciences 2015, 
112 (17), 5372–5376.
(144) Zhao, Z.; Meng, H.; Wang, N.; Donovan, M. J.; Fu, T.; You, M.; Chen, Z.; Zhang, 
X.; Tan, W. A Controlled-Release Nanocarrier with Extracellular pH Value 
Driven Tumor Targeting and Translocation for Drug Delivery. Angew. Chem. Int. 
Ed. Engl. 2013, 52 (29), 7487–7491.
(145) Yu, M.; Guo, F.; Wang, J.; Tan, F.; Li, N. Biomaterials. Biomaterials 2016, 79 (c), 
25–35.
(146) Han, L.; Ma, H.; Guo, Y.; Kuang, Y.; He, X.; Jiang, C. pH-Controlled Delivery of 
Nanoparticles Into Tumor Cells. Adv Healthc Mater 2013, 2 (11), 1435–1439.
(147) Thévenin, D.; An, M.; Engelman, D. M. pHLIP-Mediated Translocation of 
Membrane-Impermeable Molecules Into Cells. Chem. Biol. 2009, 16 (7), 754–
762.
(148) An, M.; Wijesinghe, D.; Andreev, O. A.; Reshetnyak, Y. K.; Engelman, D. M. pH-
(Low)-Insertion-Peptide (pHLIP) Translocation of Membrane Impermeable 
Phalloidin Toxin Inhibits Cancer Cell Proliferation. Proceedings of the National 
Academy of Sciences 2010, 107 (47), 20246–20250.
(149) Costinean, S.; Zanesi, N.; Pekarsky, Y.; Tili, E.; Volinia, S.; Heerema, N.; Croce, 
C. M. Pre-B Cell Proliferation and Lymphoblastic Leukemia/High-Grade 
Lymphoma in E(Mu)-miR155 Transgenic Mice. Proc. Natl. Acad. Sci. U.S.A. 
2006, 103 (18), 7024–7029.
(150) Wagner, E. Tumor-Targeted Delivery of Anti-microRNA for Cancer Therapy: 
pHLIP Is Key. Angew. Chem. Int. Ed. Engl. 2015.
(151) Moshnikova, A.; Moshnikova, V.; Andreev, O. A.; Reshetnyak, Y. K. 
Antiproliferative Effect of pHLIP-Amanitin. Biochemistry 2013, 52 (7), 1171–
1178.
(152) Song, Q.; Chuan, X.; Chen, B.; He, B.; Zhang, H.; Dai, W.; Wang, X.; Zhang, Q. 
A Smart Tumor Targeting Peptide-Drug Conjugate, pHLIP-SS-DOX: Synthesis 
and Cellular Uptake on MCF-7 and MCF-7/Adr Cells. Drug Deliv 2015, 1–13.
157
(153) Li, S.; Tian, Y.; Zhao, Y.; Zhang, Y.; Su, S.; Wang, J.; Wu, M.; Shi, Q.; Anderson, 
G. J.; Thomsen, J.; Zhao, R.; Ji, T.; Wang, J.; Nie, G. pHLIP-Mediated Targeting 
of Truncated Tissue Factor to Tumor Vessels Causes Vascular Occlusion and 
Impairs Tumor Growth. Oncotarget 2015.
(154) Cragg, G. M.; Kingston, D. G. Anticancer Agents From Natural Products, 1st ed.; 
CRS Press, Taylor & Francis Group: New York, NY, 2005.
(155) Doronina, S. O.; Toki, B. E.; Torgov, M. Y.; Mendelsohn, B. A.; Cerveny, C. G.; 
Chace, D. F.; DeBlanc, R. L.; Gearing, R. P.; Bovee, T. D.; Siegall, C. B.; 
Francisco, J. A.; Wahl, A. F.; Meyer, D. L.; Senter, P. D. Development of Potent 
Monoclonal Antibody Auristatin Conjugates for Cancer Therapy. Nature 
Biotechnology 2003, 21 (7), 778–784.
(156) Doronina, S. O.; Mendelsohn, B. A.; Bovee, T. D.; Cerveny, C. G.; Alley, S. C.; 
Meyer, D. L.; Oflazoglu, E.; Toki, B. E.; Sanderson, R. J.; Zabinski, R. F.; Wahl, 
A. F.; Senter, P. D. Enhanced Activity of Monomethylauristatin F Through 
Monoclonal Antibody Delivery: Effects of Linker Technology on Efficacy and 
Toxicity. Bioconjug Chem 2006, 17 (1), 114–124.
(157) Minko, T.; Dharap, S. S.; Pakunlu, R. I.; Wang, Y. Molecular Targeting of Drug 
Delivery Systems to Cancer. Curr Drug Targets 2004, 5 (4), 389–406.
(158) Gerlinger, M.; Rowan, A. J.; Horswell, S.; Larkin, J.; Endesfelder, D.; Gronroos, 
E.; Martinez, P.; Matthews, N.; Stewart, A.; Tarpey, P.; Varela, I.; Phillimore, B.; 
Begum, S.; McDonald, N. Q.; Butler, A.; Jones, D.; Raine, K.; Latimer, C.; 
Santos, C. R.; Nohadani, M.; Eklund, A. C.; Spencer-Dene, B.; Clark, G.; 
Pickering, L.; Stamp, G.; Gore, M.; Szallasi, Z.; Downward, J.; Futreal, P. A.; 
Swanton, C. Intratumor Heterogeneity and Branched Evolution Revealed by 
Multiregion Sequencing. N. Engl. J. Med. 2012, 366 (10), 883–892.
(159) Barok, M.; Joensuu, H.; Isola, J. Trastuzumab Emtansine: Mechanisms of Action 
and Drug Resistance. Breast Cancer Research (Online Edition) 2014, 16 (2), 
209–209.
(160) Peddi, P. F.; Hurvitz, S. A. Ado-Trastuzumab Emtansine (T-DM1) in Human 
Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer: 
Latest Evidence and Clinical Potential. Ther Adv Med Oncol 2014, 6 (5), 202–
209.
(161) Hurvitz, S. A.; Dirix, L.; Kocsis, J.; Bianchi, G. V.; Lu, J.; Vinholes, J.; Guardino, 
E.; Song, C.; Tong, B.; Ng, V.; Chu, Y.-W.; Perez, E. A. Phase II Randomized 
Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients 
with Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast 
Cancer. J. Clin. Oncol. 2013, 31 (9), 1157–1163.
(162) Chen, R.; Hou, J.; Newman, E.; Kim, Y.; Donohue, C.; Liu, X.; Thomas, S. H.; 
Forman, S. J.; Kane, S. E. CD30 Downregulation, MMAE Resistance, and 
MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin. 
Mol. Cancer Ther. 2015, 14 (6), 1376–1384.
(163) Manyak, M. J. Indium-111 Capromab Pendetide in the Management of Recurrent 
Prostate Cancer. Expert Rev Anticancer Ther 2008, 8 (2), 175–181.
158
(164) Sørlie, T.; Perou, C. M.; Tibshirani, R.; Aas, T.; Geisler, S.; Johnsen, H.; Hastie, 
T.; Eisen, M. B.; van de Rijn, M.; Jeffrey, S. S.; Thorsen, T.; Quist, H.; Matese, J. 
C.; Brown, P. O.; Botstein, D.; Lønning, P. E.; Børresen-Dale, A. L. Gene 
Expression Patterns of Breast Carcinomas Distinguish Tumor Subclasses with 
Clinical Implications. Proc. Natl. Acad. Sci. U.S.A. 2001, 98 (19), 10869–10874.
(165) Paik, S.; Shak, S.; Tang, G.; Kim, C.; Baker, J.; Cronin, M.; Baehner, F. L.; 
Walker, M. G.; Watson, D.; Park, T.; Hiller, W.; Fisher, E. R.; Wickerham, D. L.; 
Bryant, J.; Wolmark, N. A Multigene Assay to Predict Recurrence of Tamoxifen-
Treated, Node-Negative Breast Cancer. N. Engl. J. Med. 2004, 351 (27), 2817–
2826.
(166) Slamon, D. J.; Clark, G. M.; Wong, S. G.; Levin, W. J.; Ullrich, A.; McGuire, W. 
L. Human Breast Cancer: Correlation of Relapse and Survival with Amplification 
of the HER-2/Neu Oncogene. Science 1987, 235 (4785), 177–182.
(167) Sorlie, T.; Tibshirani, R.; Parker, J.; Hastie, T.; Marron, J. S.; Nobel, A.; Deng, S.; 
Johnsen, H.; Pesich, R.; Geisler, S.; Demeter, J.; Perou, C. M.; Lønning, P. E.; 
Brown, P. O.; Børresen-Dale, A.-L.; Botstein, D. Repeated Observation of Breast 
Tumor Subtypes in Independent Gene Expression Data Sets. Proc. Natl. Acad. 
Sci. U.S.A. 2003, 100 (14), 8418–8423.
(168) Carey, L. A.; Perou, C. M.; Livasy, C. A.; Dressler, L. G.; Cowan, D.; Conway, 
K.; Karaca, G.; Troester, M. A.; Tse, C. K.; Edmiston, S.; Deming, S. L.; Geradts, 
J.; Cheang, M. C. U.; Nielsen, T. O.; Moorman, P. G.; Earp, H. S.; Millikan, R. C. 
Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study. 
JAMA 2006, 295 (21), 2492–2502.
(169) Perou, C. M.; Sørlie, T.; Eisen, M. B.; van de Rijn, M.; Jeffrey, S. S.; Rees, C. A.; 
Pollack, J. R.; Ross, D. T.; Johnsen, H.; Akslen, L. A.; Fluge, O.; 
Pergamenschikov, A.; Williams, C.; Zhu, S. X.; Lønning, P. E.; Børresen-Dale, A. 
L.; Brown, P. O.; Botstein, D. Molecular Portraits of Human Breast Tumours. 
Nature 2000, 406 (6797), 747–752.
(170) Dent, R.; Trudeau, M.; Pritchard, K. I.; Hanna, W. M.; Kahn, H. K.; Sawka, C. 
A.; Lickley, L. A.; Rawlinson, E.; Sun, P.; Narod, S. A. Triple-Negative Breast 
Cancer: Clinical Features and Patterns of Recurrence. Clin. Cancer Res. 2007, 13 
(15 Pt 1), 4429–4434.
(171) Lambert, J. M.; Chari, R. V. J. Ado-Trastuzumab Emtansine (T-DM1): an 
Antibody-Drug Conjugate (ADC) for HER2-Positive Breast Cancer. J. Med. 
Chem. 2014.
(172) Alley, S. C.; Okeley, N. M.; Senter, P. D. Antibody-Drug Conjugates: Targeted 
Drug Delivery for Cancer. Curr Opin Chem Biol 2010, 14 (4), 529–537.
(173) Alley, S. C.; Zhang, X.; Okeley, N. M.; Anderson, M.; Law, C.-L.; Senter, P. D.; 
Benjamin, D. R. The Pharmacologic Basis for Antibody-Auristatin Conjugate 
Activity. J. Pharmacol. Exp. Ther. 2009, 330 (3), 932–938.
(174) Miller, J.; Doss, M.; McQuillen, R.; Shaller, C. C.; Tolner, B.; Yu, J. Q.; Chester, 
K.; Robinson, M. K. Impact of Expression System on the Function of the C6.5 
Diabody PET Radiotracer. Tumour Biol. 2012, 33 (3), 617–627.
159
(175) Robinson, M. K.; Shaller, C.; Garmestani, K.; Plascjak, P. S.; Hodge, K. M.; 
Yuan, Q.-A.; Marks, J. D.; Waldmann, T. A.; Brechbiel, M. W.; Adams, G. P. 
Effective Treatment of Established Human Breast Tumor Xenografts in 
Immunodeficient Mice with a Single Dose of the Alpha-Emitting Radioisotope 
Astatine-211 Conjugated to Anti-HER2/Neu Diabodies. Clin. Cancer Res. 2008, 
14 (3), 875–882.
(176) Cao, Y.; Marks, J. W.; Liu, Z.; Cheung, L. H.; Hittelman, W. N.; Rosenblum, M. 
G. Design Optimization and Characterization of Her2/Neu-Targeted 
Immunotoxins: Comparative in Vitro and in Vivo Efficacy Studies. Oncogene 
2014, 33 (4), 429–439.
(177) Burns, K. E.; Robinson, M. K.; Thévenin, D. Inhibition of Cancer Cell 
Proliferation and Breast Tumor Targeting of pHLIP-Monomethyl Auristatin E 
Conjugates. Mol Pharm 2015, 12 (4), 1250–1258.
(178) Gerweck, L. E.; Gerweck, L. E.; Seetharaman, K.; Seetharaman, K. Cellular pH 
Gradient in Tumor Versus Normal Tissue: Potential Exploitation for the 
Treatment of Cancer. Cancer Res. 1996, 56 (6), 1194–1198.
(179) Zhang, X.; Lin, Y.; Gillies, R. J. Tumor pH and Its Measurement. J. Nucl. Med. 
2010, 51 (8), 1167–1170.
(180) Bhujwalla, Z. M.; Artemov, D.; Ballesteros, P.; Cerdan, S.; Gillies, R. J.; 
Solaiyappan, M. Combined Vascular and Extracellular pH Imaging of Solid 
Tumors. NMR Biomed 2002, 15 (2), 114–119.
(181) Burns, K. E.; Thévenin, D. Down-Regulation of PAR1 Activity with a pHLIP-
Based Allosteric Antagonist Induces Cancer Cell Death. Biochem. J. 2015, 472 
(3), 287–295.
(182) Chan, F. K.-M.; Moriwaki, K.; De Rosa, M. J. Detection of Necrosis by Release 
of Lactate Dehydrogenase Activity. Methods Mol. Biol. 2013, 979, 65–70.
(183) Hartley, J. A.; Hamaguchi, A.; Suggitt, M.; Gregson, S. J.; Thurston, D. E.; 
Howard, P. W. DNA Interstrand Cross-Linking and in Vivo Antitumor Activity of 
the Extended Pyrrolo[2,1-C][1,4]Benzodiazepine Dimer SG2057. Invest New 
Drugs 2012, 30 (3), 950–958.
(184) Hurley, L. H.; Reck, T.; Thurston, D. E.; Langley, D. R.; Holden, K. G.; 
Hertzberg, R. P.; Hoover, J. R.; Gallagher, G.; Faucette, L. F.; Mong, S. M. 
Pyrrolo[1,4]Benzodiazepine Antitumor Antibiotics: Relationship of DNA 
Alkylation and Sequence Specificity to the Biological Activity of Natural and 
Synthetic Compounds. Chem. Res. Toxicol. 1988, 1 (5), 258–268.
(185) Bhattacharya, B. K.; Ojwang, J. O.; Rando, R. F.; Huffman, J. H.; Revankar, G. 
R. Synthesis and Anti-DNA Viral Activities in Vitro of Certain 2,4-
Disubstituted-7-(2-Deoxy-2-Fluoro-Beta-D-Arabinofuranosyl)Pyrrolo[2,3-D D 
Pyrimidine Nucleosides. J. Med. Chem. 1995, 38 (20), 3957–3966.
(186) Maruyama, I. N.; Suzuki, H.; Tanaka, N. Mechanism of Action of Neothramycin. 
I. the Effect of Macromolecular Syntheses. J. Antibiot. 1978, 31 (8), 761–768.
(187) Graves, D. E.; Pattaroni, C.; Krishnan, B. S.; Ostrander, J. M.; Hurley, L. H.; 
Krugh, T. R. The Reaction of Anthramycin with DNA. Proton and Carbon 
160
Nuclear Magnetic Resonance Studies on the Structure of the Anthramycin-DNA 
Adduct. J. Biol. Chem. 1984, 259 (13), 8202–8209.
(188) Baraldi, P. G.; Bovero, A.; Fruttarolo, F.; Preti, D.; Tabrizi, M. A.; Pavani, M. G.; 
Romagnoli, R. DNA Minor Groove Binders as Potential Antitumor and 
Antimicrobial Agents. Med Res Rev 2004, 24 (4), 475–528.
(189) Sutherland, M. S. K.; Walter, R. B.; Jeffrey, S. C.; Burke, P. J.; Yu, C.; Kostner, 
H.; Stone, I.; Ryan, M. C.; Sussman, D.; Lyon, R. P.; Zeng, W.; Harrington, K. 
H.; Klussman, K.; Westendorf, L.; Meyer, D.; Bernstein, I. D.; Senter, P. D.; 
Benjamin, D. R.; Drachman, J. G.; McEarchern, J. A. SGN-CD33A: a Novel 
CD33-Targeting Antibody-Drug Conjugate Using a Pyrrolobenzodiazepine 
Dimer Is Active in Models of Drug-Resistant AML. Blood 2013, 122 (8), 1455–
1463.
(190) Gether, U.; Kobilka, B. K. G Protein-Coupled Receptors. II. Mechanism of 
Agonist Activation. J. Biol. Chem. 1998, 273 (29), 17979–17982.
(191) Dimond, P.; Carlson, K.; Bouvier, M.; Gerard, C.; Xu, L.; Covic, L.; Agarwal, A.; 
Ernst, O. P.; Janz, J. M.; Schwartz, T. W.; Gardella, T. J.; Milligan, G.; 
Kuliopulos, A.; Sakmar, T. P.; Hunt, S. W. G Protein-Coupled Receptor 
Modulation with Pepducins: Moving Closer to the Clinic. Ann. N. Y. Acad. Sci. 
2011, 1226, 34–49.
(192) Conn, P. J.; Christopoulos, A.; Lindsley, C. W. Allosteric Modulators of GPCRs: 
a Novel Approach for the Treatment of CNS Disorders. Nat Rev Drug Discov 
2009, 8 (1), 41–54.
(193) Eglen, R. M.; Reisine, T. GPCRs Revisited: New Insights Lead to Novel Drugs. 
Pharmaceuticals 2011, 4 (2), 244–272.
(194) Canals, M.; Sexton, P. M.; Christopoulos, A. Allostery in GPCRs: “MWC” 
Revisited. Trends Biochem. Sci. 2011, 36 (12), 663–672.
(195) Covic, L.; Gresser, A. L.; Talavera, J. Activation and Inhibition of G Protein-
Coupled Receptors by Cell-Penetrating Membrane-Tethered Peptides; 2002.
(196) Kostenis, E. E.; Zeng, F. Y. F.; Wess, J. J. Functional Characterization of a Series 
of Mutant G Protein Alphaq Subunits Displaying Promiscuous Receptor 
Coupling Properties. J. Biol. Chem. 1998, 273 (28), 17886–17892.
(197) Cotecchia, S.; Ostrowski, J.; Kjelsberg, M. A.; Caron, M. G.; Lefkowitz, R. J. 
Discrete Amino Acid Sequences of the Alpha 1-Adrenergic Receptor Determine 
the Selectivity of Coupling to Phosphatidylinositol Hydrolysis. J. Biol. Chem. 
1992, 267 (3), 1633–1639.
(198) O'Callaghan, K.; Kuliopulos, A.; Covic, L. Turning Receptors on and Off with 
Intracellular Pepducins: New Insights Into G-Protein-Coupled Receptor Drug 
Development. Journal of Biological Chemistry 2012, 287 (16), 12787–12796.
(199) Agarwal, A.; Covic, L.; Sevigny, L. M.; Kaneider, N. C.; Lazarides, K.; 
Azabdaftari, G.; Sharifi, S.; Kuliopulos, A. Targeting a Metalloprotease-PAR1 
Signaling System with Cell-Penetrating Pepducins Inhibits Angiogenesis, Ascites, 
and Progression of Ovarian Cancer. Mol. Cancer Ther. 2008, 7 (9), 2746–2757.
161
(200) Yang, E.; Boire, A.; Agarwal, A.; Nguyen, N.; O'Callaghan, K.; Tu, P.; 
Kuliopulos, A.; Covic, L. Blockade of PAR1 Signaling with Cell-Penetrating 
Pepducins Inhibits Akt Survival Pathways in Breast Cancer Cells and Suppresses 
Tumor Survival and Metastasis. Cancer Res. 2009, 69 (15), 6223–6231.
(201) Tressel, S. L.; Koukos, G.; Tchernychev, B.; Jacques, S. L.; Covic, L.; 
Kuliopulos, A. Pharmacology, Biodistribution, and Efficacy of GPCR-Based 
Pepducins in Disease Models. Methods Mol. Biol. 2011, 683, 259–275.
(202) Wielders, S.; Bennaghmouch, A. Anticoagulant and Antithrombotic Properties of 
Intracellular Protease-Activated Receptor Antagonists. … of Thrombosis and … 
2007.
(203) Johannessen, L.; Remsberg, J.; Gaponenko, V.; Adams, K. M.; Barchi, J. J.; 
Tarasov, S. G.; Jiang, S.; Tarasova, N. I. Peptide Structure Stabilization by 
Membrane Anchoring and Its General Applicability to the Development of Potent 
Cell-Permeable Inhibitors. Chembiochem 2011, 12 (6), 914–921.
(204) Ossovskaya, V. S.; Bunnett, N. W. Protease-Activated Receptors: Contribution to 
Physiology and Disease. Physiol. Rev. 2004, 84 (2), 579–621.
(205) Sevigny, L. M.; Zhang, P.; Bohm, A.; Lazarides, K.; Perides, G.; Covic, L.; 
Kuliopulos, A. Interdicting Protease-Activated Receptor-2-Driven Inflammation 
with Cell-Penetrating Pepducins. Proc. Natl. Acad. Sci. U.S.A. 2011, 108 (20), 
8491–8496.
(206) Boire, A.; Covic, L.; Agarwal, A.; Jacques, S.; Sherifi, S.; Kuliopulos, A. PAR1 Is 
a Matrix Metalloprotease-1 Receptor That Promotes Invasion and Tumorigenesis 
of Breast Cancer Cells. Cell 2005, 120 (3), 11–11.
(207) Dabek, M.; Ferrier, L.; Roka, R.; Gecse, K.; Annahazi, A.; Moreau, J.; Escourrou, 
J.; Cartier, C.; Chaumaz, G.; Leveque, M.; Ait-Belgnaoui, A.; Wittmann, T.; 
Theodorou, V.; Bueno, L. Luminal Cathepsin G and Protease-Activated Receptor 
4: a Duet Involved in Alterations of the Colonic Epithelial Barrier in Ulcerative 
Colitis. Am. J. Pathol. 2009, 175 (1), 207–214.
(208) McDougall, J. J.; Zhang, C.; Cellars, L.; Joubert, E.; Dixon, C. M.; Vergnolle, N. 
Triggering of Proteinase-Activated Receptor 4 Leads to Joint Pain and 
Inflammation in Mice. Arthritis Rheum 2009, 60 (3), 728–737.
(209) Annahazi, A.; Gecse, K.; Dabek, M.; Ait-Belgnaoui, A.; Rosztóczy, A.; Roka, R.; 
Molnár, T.; Theodorou, V.; Wittmann, T.; Bueno, L.; Eutamene, H. Fecal 
Proteases From Diarrheic-IBS and Ulcerative Colitis Patients Exert Opposite 
Effect on Visceral Sensitivity in Mice. Pain 2009, 144 (1-2), 209–217.
(210) Granovsky-Grisaru, S.; Zaidoun, S.; Grisaru, D.; Yekel, Y.; Prus, D.; Beller, U.; 
Bar-Shavit, R. The Pattern of Protease Activated Receptor 1 (PAR1) Expression 
in Endometrial Carcinoma. Gynecol. Oncol. 2006, 103 (3), 802–806.
(211) Ghio, P.; Cappia, S.; Selvaggi, G.; Novello, S.; Lausi, P.; Zecchina, G.; Papotti, 
M.; Borasio, P.; Scagliotti, G. V. Prognostic Role of Protease-Activated Receptors 
1 and 4 in Resected Stage IB Non-Small-Cell Lung Cancer. Clin Lung Cancer 
2006, 7 (6), 395–400.
162
(212) Merritt, W. M.; Lin, Y. G.; Spannuth, W. A. 2008. Effect of Interleukin-8 Gene 
Silencing with Liposomeencapsulated Small Interfering RNA on Ovarian Cancer 
Cell Growth. J Natl Cancer Inst 100: 359-372. 148 …. University of Iowa 
Medical … 1976.
(213) Agarwal, A.; Tressel, S. L.; Kaimal, R.; Balla, M.; Lam, F. H.; Covic, L.; 
Kuliopulos, A. Identification of a Metalloprotease-Chemokine Signaling System 
in the Ovarian Cancer Microenvironment: Implications for Antiangiogenic 
Therapy. Cancer Res. 2010, 70 (14), 5880–5890.
(214) Hofmann, K. P.; Scheerer, P.; Hildebrand, P. W.; Choe, H.-W.; Park, J. H.; Heck, 
M.; Ernst, O. P. A G Protein-Coupled Receptor at Work: the Rhodopsin Model. 
Trends Biochem. Sci. 2009, 34 (11), 540–552.
(215) Even-Ram, S.; Uziely, B.; Cohen, P.; Grisaru-Granovsky, S.; Maoz, M.; 
Ginzburg, Y.; Reich, R.; Vlodavsky, I.; Bar-Shavit, R. Thrombin Receptor 
Overexpression in Malignant and Physiological Invasion Processes. Nat. Med. 
1998, 4 (8), 909–914.
(216) Grisaru-Granovsky, S.; Salah, Z.; Maoz, M.; Pruss, D.; Beller, U.; Bar-Shavit, R. 
Differential Expression of Protease Activated Receptor 1 (Par1) and pY397FAK 
in Benign and Malignant Human Ovarian Tissue Samples. Int. J. Cancer 2005, 
113 (3), 372–378.
(217) Heider, I.; Schulze, B.; Oswald, E.; Henklein, P.; Scheele, J.; Kaufmann, R. 
PAR1-Type Thrombin Receptor Stimulates Migration and Matrix Adhesion of 
Human Colon Carcinoma Cells by a PKCepsilon-Dependent Mechanism. Oncol. 
Res. 2004, 14 (10), 475–482.
(218) Nierodzik, M. L.; Kajumo, F.; Karpatkin, S. Effect of Thrombin Treatment of 
Tumor Cells on Adhesion of Tumor Cells to Platelets in Vitro and Tumor 
Metastasis in Vivo. Cancer Res. 1992, 52 (12), 3267–3272.
(219) Kamath, L.; Meydani, A.; Foss, F.; Kuliopulos, A. Signaling From Protease-
Activated Receptor-1 Inhibits Migration and Invasion of Breast Cancer Cells. 
Cancer Res. 2001, 61 (15), 5933–5940.
(220) Jorgensen, W. L.; Duffy, E. M. Prediction of Drug Solubility From Structure. Adv. 
Drug Deliv. Rev. 2002, 54 (3), 355–366.
(221) Koszałka, P.; Kamysz, E.; Wejda, M.; Kamysz, W.; Bigda, J. Antitumor Activity 
of Antimicrobial Peptides Against U937 Histiocytic Cell Line. Acta Biochim. Pol. 
2011, 58 (1), 111–117.
(222) Utsugi, T.; Schroit, A. J.; Connor, J.; Bucana, C. D.; Fidler, I. J. Elevated 
Expression of Phosphatidylserine in the Outer Membrane Leaflet of Human 
Tumor Cells and Recognition by Activated Human Blood Monocytes. Cancer 
Res. 1991, 51 (11), 3062–3066.
(223) Gaspar, D. From Antimicrobial to Anticancer Peptides. a Review. 2013, 1–16.
(224) Mader, J. S.; Hoskin, D. W. Cationic Antimicrobial Peptides as Novel Cytotoxic 
Agents for Cancer Treatment. Expert Opin Investig Drugs 2006, 8, 933–946.
163
(225) Hoskin, D. W.; Ramamoorthy, A. Studies on Anticancer Activities of 
Antimicrobial Peptides. Biochimica et Biophysica Acta (BBA) - Biomembranes 
2008, 1778 (2), 357–375.
(226) Fulda, S. Tumor Resistance to Apoptosis. Int. J. Cancer 2009, 124 (3), 511–515.
(227) Indran, I. R.; Tufo, G.; Pervaiz, S.; Brenner, C. Recent Advances in Apoptosis, 
Mitochondria and Drug Resistance in Cancer Cells. Biochim. Biophys. Acta 2011, 
1807 (6), 735–745.
(228) Javadpour, M. M.; Juban, M. M.; Lo, W. C.; Bishop, S. M.; Alberty, J. B.; 
Cowell, S. M.; Becker, C. L.; McLaughlin, M. L. De Novo Antimicrobial 
Peptides with Low Mammalian Cell Toxicity. J. Med. Chem. 1996, 39 (16), 
3107–3113.
(229) Oehlke, J.; Scheller, A.; Wiesner, B.; Krause, E.; Beyermann, M.; Klauschenz, E.; 
Melzig, M.; Bienert, M. Cellular Uptake of an Alpha-Helical Amphipathic Model 
Peptide with the Potential to Deliver Polar Compounds Into the Cell Interior 
Non-Endocytically. Biochim. Biophys. Acta 1998, 1414 (1-2), 127–139.
(230) Ellerby, H. M.; Arap, W.; Ellerby, L. M.; Kain, R.; Andrusiak, R.; Rio, G. D.; 
Krajewski, S.; Lombardo, C. R.; Rao, R.; Ruoslahti, E.; Bredesen, D. E.; 
Pasqualini, R. Anti-Cancer Activity of Targeted Pro-Apoptotic Peptides. Nat. 
Med. 1999, 5 (9), 1032–1038.
(231) Law, B.; Quinti, L.; Choi, Y.; Weissleder, R.; Tung, C.-H. A Mitochondrial 
Targeted Fusion Peptide Exhibits Remarkable Cytotoxicity. Mol. Cancer Ther. 
2006, 5 (8), 1944–1949.
(232) Mai, J. C.; Mi, Z.; Kim, S. H.; Ng, B.; Robbins, P. D. A Proapoptotic Peptide for 
the Treatment of Solid Tumors. Cancer Res. 2001, 61 (21), 7709–7712.
(233) Marks, A. J.; Cooper, M. S.; Anderson, R. J.; Orchard, K. H.; Hale, G.; North, J. 
M.; Ganeshaguru, K.; Steele, A. J.; Mehta, A. B.; Lowdell, M. W.; 
Wickremasinghe, R. G. Selective Apoptotic Killing of Malignant Hemopoietic 
Cells by Antibody-Targeted Delivery of an Amphipathic Peptide. Cancer Res. 
2005, 65 (6), 2373–2377.
(234) Rege, K.; Patel, S. J.; Megeed, Z.; Yarmush, M. L. Amphipathic Peptide-Based 
Fusion Peptides and Immunoconjugates for the Targeted Ablation of Prostate 
Cancer Cells. Cancer Res. 2007, 67 (13), 6368–6375.
(235) Standley, S. M.; Toft, D. J.; Cheng, H.; Soukasene, S.; Chen, J.; Raja, S. M.; 
Band, V.; Band, H.; Cryns, V. L.; Stupp, S. I. Induction of Cancer Cell Death by 
Self-Assembling Nanostructures Incorporating a Cytotoxic Peptide. Cancer Res. 
2010, 70 (8), 3020–3026.
(236) Agemy, L.; Friedmann-Morvinski, D.; Kotamraju, V. R.; Roth, L.; Sugahara, K. 
N.; Girard, O. M.; Mattrey, R. F.; Verma, I. M.; Ruoslahti, E. Targeted 
Nanoparticle Enhanced Proapoptotic Peptide as Potential Therapy for 
Glioblastoma. Proceedings of the National Academy of Sciences 2011, 108 (42), 
17450–17455.
(237) Makovitzki, A.; Avrahami, D.; Shai, Y. Ultrashort Antibacterial and Antifungal 
Lipopeptides. Proc. Natl. Acad. Sci. U.S.A. 2006, 103 (43), 15997–16002.
164
(238) Makovitzki, A.; Viterbo, A.; Brotman, Y.; Chet, I.; Shai, Y. Inhibition of Fungal 
and Bacterial Plant Pathogens in Vitro and in Planta with Ultrashort Cationic 
Lipopeptides. Appl. Environ. Microbiol. 2007, 73 (20), 6629–6636.
(239) Laverty, G.; McLaughlin, M.; Shaw, C.; Gorman, S. P.; Gilmore, B. F. 
Antimicrobial Activity of Short, Synthetic Cationic Lipopeptides. Chem Biol 
Drug Design 2010, 75 (6), 563–569.
(240) Sioud, M.; Mobergslien, A. Selective Killing of Cancer Cells by Peptide-Targeted 
Delivery of an Anti-Microbial Peptide. Biochem. Pharmacol. 2012, 84 (9), 1123–
1132.
(241) Costantini, P. P.; Jacotot, E. E.; Decaudin, D. D.; Kroemer, G. G. Mitochondrion 
as a Novel Target of Anticancer Chemotherapy. J. Natl. Cancer Inst. 2000, 92 
(13), 1042–1053.
(242) Madani, F.; Abdo, R.; Lindberg, S.; Hirose, H.; Futaki, S.; Langel, U.; Gräslund, 
A. Modeling the Endosomal Escape of Cell-Penetrating Peptides Using a 
Transmembrane pH Gradient. Biochim. Biophys. Acta 2013, 1828 (4), 1198–
1204.
(243) Björklund, J.; Biverståhl, H.; Gräslund, A.; Mäler, L.; Brzezinski, P. Real-Time 
Transmembrane Translocation of Penetratin Driven by Light-Generated Proton 
Pumping. Biophys. J. 2006, 91 (4), L29–L31.
(244) Trapp, S.; Horobin, R. W. A Predictive Model for the Selective Accumulation of 
Chemicals in Tumor Cells. Eur Biophys J 2005, 34 (7), 959–966.
(245) Candé, C.; Vahsen, N.; Garrido, C.; Kroemer, G. Apoptosis-Inducing Factor 
(AIF): Caspase-Independent After All. Cell Death Differ. 2004, 11 (6), 591–595.
(246) Li, L. Y.; Luo, X.; Wang, X. Endonuclease G Is an Apoptotic DNase When 
Released From Mitochondria. Nature 2001, 412 (6842), 95–99.
(247) Dathe, M.; Wieprecht, T.; Nikolenko, H.; Handel, L.; Maloy, W. L.; MacDonald, 
D. L.; Beyermann, M.; Bienert, M. Hydrophobicity, Hydrophobic Moment and 
Angle Subtended by Charged Residues Modulate Antibacterial and Haemolytic 
Activity of Amphipathic Helical Peptides. FEBS Lett. 1997, 403 (2), 208–212.
(248) Alvarez-Bravo, J.; Kurata, S.; Natori, S. Novel Synthetic Antimicrobial Peptides 
Effective Against Methicillin-Resistant Staphylococcus Aureus. Biochem. J. 
1994, 302 ( Pt 2), 535–538.
(249) Nakatsuji, T. T.; Gallo, R. L. R. Antimicrobial Peptides: Old Molecules with New 
Ideas. J Invest Dermatol 2012, 132 (3 Pt 2), 887–895.
(250) Hamel E.;Interactions of Anitmitotic Peptides and Depsipeptides with Tubulin. 
Peptide Science 2002, 66, 142-160
165
Kelly Burns
Lehigh University, Department of Chemistry
6 East Packer Avenue, Bethlehem, PA 18015
 keb411@lehigh.edu
EDUCATION
PhD, Chemistry, Lehigh University, Bethlehem, PA 
Anticipated June 16, 2016
• Thesis title: “Specific Delivery of Therapeutics to Cancer Cells Using pHLIP”
• Advisor: Prof. Damien Thévenin 
BS, Chemistry, Minor: Biology, Magna Cum Laude, King’s College, Wilkes-Barre, PA, 
May 2011
RESEARCH EXPERIENCE
Graduate Research Assistant, Lehigh University, Bethlehem, PA, 2011-Present
Advisor: Prof. Damien Thévenin 
• Developed novel strategies to specifically target and deliver small therapeutic 
molecules and peptides to cancer cells using the pH(Low) Insertion Peptide 
(pHLIP). 
• Constructed and optimized the protocol for the synthesis and purification of 
pHLIP and conjugations to peptides, drugs and fluorophores
• Extensively designed and performed cellular treatment and viability assays with 
human cancer cells.  
Undergraduate Research Assistant, King’s College, Wilkes-Barre, PA, 2010-2011
Advisor: Prof. Frederick Sauls
• Studied the complexation of methamphetamines with β-cyclodextrin, in order to 
determine chirality and ultimately reveal the synthetic route of the product. 
TEACHING EXPERIENCE
Guest Lecturer, Lehigh University, Bethlehem, PA
• Bioscience in the 21st Century (Prof. Vassie Ware), September 9, 2015. Title: 
“Drug Delivery”
• General Chemistry II, Chemical Equilibrium in Aqueous Systems (Prof. Rebecca 
Miller), March 17, 2014. Title: “Buffers and Henderson-Hasselbach equation”
Graduate Teaching Assistant, Lehigh University, Bethlehem, PA, 2011-2014
• Instructor, General Chemistry II (Chemical Equilibrium in Aqueous Systems) 
Laboratory Spring 2013 
166
• Prepared and presented pre-laboratory lectures 
• Full responsibility of laboratory section including TA responsibilities
• Teaching Assistant, General Chemistry II (Chemical Equilibrium in Aqueous 
Systems) Laboratory 2011-2014 
• Supervised and instructed students in general chemistry techniques
• Emphasized keeping complete and accurate scientific notebooks
• Responsible for grading full lab reports as well as lecture exams
PRESENTATIONS
• Graduate Research Thesis Seminar, Lehigh University, Bethlehem, PA; March 
2016 University of Delaware Membrane Protein Symposium, Newark, DE; 
Poster Presentation, May 2015 
• Biophysical Society 59th Annual Meeting, Baltimore, MD; Poster Presentation, 
February 2015
• University of Delaware Membrane Protein Symposium, Newark, DE; Poster 
Presentation, May 2014 
• 2013 3rd regional meeting of the Biophysical Society at Penn State University, 
State College, PA; Poster Presentation, October 2013
• University of Delaware Membrane Protein Symposium Newark, DE; Poster 
Presentation, April 2013
• 2012 2nd regional meeting of the Biophysical Society at Lehigh University, 
Bethlehem, PA; Poster Presentation, September 2012
• University of Delaware Membrane Protein Symposium, Newark, DE; Poster 
Presentation, May 2012
• Graduate Research Seminar, Lehigh University, Bethlehem, PA; November 2012
• Undergraduate Poster Presentation, Misericordia University, Dallas, PA; May 
2011
• Undergraduate Research Seminar, Wilkes University, Wilkes-Barre, PA; 
November 2010
PUBLICATIONS
• Burns, K. E., Hensley, H. H., Robinson, M. K., Thévenin, D.; “Therapeutic 
Efficacy of a Family of pHLIP-MMAF Conjugates in Cancer Cells & Mouse 
Models” 2016, Submitted
• Burns, K. E., McCleerey, T., Thévenin, D.; “pH-Selective Cytotoxicity of 
pHLIP-Antimicrobial Peptide Conjugates” Sci. Rep. 2016, 6, 28465; doi:10.1038/
srep28465 (In Press)
• Burns, K. E., Thévenin, D.; “Down-Regulation of PAR1 Activity with a pHLIP-
based Allosteric Antagonist Induces Cancer Cell Death ” Biochem J. 2015, 472, 
287-295
• Burns, K. E., Robinson, M. K., Thévenin, D.; “Inhibition of Cancer Cell 
Proliferation and Breast Tumor Targeting of pHLIP-Monomethyl Auristatin E 
Conjugates” Mol. Pharmaceutics 2015, 12 (4), 1250-1258
167
PATENTS:
• Provisional Application for Patent: Conjugates of pH Low Insertion Peptide and 
Monomethyl Auristatins in the Treatment of Solid Tumors. (US Patent 
Application Number: 62/303,414)
HONORS
• Lehigh University Department of Chemistry Department Fellowship; 2015-2016
• Lehigh University College of Arts & Sciences Summer Research Fellowship; 
2014
• King’s College/American Society Division of Analytical Chemistry 2010 
Undergraduate Award in Analytical Chemistry; 2010
VOLUNTEER
• STARS Academy Program-Laboratory Assistant, Lehigh University; July 2014
• STEM Panelist, Lehigh University; November 2013 
• Dean’s Graduate Student Advisory Council; September 2012
168
